C12N1/00	7	Microorganisms; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K35/66, from algae A61K36/02, from fungi A61K36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor	C12N1/00	C12N1/00		2591
C12N1/005	8	{after treatment of microbial biomass not covered by C12N1/02&#160;-&#160;C12N1/08}	C12N1/00	C12N1/00		597
C12N1/02	8	Separating microorganisms from their culture media	C12N1/02	C12N1/02		4124
C12N1/04	8	Preserving or maintaining viable microorganisms (immobilised microorganisms C12N11/00)	C12N1/04	C12N1/04		3539
C12N1/06	8	Lysis of microorganisms	C12N1/06	C12N1/06		1083
C12N1/063	9	of yeast	C12N1/063	C12N1/063		369
C12N1/066	9	by physical processes	C12N1/066	C12N1/066		712
C12N1/08	8	Reducing the nucleic acid content	C12N1/08	C12N1/08		154
C12N1/10	8	Protozoa; Culture media therefor	C12N1/10	C12N1/10		326
C12N1/105	9	Protozoal isolates	C12N1/105	C12N1/105		74
C12N1/12	8	Unicellular algae; Culture media therefor (as new plants A01H13/00)	C12N1/12	C12N1/12		4992
C12N1/125	9	Unicellular algae isolates	C12N1/125	C12N1/125		663
C12N1/14	8	Fungi (culture of mushrooms A01G18/00; as new plants A01H15/00); Culture media therefor	C12N1/14	C12N1/14		12856
C12N1/145	9	Fungi isolates	C12N1/145	C12N1/145		6284
C12N1/16	9	Yeasts; Culture media therefor	C12N1/16	C12N1/16		6556
C12N1/165	10	Yeast isolates	C12N1/165	C12N1/165		1104
C12N1/18	10	Baker&apos;s yeast; Brewer&apos;s yeast	C12N1/18	C12N1/18		2834
C12N1/185	11	Saccharomyces isolates	C12N1/185	C12N1/185		1367
C12N1/20	8	Bacteria; Culture media therefor	C12N1/20	C12N1/20		44694
C12N1/205	9	Bacterial isolates	C12N1/205	C12N1/205		27558
C12N1/22	8	Processes using, or culture media containing, cellulose or hydrolysates thereof	C12N1/22	C12N1/22		764
C12N1/24	8	Processes using, or culture media containing, waste sulfite liquor	C12N1/24	C12N1/24		92
C12N1/26	8	Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms C10G32/00)	C12N1/26	C12N1/26		365
C12N1/28	9	aliphatic	C12N1/28	C12N1/28		161
C12N1/30	10	having five or less carbon atoms	C12N1/30	C12N1/30		106
C12N1/32	8	Processes using, or culture media containing, lower alkanols, i.e. C1 to C6	C12N1/32	C12N1/32		395
C12N1/34	8	Processes using foam culture	C12N1/34	C12N1/34		55
C12N1/36	8	Adaptation or attenuation of cells	C12N1/36	C12N1/36		2055
C12N1/38	8	Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N1/34 takes precedence)	C12N1/38	C12N1/38		3965
C12N3/00	7	Spore forming or isolating processes	C12N3/00	C12N3/00		1029
C12N5/00	7	Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)<br><br><u>NOTE</u><br><br>In this group, the following words are used with the meanings indicated: <br>a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta; <br>a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm); <br>a "multipotent" cell is restricted to one lineage; <br>"progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.	C12N5/00	C12N5/00		2101
C12N5/0006	8	{Modification of the membrane of cells, e.g. cell decoration}	C12N5/00	C12N5/00		424
C12N5/0012	8	{Cell encapsulation}	C12N5/00	C12N5/00		474
C12N5/0018	8	{Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}	C12N5/00	C12N5/00		1503
C12N5/0025	9	{Culture media for plant cell or plant tissue culture}	C12N5/00	C12N5/00		1000
C12N5/0031	9	{Serum-free culture media}<br><br><u>WARNING</u><br> This group is no longer used for the classification of new documents as from 2012-01-01. The backlog of this group is being continuously reclassified to C12N5/0037&#160;-&#160;C12N5/0056	C12N5/00	C12N5/00		148
C12N5/0037	9	{Serum-free medium, which may still contain naturally-sourced components}	C12N5/00	C12N5/00		377
C12N5/0043	9	{Medium free of human- or animal-derived components}	C12N5/00	C12N5/00		107
C12N5/005	9	{Protein-free medium}	C12N5/00	C12N5/00		77
C12N5/0056	9	{Xeno-free medium}	C12N5/00	C12N5/00		44
C12N5/0062	8	{General methods for three-dimensional culture}	C12N5/00	C12N5/00		1559
C12N5/0068	8	{General culture methods using substrates (for specific animal cell type C12N5/06)}	C12N5/00	C12N5/00		2836
C12N5/0075	9	{using microcarriers}	C12N5/00	C12N5/00		623
C12N5/0081	8	{Purging biological preparations of unwanted cells}	C12N5/00	C12N5/00		300
C12N5/0087	9	{Purging against subsets of blood cells, e.g. purging alloreactive T cells}	C12N5/00	C12N5/00		316
C12N5/0093	9	{Purging against cancer cells}	C12N5/00	C12N5/00		122
C12N5/04	8	Plant cells or tissues {(culture media C12N5/0025)}	C12N5/04	C12N5/04		2483
C12N5/06	8	{Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}<br><br><u>NOTE</u><br><br>In this group, the following words are used with the meanings indicated: <br>a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta; <br>a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm); <br>a "multipotent" cell is restricted to one lineage.  "Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. The last place priority rule does not apply between the subgroups of this group	C12N5/07	C12N5/06		2484
C12N5/0601	9	{Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}	C12N5/07	C12N5/06		491
C12N5/0602	9	{Vertebrate cells}<br><br><u>NOTE</u><br><br>Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for.	C12N5/071	C12N5/06		1454
C12N5/0603	10	{Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}	C12N5/073	C12N5/06		709
C12N5/0604	11	{Whole embryos; Culture medium therefor}	C12N5/073	C12N5/06		814
C12N5/0605	11	{Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton&apos;s jelly}	C12N5/073	C12N5/06		913
C12N5/0606	11	{Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}	C12N5/0735	C12N5/06		2081
C12N5/0607	10	{Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}	C12N5/074	C12N5/06		696
C12N5/0608	10	{Germ cells (production of embryos, nuclear transfer A01K67/027)}	C12N5/071	C12N5/06		69
C12N5/0609	11	{Oocytes, oogonia (fertilised oocytes C12N5/0604)}	C12N5/075	C12N5/06		782
C12N5/061	11	{Sperm cells, spermatogonia}	C12N5/076	C12N5/06		747
C12N5/0611	11	{Primordial germ cells, e.g. embryonic germ cells [EG]}	C12N5/0735	C12N5/06		218
C12N5/0612	11	{sorting of gametes, e.g. according to sex or motility}	C12N5/071	C12N5/06		243
C12N5/0613	10	{Cells from endocrine organs (pancreas C12N5/0676, gonads C12N5/0681)}	C12N5/071	C12N5/06		37
C12N5/0614	11	{Adrenal gland}	C12N5/071	C12N5/06		35
C12N5/0615	11	{Pineal gland}	C12N5/071	C12N5/06		2
C12N5/0616	11	{Pituitary gland}	C12N5/071	C12N5/06		26
C12N5/0617	11	{Thyroid and parathyroid glands}	C12N5/071	C12N5/06		61
C12N5/0618	10	{Cells of the nervous system}	C12N5/079	C12N5/06		969
C12N5/0619	11	{Neurons}	C12N5/0793	C12N5/06		2002
C12N5/062	11	{Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}	C12N5/0793	C12N5/06		309
C12N5/0621	11	{Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062)}	C12N5/079	C12N5/06		797
C12N5/0622	11	{Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}	C12N5/079	C12N5/06		1009
C12N5/0623	11	{Stem cells}	C12N5/0797	C12N5/06		1358
C12N5/0625	10	{Epidermal cells, skin cells; Cells of the oral mucosa}	C12N5/071	C12N5/06		964
C12N5/0626	11	{Melanocytes}	C12N5/071	C12N5/06		181
C12N5/0627	11	{Hair cells}	C12N5/071	C12N5/06		258
C12N5/0628	12	{Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N5/0666)}	C12N5/071	C12N5/06		164
C12N5/0629	11	{Keratinocytes; Whole skin}	C12N5/071	C12N5/06		588
C12N5/063	12	{Kereatinocyte stem cells; Keratinocyte progenitors}	C12N5/071	C12N5/06		51
C12N5/0631	11	{Mammary cells}	C12N5/071	C12N5/06		435
C12N5/0632	11	{Cells of the oral mucosa}	C12N5/071	C12N5/06		84
C12N5/0633	11	{Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands}	C12N5/071	C12N5/06		131
C12N5/0634	10	{Cells from the blood or the immune system}<br><br><u>NOTE</u><br><br>Committed progenitors are classified with their progeny.	C12N5/078	C12N5/06		1648
C12N5/0635	11	{B lymphocytes}	C12N5/0781	C12N5/06		738
C12N5/0636	11	{T lymphocytes}	C12N5/0783	C12N5/06		7830
C12N5/0637	12	{Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}	C12N5/0783	C12N5/06		730
C12N5/0638	12	{Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}	C12N5/0783	C12N5/06		1380
C12N5/0639	11	{Dendritic cells, e.g. Langherhans cells in the epidermis}	C12N5/0784	C12N5/06		1534
C12N5/064	12	{Immunosuppressive dendritic cells}	C12N5/0784	C12N5/06		163
C12N5/0641	11	{Erythrocytes}	C12N5/078	C12N5/06		585
C12N5/0642	11	{Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells}	C12N5/0787	C12N5/06		331
C12N5/0643	11	{Osteoclasts}	C12N5/078	C12N5/06		71
C12N5/0644	11	{Platelets; Megakaryocytes}	C12N5/078	C12N5/06		509
C12N5/0645	11	{Macrophages, e.g. Kuepfer cells in the liver; Monocytes}	C12N5/0786	C12N5/06		1519
C12N5/0646	11	{Natural killers cells [NK], NKT cells}	C12N5/0783	C12N5/06		3045
C12N5/0647	11	{Haematopoietic stem cells; Uncommitted or multipotent progenitors}	C12N5/0789	C12N5/06		2053
C12N5/0648	11	{Splenocytes}	C12N5/078	C12N5/06		74
C12N5/065	11	{Thymocytes}	C12N5/078	C12N5/06		85
C12N5/0651	11	{Lymph nodes}	C12N5/078	C12N5/06		44
C12N5/0652	10	{Cells of skeletal and connective tissues; Mesenchyme}	C12N5/077	C12N5/06		271
C12N5/0653	11	{Adipocytes; Adipose tissue}	C12N5/077	C12N5/06		949
C12N5/0654	11	{Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}	C12N5/077	C12N5/06		1138
C12N5/0655	11	{Chondrocytes; Cartilage}	C12N5/077	C12N5/06		1116
C12N5/0656	11	{Adult fibroblasts}	C12N5/077	C12N5/06		1725
C12N5/0657	11	{Cardiomyocytes; Heart cells}	C12N5/077	C12N5/06		1522
C12N5/0658	11	{Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}	C12N5/077	C12N5/06		997
C12N5/0659	12	{Satellite cells}	C12N5/077	C12N5/06		200
C12N5/066	11	{Tenocytes; Tendons, Ligaments}	C12N5/077	C12N5/06		90
C12N5/0661	11	{Smooth muscle cells}	C12N5/077	C12N5/06		141
C12N5/0662	11	{Stem cells}	C12N5/0775	C12N5/06		1958
C12N5/0663	12	{Bone marrow mesenchymal stem cells (BM-MSC)}	C12N5/0775	C12N5/06		2118
C12N5/0664	12	{Dental pulp stem cells, Dental follicle stem cells}	C12N5/0775	C12N5/06		420
C12N5/0665	12	{Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}	C12N5/0775	C12N5/06		1199
C12N5/0666	12	{Mesenchymal stem cells from hair follicles}	C12N5/0775	C12N5/06		107
C12N5/0667	12	{Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}	C12N5/0775	C12N5/06		1918
C12N5/0668	12	{Mesenchymal stem cells from other natural sources}	C12N5/0775	C12N5/06		2441
C12N5/0669	11	{Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663)}	C12N5/077	C12N5/06		227
C12N5/067	10	{Hepatocytes}	C12N5/071	C12N5/06		1420
C12N5/0671	11	{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}	C12N5/071	C12N5/06		609
C12N5/0672	11	{Stem cells; Progenitor cells; Precursor cells; Oval cells}	C12N5/071	C12N5/06		274
C12N5/0676	10	{Pancreatic cells}	C12N5/071	C12N5/06		1112
C12N5/0677	11	{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}	C12N5/071	C12N5/06		400
C12N5/0678	11	{Stem cells; Progenitor cells; Precursor cells}	C12N5/071	C12N5/06		262
C12N5/0679	10	{Cells of the gastro-intestinal tract}	C12N5/071	C12N5/06		882
C12N5/068	11	{Stem cells; Progenitors}	C12N5/071	C12N5/06		124
C12N5/0681	10	{Cells of the genital tract; Non-germinal cells from gonads}	C12N5/071	C12N5/06		10
C12N5/0682	11	{Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609)}	C12N5/071	C12N5/06		1578
C12N5/0683	11	{Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N5/061)}	C12N5/071	C12N5/06		234
C12N5/0684	10	{Cells of the urinary tract or kidneys}	C12N5/071	C12N5/06		110
C12N5/0685	11	{Bladder epithelial cells}	C12N5/071	C12N5/06		43
C12N5/0686	11	{Kidney cells}	C12N5/071	C12N5/06		2571
C12N5/0687	11	{Renal stem cells; Renal progenitors}	C12N5/071	C12N5/06		90
C12N5/0688	10	{Cells from the lungs or the respiratory tract}	C12N5/071	C12N5/06		795
C12N5/0689	11	{Stem cells; Progenitors}	C12N5/071	C12N5/06		104
C12N5/069	10	{Vascular Endothelial cells}	C12N5/071	C12N5/06		1263
C12N5/0691	11	{Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}	C12N5/071	C12N5/06		509
C12N5/0692	11	{Stem cells; Progenitor cells; Precursor cells}	C12N5/071	C12N5/06		338
C12N5/0693	10	{Tumour cells; Cancer cells}	C12N5/09	C12N5/06		4619
C12N5/0694	11	{Cells of blood, e.g. leukemia cells, myeloma cells}	C12N5/09	C12N5/06		467
C12N5/0695	11	{Stem cells; Progenitor cells; Precursor cells}	C12N5/095	C12N5/06		351
C12N5/0696	10	{Artificially induced pluripotent stem cells, e.g. iPS}	C12N5/074	C12N5/06		2451
C12N5/0697	9	{Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}	C12N5/071	C12N5/06		1281
C12N5/0698	10	{Skin equivalents}	C12N5/071	C12N5/06		473
C12N5/10	8	Cells modified by introduction of foreign genetic material	C12N5/10	C12N5/10		3322
C12N5/12	9	Fused cells, e.g. hybridomas	C12N5/12	C12N5/12		275
C12N5/14	10	Plant cells	C12N5/14	C12N5/14		242
C12N5/16	10	Animal cells	C12N5/16	C12N5/16		692
C12N5/163	11	{one of the fusion partners being a B or a T lymphocyte}	C12N5/16	C12N5/16		632
C12N5/166	11	{resulting from interspecies fusion}	C12N5/26	C12N5/16		75
C12N5/52	8	{Chemical aspects of preservation of animal cells or human cells (Preservation of excised living parts of human of bodies A01N1/10)}<br><br><u>WARNING</u><br>Group C12N5/52 is incomplete pending reclassification of documents from group A01N1/12.<br>Groups A01N1/12 and C12N5/52 should be considered in order to perform a complete search.	C12N5/00	C12N5/52		3
C12N5/522	9	{Preservation media}<br><br><u>WARNING</u><br>Group C12N5/522 is incomplete pending reclassification of documents from group A01N1/122.<br>Groups A01N1/122 and C12N5/522 should be considered in order to perform a complete search.	C12N5/00	C12N5/522		33
C12N5/524	10	{Disinfecting agents, e.g. antimicrobials}<br><br><u>WARNING</u><br>Group C12N5/524 is incomplete pending reclassification of documents from group A01N1/124.<br>Groups A01N1/124 and C12N5/524 should be considered in order to perform a complete search.	C12N5/00	C12N5/524		8
C12N5/525	10	{Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators}<br><br><u>WARNING</u><br>Group C12N5/525 is incomplete pending reclassification of documents from group A01N1/125.<br>Groups A01N1/125 and C12N5/525 should be considered in order to perform a complete search.	C12N5/00	C12N5/525		70
C12N5/526	10	{Physiologically active agents, e.g. antioxidants or nutrients}<br><br><u>WARNING</u><br>Group C12N5/526 is incomplete pending reclassification of documents from group A01N1/126.<br>Groups A01N1/126 and C12N5/526 should be considered in order to perform a complete search.	C12N5/00	C12N5/526		32
C12N5/528	9	{Chemically defined matrices for immobilising, holding or storing animal or human cells, e.g. alginate gels; Chemically altering animal or human cells}<br><br><u>WARNING</u><br>Group C12N5/528 is incomplete pending reclassification of documents from group A01N1/128.<br>Groups A01N1/128 and C12N5/528 should be considered in order to perform a complete search.	C12N5/00	C12N5/528		3
C12N5/54	8	{Mechanical aspects of preservation of animal cells or human cells; Apparatus or containers therefor (Preservation of excised living parts of human of bodies A01N1/10)}<br><br><u>WARNING</u><br>Group C12N5/54 is incomplete pending reclassification of documents from groups A01N1/14, A61J1/10, A61J1/12, A61J1/16, A61J1/165, A61M1/0272 and A61M1/0277.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N5/00	C12N5/54		6
C12N5/542	9	{Apparatus}<br><br><u>WARNING</u><br>Group C12N5/542 is incomplete pending reclassification of documents from groups A01N1/142, A61J1/10, A61J1/12, A61J1/16, A61J1/165, A61M1/0272 and A61M1/0277.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N5/00	C12N5/542		14
C12N5/544	10	{for temperature control, e.g. refrigerators or freeze-drying apparatus}<br><br><u>WARNING</u><br>Group C12N5/544 is incomplete pending reclassification of documents from groups A01N1/144, A61J1/10, A61J1/12, A61J1/16, A61J1/165, A61M1/0272 and A61M1/0277.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N5/00	C12N5/544		13
C12N5/545	11	{Stationary or portable vessels generating cryogenic temperatures, e.g. liquid nitrogen baths}<br><br><u>WARNING</u><br>Group C12N5/545 is incomplete pending reclassification of documents from groups A01N1/145, A61J1/10, A61J1/12, A61J1/16, A61J1/165, A61M1/0272 and A61M1/0277.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N5/00	C12N5/545		18
C12N5/546	9	{Non-refrigerated containers specially adapted for transporting or storing animal cells or human cells whilst preserving}<br><br><u>WARNING</u><br>Group C12N5/546 is incomplete pending reclassification of documents from groups A01N1/146, A61J1/10, A61J1/12, A61J1/16, A61J1/165, A61M1/0272 and A61M1/0277.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N5/00	C12N5/546		7
C12N5/547	10	{Carriers for immersion in cryogenic fluid for slow freezing or vitrification}<br><br><u>WARNING</u><br>Group C12N5/547 is incomplete pending reclassification of documents from groups A01N1/147, A61J1/10, A61J1/12, A61J1/16, A61J1/165, A61M1/0272 and A61M1/0277.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N5/00	C12N5/547		22
C12N5/548	10	{with provisions specially adapted for transporting}<br><br><u>WARNING</u><br>Group C12N5/548 is incomplete pending reclassification of documents from groups A01N1/148, A61J1/10, A61J1/12, A61J1/16, A61J1/165, A61M1/0272 and A61M1/0277.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N5/00	C12N5/548		7
C12N5/56	8	{Physical preservation processes for animal cells or human cells}<br><br><u>WARNING</u><br>Group C12N5/56 is incomplete pending reclassification of documents from group A01N1/16.<br>Groups A01N1/16 and C12N5/56 should be considered in order to perform a complete search.	C12N5/00	C12N5/56		3
C12N5/562	9	{Temperature processes, e.g. following predefined temperature changes over time}<br><br><u>WARNING</u><br>Group C12N5/562 is incomplete pending reclassification of documents from group A01N1/162.<br>Groups A01N1/162 and C12N5/562 should be considered in order to perform a complete search.	C12N5/00	C12N5/562		42
C12N5/565	9	{Pressure processes, e.g. following predefined pressure changes over time}<br><br><u>WARNING</u><br>Group C12N5/565 is incomplete pending reclassification of documents from group A01N1/165.<br>Groups A01N1/165 and C12N5/565 should be considered in order to perform a complete search.	C12N5/00	C12N5/565		6
C12N5/568	9	{using electromagnetic fields or radiation; using acoustic waves or corpuscular radiation}<br><br><u>WARNING</u><br>Group C12N5/568 is incomplete pending reclassification of documents from group A01N1/168.<br>Groups A01N1/168 and C12N5/568 should be considered in order to perform a complete search.	C12N5/00	C12N5/568		5
C12N7/00	7	Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)<br><br><u>WARNING</u><br> From 2012-03-15 groups C12N7/02 - C12N7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N2710/00-C12N2795/00. 	C12N7/00	C12N7/00		16010
C12N7/02	8	Recovery or purification	C12N7/02	C12N7/02		335
C12N7/025	9	{Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}	C12N7/02	C12N7/02		31
C12N7/04	8	Inactivation or attenuation; Producing viral sub-units	C12N7/04	C12N7/04		299
C12N7/045	9	{Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}	C12N7/04	C12N7/04		77
C12N7/06	9	{Inactivation or attenuation} by chemical treatment	C12N7/06	C12N7/06		65
C12N7/08	9	{Inactivation or attenuation} by serial passage of virus	C12N7/08	C12N7/08		27
C12N9/00	7	Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)<br><br><u>NOTE</u><br><br>Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.	C12N9/00	C12N9/00		2975
C12N9/0002	8	{Antibodies with enzymatic activity, e.g. abzymes}	C12N9/00	C12N9/00		148
C12N9/0004	8	{Oxidoreductases (1.)}	C12N9/02	C12N9/00		2131
C12N9/0006	9	{acting on CH-OH groups as donors (1.1)}	C12N9/04	C12N9/00		7210
C12N9/0008	9	{acting on the aldehyde or oxo group of donors (1.2)}	C12N9/02	C12N9/00		2362
C12N9/001	9	{acting on the CH-CH group of donors (1.3)}	C12N9/02	C12N9/00		1474
C12N9/0012	9	{acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}	C12N9/06	C12N9/00		110
C12N9/0014	10	{acting on the CH-NH2 group of donors (1.4)}	C12N9/06	C12N9/00		130
C12N9/0016	11	{with NAD or NADP as acceptor (1.4.1)}	C12N9/06	C12N9/00		605
C12N9/0018	12	{Phenylalanine dehydrogenase (1.4.1.20)}	C12N9/06	C12N9/00		54
C12N9/002	11	{with a cytochrome as acceptor (1.4.2)}	C12N9/06	C12N9/00		9
C12N9/0022	11	{with oxygen as acceptor (1.4.3)}	C12N9/06	C12N9/00		409
C12N9/0024	12	{D-Amino acid oxidase (1.4.3.3)}	C12N9/06	C12N9/00		93
C12N9/0026	10	{acting on CH-NH groups of donors (1.5)}	C12N9/06	C12N9/00		81
C12N9/0028	11	{with NAD or NADP as acceptor (1.5.1)}	C12N9/06	C12N9/00		313
C12N9/003	12	{Dihydrofolate reductase [DHFR] (1.5.1.3)}	C12N9/06	C12N9/00		165
C12N9/0032	11	{with oxygen as acceptor (1.5.3)}	C12N9/06	C12N9/00		95
C12N9/0034	12	{Sarcosine oxidase (1.5.3.1)}	C12N9/06	C12N9/00		28
C12N9/0036	10	{acting on NADH or NADPH (1.6)}	C12N9/02	C12N9/00		688
C12N9/0038	11	{with a heme protein as acceptor (1.6.2)}	C12N9/02	C12N9/00		28
C12N9/004	12	{Cytochrome-b5 reductase (1.6.2.2)}	C12N9/02	C12N9/00		31
C12N9/0042	12	{NADPH-cytochrome P450 reductase (1.6.2.4)}	C12N9/02	C12N9/00		318
C12N9/0044	10	{acting on other nitrogen compounds as donors (1.7)}	C12N9/06	C12N9/00		162
C12N9/0046	11	{with oxygen as acceptor (1.7.3)}	C12N9/06	C12N9/00		58
C12N9/0048	12	{Uricase (1.7.3.3)}	C12N9/06	C12N9/00		166
C12N9/0051	9	{acting on a sulfur group of donors (1.8)}	C12N9/02	C12N9/00		403
C12N9/0053	9	{acting on a heme group of donors (1.9)}	C12N9/02	C12N9/00		114
C12N9/0055	9	{acting on diphenols and related substances as donors (1.10)}	C12N9/02	C12N9/00		36
C12N9/0057	10	{with oxygen as acceptor (1.10.3)}	C12N9/02	C12N9/00		41
C12N9/0059	11	{Catechol oxidase (1.10.3.1), i.e. tyrosinase}	C12N9/02	C12N9/00		259
C12N9/0061	11	{Laccase (1.10.3.2)}	C12N9/02	C12N9/00		853
C12N9/0063	11	{Ascorbate oxidase (1.10.3.3)}	C12N9/02	C12N9/00		25
C12N9/0065	9	{acting on hydrogen peroxide as acceptor (1.11)}	C12N9/08	C12N9/00		1749
C12N9/0067	9	{acting on hydrogen as donor (1.12)}	C12N9/02	C12N9/00		103
C12N9/0069	9	{acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}	C12N9/02	C12N9/00		1642
C12N9/0071	9	{acting on paired donors with incorporation of molecular oxygen (1.14)}	C12N9/02	C12N9/00		2825
C12N9/0073	10	{with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}	C12N9/02	C12N9/00		811
C12N9/0075	11	{Nitric-oxide synthase (1.14.13.39)}	C12N9/02	C12N9/00		106
C12N9/0077	10	{with a reduced iron-sulfur protein as one donor (1.14.15)}	C12N9/02	C12N9/00		537
C12N9/0079	11	{Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}	C12N9/02	C12N9/00		51
C12N9/0081	11	{Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)}	C12N9/02	C12N9/00		241
C12N9/0083	10	{Miscellaneous (1.14.99)}	C12N9/02	C12N9/00		759
C12N9/0085	11	{Steroid 17 alpha-monooxygenase (1.14.99.9)}	C12N9/02	C12N9/00		11
C12N9/0087	11	{Steroid 21-monooxygenase (1.14.99.10)}	C12N9/02	C12N9/00		7
C12N9/0089	9	{acting on superoxide as acceptor (1.15)}	C12N9/02	C12N9/00		801
C12N9/0091	9	{oxidizing metal ions (1.16)}	C12N9/02	C12N9/00		74
C12N9/0093	9	{acting on CH or CH2 groups (1.17)}	C12N9/02	C12N9/00		217
C12N9/0095	9	{acting on iron-sulfur proteins as donor (1.18)}	C12N9/02	C12N9/00		164
C12N9/0097	9	{acting on reduced flavodoxin as donor (1.19)}	C12N9/02	C12N9/00		17
C12N9/10	8	Transferases (2.) (ribonucleases C12N9/22)	C12N9/10	C12N9/10		1065
C12N9/1003	9	{transferring one-carbon groups (2.1)}	C12N9/10	C12N9/10		58
C12N9/1007	10	{Methyltransferases (general) (2.1.1.)}	C12N9/10	C12N9/10		1798
C12N9/1011	11	{Catechol O-methyltransferase (2.1.1.6)}	C12N9/10	C12N9/10		36
C12N9/1014	10	{Hydroxymethyl-, formyl-transferases (2.1.2)}	C12N9/10	C12N9/10		180
C12N9/1018	10	{Carboxy- and carbamoyl transferases (2.1.3)}	C12N9/10	C12N9/10		127
C12N9/1022	9	{transferring aldehyde or ketonic groups (2.2)}	C12N9/10	C12N9/10		691
C12N9/1025	9	{Acyltransferases (2.3)}	C12N9/10	C12N9/10		723
C12N9/1029	10	{transferring groups other than amino-acyl groups (2.3.1)}	C12N9/10	C12N9/10		3411
C12N9/1033	11	{Chloramphenicol O-acetyltransferase (2.3.1.28)}	C12N9/10	C12N9/10		69
C12N9/1037	11	{Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}	C12N9/10	C12N9/10		123
C12N9/104	10	{Aminoacyltransferases (2.3.2)}	C12N9/10	C12N9/10		442
C12N9/1044	11	{Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}	C12N9/10	C12N9/10		411
C12N9/1048	9	{Glycosyltransferases (2.4)}	C12N9/10	C12N9/10		787
C12N9/1051	10	{Hexosyltransferases (2.4.1)}	C12N9/10	C12N9/10		3268
C12N9/1055	11	{Levansucrase (2.4.1.10)}	C12N9/10	C12N9/10		101
C12N9/1059	11	{Cellulose synthases (2.4.1.12; 2.4.1.29)}	C12N9/10	C12N9/10		98
C12N9/1062	11	{Sucrose synthase (2.4.1.13)}	C12N9/10	C12N9/10		156
C12N9/1066	11	{Sucrose phosphate synthase (2.4.1.14)}	C12N9/10	C12N9/10		35
C12N9/107	11	{1,4-Alpha-glucan branching enzyme (2.4.1.18)}	C12N9/10	C12N9/10		129
C12N9/1074	11	{Cyclomaltodextrin glucanotransferase (2.4.1.19)}	C12N9/10	C12N9/10		255
C12N9/1077	10	{Pentosyltransferases (2.4.2)}	C12N9/10	C12N9/10		743
C12N9/1081	10	{transferring other glycosyl groups (2.4.99)}	C12N9/10	C12N9/10		288
C12N9/1085	9	{transferring alkyl or aryl groups other than methyl groups (2.5)}	C12N9/10	C12N9/10		1789
C12N9/1088	10	{Glutathione transferase (2.5.1.18)}	C12N9/10	C12N9/10		291
C12N9/1092	10	{3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}	C12N9/10	C12N9/10		280
C12N9/1096	9	{transferring nitrogenous groups (2.6)}	C12N9/10	C12N9/10		1402
C12N9/12	9	transferring phosphorus containing groups, e.g. kinases (2.7)	C12N9/12	C12N9/12		2876
C12N9/1205	10	{Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}	C12N9/12	C12N9/12		4256
C12N9/1211	11	{Thymidine kinase (2.7.1.21)}	C12N9/12	C12N9/12		247
C12N9/1217	10	{Phosphotransferases with a carboxyl group as acceptor (2.7.2)}	C12N9/12	C12N9/12		523
C12N9/1223	10	{Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}	C12N9/12	C12N9/12		129
C12N9/1229	10	{Phosphotransferases with a phosphate group as acceptor (2.7.4)}	C12N9/12	C12N9/12		512
C12N9/1235	10	{Diphosphotransferases (2.7.6)}	C12N9/12	C12N9/12		122
C12N9/1241	10	{Nucleotidyltransferases (2.7.7)}	C12N9/12	C12N9/12		1621
C12N9/1247	11	{DNA-directed RNA polymerase (2.7.7.6)}	C12N9/12	C12N9/12		488
C12N9/1252	11	{DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}	C12N9/12	C12N9/12		1355
C12N9/1258	11	{Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}	C12N9/12	C12N9/12		32
C12N9/1264	11	{DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}	C12N9/12	C12N9/12		125
C12N9/127	11	{RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}	C12N9/12	C12N9/12		241
C12N9/1276	11	{RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}	C12N9/12	C12N9/12		1031
C12N9/1282	11	{RNA uridylyltransferase (2.7.7.52)}	C12N9/12	C12N9/12		4
C12N9/1288	10	{Transferases for other substituted phosphate groups (2.7.8)}	C12N9/12	C12N9/12		267
C12N9/1294	10	{Phosphotransferases with paired acceptors (2.7.9)}	C12N9/12	C12N9/12		95
C12N9/13	9	{transferring sulfur containing groups (2.8)}	C12N9/10	C12N9/13		551
C12N9/14	8	Hydrolases (3)	C12N9/14	C12N9/14		2579
C12N9/16	9	acting on ester bonds (3.1)	C12N9/16	C12N9/16		5365
C12N9/18	10	Carboxylic ester hydrolases {(3.1.1)}	C12N9/18	C12N9/18		2615
C12N9/20	11	Triglyceride splitting, e.g. by means of lipase	C12N9/20	C12N9/20		2712
C12N9/22	10	Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}<br><br><u>WARNING</u><br>Group C12N9/22 is incomplete pending reclassification of documents from group C12N2310/20. <br>Group C12N9/22 is also impacted by reclassification into groups C12N9/222 - C12N9/226. <br>Groups C12N9/22, C12N9/222 - C12N9/226 and C12N2310/20 should be considered in order to perform a complete search.	C12N9/22	C12N9/22		11775
C12N9/222	11	{Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}<br><br><u>WARNING</u><br>Groups C12N9/222 - C12N9/226 are incomplete pending reclassification of documents from groups C12N9/22 and C12N2310/20.<br>All groups listed in this Warning should be considered in order to perform a complete search.	C12N9/22	C12N9/22		97
C12N9/224	12	{Class 1 CAS enzyme complex, e.g. multi-enzyme}	C12N9/22	C12N9/22		13
C12N9/226	12	{Class 2 CAS enzyme complex, e.g. single CAS protein}	C12N9/22	C12N9/22		335
C12N9/24	9	acting on glycosyl compounds (3.2)	C12N9/24	C12N9/24		600
C12N9/2402	10	{hydrolysing O- and S- glycosyl compounds (3.2.1)}	C12N9/24	C12N9/24		2958
C12N9/2405	11	{Glucanases}	C12N9/24	C12N9/24		294
C12N9/2408	12	{acting on alpha -1,4-glucosidic bonds}	C12N9/26	C12N9/24		702
C12N9/2411	13	{Amylases}	C12N9/26	C12N9/24		606
C12N9/2414	14	{Alpha-amylase (3.2.1.1.)}	C12N9/26	C12N9/24		538
C12N9/2417	15	{from microbiological source}	C12N9/28	C12N9/24		829
C12N9/242	16	{Fungal source}	C12N9/30	C12N9/24		300
C12N9/2422	15	{from plant source}	C12N9/32	C12N9/24		82
C12N9/2425	14	{Beta-amylase (3.2.1.2)}	C12N9/26	C12N9/24		155
C12N9/2428	14	{Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}	C12N9/34	C12N9/24		663
C12N9/2431	13	{Beta-fructofuranosidase (3.2.1.26), i.e. invertase}	C12N9/26	C12N9/24		151
C12N9/2434	12	{acting on beta-1,4-glucosidic bonds}	C12N9/42	C12N9/24		541
C12N9/2437	13	{Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}	C12N9/42	C12N9/24		2827
C12N9/244	13	{Endo-1,3(4)-beta-glucanase (3.2.1.6)}	C12N9/42	C12N9/24		266
C12N9/2442	13	{Chitinase (3.2.1.14)}	C12N9/42	C12N9/24		460
C12N9/2445	13	{Beta-glucosidase (3.2.1.21)}	C12N9/42	C12N9/24		976
C12N9/2448	13	{Licheninase (3.2.1.73)}	C12N9/42	C12N9/24		76
C12N9/2451	12	{acting on alpha-1,6-glucosidic bonds}	C12N9/44	C12N9/24		145
C12N9/2454	13	{Dextranase (3.2.1.11)}	C12N9/46	C12N9/24		142
C12N9/2457	13	{Pullulanase (3.2.1.41)}	C12N9/44	C12N9/24		302
C12N9/246	13	{Isoamylase (3.2.1.68)}	C12N9/44	C12N9/24		68
C12N9/2462	11	{Lysozyme (3.2.1.17)}	C12N9/36	C12N9/24		885
C12N9/2465	11	{acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}	C12N9/40	C12N9/24		350
C12N9/2468	11	{acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}	C12N9/38	C12N9/24		270
C12N9/2471	12	{Beta-galactosidase (3.2.1.23), i.e. exo-(1--&gt;4)-beta-D-galactanase}	C12N9/38	C12N9/24		696
C12N9/2474	11	{Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}	C12N9/26	C12N9/24		233
C12N9/2477	11	{Hemicellulases not provided in a preceding group}	C12N9/24	C12N9/24		130
C12N9/248	12	{Xylanases}	C12N9/24	C12N9/24		946
C12N9/2482	13	{Endo-1,4-beta-xylanase (3.2.1.8)}	C12N9/24	C12N9/24		488
C12N9/2485	13	{Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}	C12N9/24	C12N9/24		41
C12N9/2488	12	{Mannanases}	C12N9/24	C12N9/24		198
C12N9/2491	13	{Beta-mannosidase (3.2.1.25), i.e. mannanase}	C12N9/24	C12N9/24		130
C12N9/2494	13	{Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}	C12N9/24	C12N9/24		247
C12N9/2497	10	{hydrolysing N- glycosyl compounds (3.2.2)}	C12N9/24	C12N9/24		295
C12N9/48	9	acting on peptide bonds (3.4)	C12N9/48	C12N9/48		797
C12N9/485	10	{Exopeptidases (3.4.11-3.4.19)}	C12N9/48	C12N9/48		890
C12N9/50	10	Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}	C12N9/50	C12N9/50		1310
C12N9/503	11	{derived from viruses}	C12N9/50	C12N9/50		148
C12N9/506	12	{derived from RNA viruses}	C12N9/50	C12N9/50		289
C12N9/52	11	derived from bacteria {or Archaea}<br><br><u>NOTE</u><br><br>In this group, Archaea, formerly known as Archaebacteria, are classified with bacteria.	C12N9/52	C12N9/52		1698
C12N9/54	12	bacteria being Bacillus	C12N9/54	C12N9/54		1653
C12N9/58	11	derived from fungi	C12N9/58	C12N9/58		462
C12N9/60	12	from yeast	C12N9/60	C12N9/60		230
C12N9/62	12	from Aspergillus	C12N9/62	C12N9/62		290
C12N9/63	11	{derived from plants}	C12N9/50	C12N9/63		518
C12N9/64	11	derived from animal tissue	C12N9/64	C12N9/64		316
C12N9/6402	12	{from non-mammals}	C12N9/64	C12N9/64		62
C12N9/6405	13	{not being snakes}	C12N9/64	C12N9/64		61
C12N9/6408	14	{Serine endopeptidases (3.4.21)}	C12N9/64	C12N9/64		238
C12N9/641	14	{Cysteine endopeptidases (3.4.22)}	C12N9/64	C12N9/64		162
C12N9/6413	14	{Aspartic endopeptidases (3.4.23)}	C12N9/64	C12N9/64		32
C12N9/6416	14	{Metalloendopeptidases (3.4.24)}	C12N9/64	C12N9/64		105
C12N9/6418	13	{from snakes}	C12N9/64	C12N9/64		120
C12N9/6421	12	{from mammals}	C12N9/64	C12N9/64		356
C12N9/6424	13	{Serine endopeptidases (3.4.21)}	C12N9/64	C12N9/64		824
C12N9/6427	14	{Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}	C12N9/76	C12N9/64		463
C12N9/6429	14	{Thrombin (3.4.21.5)}	C12N9/74	C12N9/64		350
C12N9/6432	14	{Coagulation factor Xa (3.4.21.6)}	C12N9/64	C12N9/64		180
C12N9/6435	14	{Plasmin (3.4.21.7), i.e. fibrinolysin}	C12N9/68	C12N9/64		281
C12N9/6437	14	{Coagulation factor VIIa (3.4.21.21)}	C12N9/64	C12N9/64		267
C12N9/644	14	{Coagulation factor IXa (3.4.21.22)}	C12N9/64	C12N9/64		389
C12N9/6443	14	{Coagulation factor XIa (3.4.21.27)}	C12N9/64	C12N9/64		28
C12N9/6445	14	{Kallikreins (3.4.21.34; 3.4.21.35)}	C12N9/64	C12N9/64		244
C12N9/6448	14	{Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}	C12N9/64	C12N9/64		93
C12N9/6451	14	{Coagulation factor XIIa (3.4.21.38)}	C12N9/64	C12N9/64		22
C12N9/6454	14	{Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}	C12N9/64	C12N9/64		135
C12N9/6456	14	{Plasminogen activators}	C12N9/72	C12N9/64		182
C12N9/6459	15	{t-plasminogen activator (3.4.21.68), i.e. tPA}	C12N9/72	C12N9/64		514
C12N9/6462	15	{u-Plasminogen activator (3.4.21.73), i.e. urokinase}	C12N9/72	C12N9/64		364
C12N9/6464	14	{Protein C (3.4.21.69)}	C12N9/64	C12N9/64		153
C12N9/6467	14	{Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}	C12N9/64	C12N9/64		70
C12N9/647	14	{Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups}	C12N9/64	C12N9/64		165
C12N9/6472	13	{Cysteine endopeptidases (3.4.22)}	C12N9/64	C12N9/64		434
C12N9/6475	14	{Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}	C12N9/64	C12N9/64		194
C12N9/6478	13	{Aspartic endopeptidases (3.4.23)}	C12N9/64	C12N9/64		159
C12N9/6481	14	{Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}	C12N9/64	C12N9/64		257
C12N9/6483	14	{Chymosin (3.4.23.4), i.e. rennin}	C12N9/64	C12N9/64		104
C12N9/6486	14	{Renin (3.4.23.15)}	C12N9/64	C12N9/64		13
C12N9/6489	13	{Metalloendopeptidases (3.4.24)}	C12N9/64	C12N9/64		455
C12N9/6491	14	{Matrix metalloproteases [MMP&apos;s], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}	C12N9/64	C12N9/64		320
C12N9/6494	14	{Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}	C12N9/64	C12N9/64		39
C12N9/6497	14	{Endothelin-converting enzyme (3.4.24.71)}	C12N9/64	C12N9/64		25
C12N9/78	9	acting on carbon to nitrogen bonds other than peptide bonds (3.5)	C12N9/78	C12N9/78		1972
C12N9/80	10	acting on amide bonds in linear amides {(3.5.1)}	C12N9/80	C12N9/80		1598
C12N9/82	11	Asparaginase {(3.5.1.1)}	C12N9/82	C12N9/82		255
C12N9/84	11	Penicillin amidase {(3.5.1.11)}	C12N9/84	C12N9/84		189
C12N9/86	10	acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}	C12N9/86	C12N9/86		449
C12N9/88	8	Lyases (4.)	C12N9/88	C12N9/88		9143
C12N9/90	8	Isomerases (5.)	C12N9/90	C12N9/90		3881
C12N9/92	9	Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}	C12N9/92	C12N9/92		577
C12N9/93	8	{Ligases (6)}	C12N9/00	C12N9/93		3861
C12N9/94	8	Pancreatin	C12N9/94	C12N9/94		128
C12N9/96	8	Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates	C12N9/96	C12N9/96		2311
C12N9/98	8	Preparation of granular or free-flowing enzyme compositions (C12N9/96 takes precedence)	C12N9/98	C12N9/98		188
C12N9/99	8	Enzyme inactivation by chemical treatment	C12N9/99	C12N9/99		456
C12N11/00	7	Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof	C12N11/00	C12N11/00		683
C12N11/02	8	Enzymes or microbial cells immobilised on or in an organic carrier	C12N11/02	C12N11/02		1391
C12N11/04	9	entrapped within the carrier, e.g. gel or hollow fibres	C12N11/04	C12N11/04		2104
C12N11/06	9	attached to the carrier via a bridging agent	C12N11/06	C12N11/06		390
C12N11/08	9	the carrier being a synthetic polymer	C12N11/08	C12N11/08		887
C12N11/082	10	obtained by reactions only involving carbon-to-carbon unsaturated bonds	C12N11/082	C12N11/082		633
C12N11/084	11	Polymers containing vinyl alcohol units	C12N11/084	C12N11/084		314
C12N11/087	11	Acrylic polymers	C12N11/087	C12N11/087		622
C12N11/089	10	obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds	C12N11/089	C12N11/089		805
C12N11/091	11	Phenol resins; Amino resins	C12N11/091	C12N11/091		166
C12N11/093	11	Polyurethanes	C12N11/093	C12N11/093		195
C12N11/096	11	Polyesters; Polyamides	C12N11/096	C12N11/096		256
C12N11/098	10	formed in the presence of the enzymes or microbial cells	C12N11/098	C12N11/098		178
C12N11/10	9	the carrier being a carbohydrate	C12N11/10	C12N11/10		2227
C12N11/12	10	Cellulose or derivatives thereof	C12N11/12	C12N11/12		618
C12N11/14	8	Enzymes or microbial cells immobilised on or in an inorganic carrier	C12N11/14	C12N11/14		3485
C12N11/16	8	Enzymes or microbial cells immobilised on or in a biological cell	C12N11/16	C12N11/16		170
C12N11/18	8	Multi-enzyme systems	C12N11/18	C12N11/18		320
C12N13/00	7	Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves	C12N13/00	C12N13/00		4274
C12N15/00	7	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per seC12N1/00, C12N5/00, C12N7/00; new plants per seA01H; plant reproduction by tissue culture techniques A01H4/00; new animals per seA01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)	C12N15/00	C12N15/00		2163
C12N15/01	8	Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor	C12N15/01	C12N15/01		1585
C12N15/02	8	Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K16/00; apparatus for cell fusion C12M)}	C12N15/02	C12N15/02		244
C12N15/03	9	Bacteria	C12N15/03	C12N15/03		179
C12N15/04	9	Fungi	C12N15/04	C12N15/04		162
C12N15/09	8	Recombinant DNA-technology	C12N15/09	C12N15/09		3078
C12N15/10	9	Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)<br><br><u>NOTE</u><br><br>In groups C12N15/10 - C12N15/1096, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N.	C12N15/10	C12N15/10		3732
C12N15/1003	10	{Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}	C12N15/10	C12N15/10		3368
C12N15/1006	11	{by means of a solid support carrier, e.g. particles, polymers}	C12N15/10	C12N15/10		1314
C12N15/101	12	{by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}	C12N15/10	C12N15/10		955
C12N15/1013	12	{by using magnetic beads}	C12N15/10	C12N15/10		2157
C12N15/1017	11	{by filtration, e.g. using filters, frits, membranes}	C12N15/10	C12N15/10		874
C12N15/102	10	{Mutagenizing nucleic acids}	C12N15/10	C12N15/10		3472
C12N15/1024	11	{In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}	C12N15/10	C12N15/10		188
C12N15/1027	11	{by DNA shuffling, e.g. RSR, STEP, RPR}	C12N15/10	C12N15/10		349
C12N15/1031	11	{mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}	C12N15/10	C12N15/10		405
C12N15/1034	10	{Isolating an individual clone by screening libraries}	C12N15/10	C12N15/10		958
C12N15/1037	11	{Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}	C12N15/10	C12N15/10		1472
C12N15/1041	11	{Ribosome/Polysome display, e.g. SPERT, ARM}	C12N15/10	C12N15/10		89
C12N15/1044	11	{Preparation or screening of libraries displayed on scaffold proteins}	C12N15/10	C12N15/10		129
C12N15/1048	11	{SELEX}	C12N15/10	C12N15/10		627
C12N15/1051	11	{Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}	C12N15/10	C12N15/10		182
C12N15/1055	11	{Protein x Protein interaction, e.g. two hybrid selection}	C12N15/10	C12N15/10		494
C12N15/1058	11	{Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}	C12N15/10	C12N15/10		541
C12N15/1062	11	{mRNA-Display, e.g. polypeptide and encoding template are connected covalently}	C12N15/10	C12N15/10		185
C12N15/1065	11	{Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}	C12N15/10	C12N15/10		1087
C12N15/1068	11	{Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}	C12N15/10	C12N15/10		395
C12N15/1072	11	{Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}	C12N15/10	C12N15/10		243
C12N15/1075	11	{by coupling phenotype to genotype, not provided for in other groups of this subclass}	C12N15/10	C12N15/10		331
C12N15/1079	11	{Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N15/1086)}	C12N15/10	C12N15/10		359
C12N15/1082	11	{Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}	C12N15/10	C12N15/10		529
C12N15/1086	11	{Preparation or screening of expression libraries, e.g. reporter assays}	C12N15/10	C12N15/10		742
C12N15/1089	11	{Design, preparation, screening or analysis of libraries using computer algorithms}	C12N15/10	C12N15/10		334
C12N15/1093	11	{General methods of preparing gene libraries, not provided for in other subgroups}	C12N15/10	C12N15/10		1681
C12N15/1096	10	{cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}	C12N15/10	C12N15/10		1262
C12N15/11	9	DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}<br><br><u>NOTE</u><br><br>Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N9/00 according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups C12N15/11 - C12N15/117 cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The C12N2300/00 indexing scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group C12N15/111.	C12N15/11	C12N15/11		8431
C12N15/111	10	{General methods applicable to biologically active non-coding nucleic acids}	C12N15/11	C12N15/11		4698
C12N15/113	10	Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}	C12N15/113	C12N15/113		22697
C12N15/1131	11	{against viruses}	C12N15/113	C12N15/113		1396
C12N15/1132	12	{against retroviridae, e.g. HIV}	C12N15/113	C12N15/113		452
C12N15/1133	12	{against herpetoviridae, e.g. HSV}	C12N15/113	C12N15/113		173
C12N15/1135	11	{against oncogenes or tumor suppressor genes}	C12N15/113	C12N15/113		1986
C12N15/1136	11	{against growth factors, growth regulators, cytokines, lymphokines or hormones}	C12N15/113	C12N15/113		1447
C12N15/1137	11	{against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}	C12N15/113	C12N15/113		5526
C12N15/1138	11	{against receptors or cell surface proteins}	C12N15/113	C12N15/113		3969
C12N15/115	10	Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}<br><br><u>NOTE</u><br><br> Aptamers fused to compounds which are already classified in groups C12N15/11&#160;-&#160;C12N15/117, are classified with the corresponding compound 	C12N15/115	C12N15/115		3843
C12N15/117	10	Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs	C12N15/117	C12N15/117		709
C12N15/52	10	Genes encoding for enzymes or proenzymes<br><br><u>NOTE</u><br><br>In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.	C12N15/52	C12N15/52		7724
C12N15/62	10	DNA sequences coding for fusion proteins<br><br><u>NOTE</u><br><br> In this group, the following term is used with the meaning indicated: <br>"fusion" means the fusion of two different proteins.	C12N15/62	C12N15/62		6030
C12N15/625	11	{containing a sequence coding for a signal sequence}	C12N15/62	C12N15/62		840
C12N15/63	9	Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression	C12N15/63	C12N15/63		7625
C12N15/635	10	{Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}	C12N15/63	C12N15/63		666
C12N15/64	10	General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host<br><br><u>NOTE</u><br><br>In the group C12N15/64, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N	C12N15/64	C12N15/64		1378
C12N15/65	10	using markers (enzymes used as markers C12N15/52)<br><br><u>NOTE</u><br><br>In the group C12N15/65, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N	C12N15/65	C12N15/65		3190
C12N15/66	10	General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease<br><br><u>NOTE</u><br><br> In this group, the following expression is used with the meaning indicated: <br>"non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.<br>In the group C12N15/66, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N	C12N15/66	C12N15/66		3525
C12N15/67	10	General methods for enhancing the expression	C12N15/67	C12N15/67		2732
C12N15/68	11	Stabilisation of the vector	C12N15/68	C12N15/68		200
C12N15/69	11	Increasing the copy number of the vector	C12N15/69	C12N15/69		230
C12N15/70	10	Vectors or expression systems specially adapted for E. coli<br><br><u>NOTE</u><br><br>This group covers the use of E. coli as host.<br>Shuttle vectors also replicating in E. coli are classified according to the other host.	C12N15/70	C12N15/70		20529
C12N15/71	11	Expression systems using regulatory sequences derived from the trp-operon	C12N15/71	C12N15/71		123
C12N15/72	11	Expression systems using regulatory sequences derived from the lac-operon	C12N15/72	C12N15/72		216
C12N15/73	11	Expression systems using phage (lambda) regulatory sequences	C12N15/73	C12N15/73		199
C12N15/74	10	Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora<br><br><u>NOTE</u><br><br>This group covers the use of prokaryotes as hosts.	C12N15/74	C12N15/74		4746
C12N15/743	11	{for Agrobacterium; Rhizobium; Bradyrhizobium}	C12N15/74	C12N15/74		264
C12N15/746	11	{for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}	C12N15/74	C12N15/74		773
C12N15/75	11	for Bacillus	C12N15/75	C12N15/75		2335
C12N15/76	11	for Actinomyces; for Streptomyces	C12N15/76	C12N15/76		726
C12N15/77	11	for Corynebacterium; for Brevibacterium	C12N15/77	C12N15/77		1617
C12N15/78	11	for Pseudomonas	C12N15/78	C12N15/78		518
C12N15/79	10	Vectors or expression systems specially adapted for eukaryotic hosts<br><br><u>NOTE</u><br><br>This group covers the use of eukaryotes as hosts.	C12N15/79	C12N15/79		1103
C12N15/80	11	for fungi	C12N15/80	C12N15/80		2366
C12N15/81	12	for yeasts	C12N15/81	C12N15/81		4791
C12N15/815	13	{for yeasts other than Saccharomyces}	C12N15/81	C12N15/81		3975
C12N15/82	11	for plant cells {, e.g. plant artificial chromosomes (PACs)}<br><br><u>WARNING</u><br>Documents are being continuously reclassified into this new classification scheme. See Warning notes below	C12N15/82	C12N15/82		1245
C12N15/8201	12	{Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}	C12N15/82	C12N15/82		656
C12N15/8202	13	{by biological means, e.g. cell mediated or natural vector}	C12N15/82	C12N15/82		261
C12N15/8203	14	{Virus mediated transformation}	C12N15/82	C12N15/82		459
C12N15/8205	14	{Agrobacterium mediated transformation}	C12N15/82	C12N15/82		5929
C12N15/8206	13	{by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}	C12N15/82	C12N15/82		398
C12N15/8207	14	{by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}	C12N15/82	C12N15/82		434
C12N15/8209	13	{Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}<br><br><u>NOTE</u><br><br>Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N15/8209.	C12N15/82	C12N15/82		673
C12N15/821	14	{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}	C12N15/82	C12N15/82		165
C12N15/8212	15	{Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid}	C12N15/82	C12N15/82		606
C12N15/8213	13	{Targeted insertion of genes into the plant genome by homologous recombination}	C12N15/82	C12N15/82		1489
C12N15/8214	13	{Plastid transformation}	C12N15/82	C12N15/82		375
C12N15/8216	12	{Methods for controlling, regulating or enhancing expression of transgenes in plant cells}	C12N15/82	C12N15/82		2293
C12N15/8217	13	{Gene switch}	C12N15/82	C12N15/82		179
C12N15/8218	13	{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}	C12N15/82	C12N15/82		4730
C12N15/822	13	{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}	C12N15/82	C12N15/82		35
C12N15/8221	13	{Transit peptides}	C12N15/82	C12N15/82		137
C12N15/8222	13	{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}	C12N15/82	C12N15/82		736
C12N15/8223	14	{Vegetative tissue-specific promoters}	C12N15/82	C12N15/82		343
C12N15/8225	15	{Leaf-specific, e.g. including petioles, stomata}	C12N15/82	C12N15/82		284
C12N15/8226	15	{Stem-specific, e.g. including tubers, beets}	C12N15/82	C12N15/82		159
C12N15/8227	15	{Root-specific}	C12N15/82	C12N15/82		440
C12N15/8229	15	{Meristem-specific, e.g. nodal, apical}	C12N15/82	C12N15/82		103
C12N15/823	14	{Reproductive tissue-specific promoters}	C12N15/82	C12N15/82		160
C12N15/8231	15	{Male-specific, e.g. anther, tapetum, pollen}	C12N15/82	C12N15/82		273
C12N15/8233	15	{Female-specific, e.g. pistil, ovule}	C12N15/82	C12N15/82		146
C12N15/8234	15	{Seed-specific, e.g. embryo, endosperm}	C12N15/82	C12N15/82		643
C12N15/8235	15	{Fruit-specific}	C12N15/82	C12N15/82		133
C12N15/8237	13	{Externally regulated expression systems}	C12N15/82	C12N15/82		520
C12N15/8238	14	{chemically inducible, e.g. tetracycline}	C12N15/82	C12N15/82		385
C12N15/8239	14	{pathogen inducible}	C12N15/82	C12N15/82		193
C12N15/8241	12	{Phenotypically and genetically modified plants via recombinant DNA technology}	C12N15/82	C12N15/82		1407
C12N15/8242	13	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}	C12N15/82	C12N15/82		762
C12N15/8243	14	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}	C12N15/82	C12N15/82		3546
C12N15/8245	15	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}	C12N15/82	C12N15/82		2452
C12N15/8246	16	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}	C12N15/82	C12N15/82		508
C12N15/8247	15	{involving modified lipid metabolism, e.g. seed oil composition}	C12N15/82	C12N15/82		2625
C12N15/8249	15	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}	C12N15/82	C12N15/82		380
C12N15/825	15	{involving pigment biosynthesis}<br><br><u>NOTE</u><br><br>Transgenic plants with altered flower morphology are also classified in this group.	C12N15/82	C12N15/82		1327
C12N15/8251	15	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}	C12N15/82	C12N15/82		1635
C12N15/8253	16	{Methionine or cysteine}	C12N15/82	C12N15/82		140
C12N15/8254	16	{Tryptophan or lysine}	C12N15/82	C12N15/82		154
C12N15/8255	15	{involving lignin biosynthesis}	C12N15/82	C12N15/82		394
C12N15/8257	14	{for the production of primary gene products, e.g. pharmaceutical products, interferon}	C12N15/82	C12N15/82		1484
C12N15/8258	15	{for the production of oral vaccines (antigens) or immunoglobulins}	C12N15/82	C12N15/82		544
C12N15/8259	14	{Phytoremediation}	C12N15/82	C12N15/82		135
C12N15/8261	13	{with agronomic (input) traits, e.g. crop yield}	C12N15/82	C12N15/82		6898
C12N15/8262	14	{involving plant development}	C12N15/82	C12N15/82		296
C12N15/8263	15	{Ablation; Apoptosis}	C12N15/82	C12N15/82		96
C12N15/8265	15	{Transgene containment, e.g. gene dispersal}	C12N15/82	C12N15/82		78
C12N15/8266	15	{Abscission; Dehiscence; Senescence}	C12N15/82	C12N15/82		260
C12N15/8267	15	{Seed dormancy, germination or sprouting}	C12N15/82	C12N15/82		378
C12N15/8269	15	{Photosynthesis}	C12N15/82	C12N15/82		437
C12N15/827	15	{Flower development or morphology, e.g. flowering promoting factor [FPF]}	C12N15/82	C12N15/82		1331
C12N15/8271	14	{for stress resistance, e.g. heavy metal resistance}	C12N15/82	C12N15/82		3066
C12N15/8273	15	{for drought, cold, salt resistance}	C12N15/82	C12N15/82		4648
C12N15/8274	15	{for herbicide resistance}	C12N15/82	C12N15/82		2539
C12N15/8275	16	{Glyphosate}	C12N15/82	C12N15/82		1329
C12N15/8277	16	{Phosphinotricin}	C12N15/82	C12N15/82		388
C12N15/8278	16	{Sulfonylurea}	C12N15/82	C12N15/82		594
C12N15/8279	15	{for biotic stress resistance, pathogen resistance, disease resistance}	C12N15/82	C12N15/82		1988
C12N15/8281	16	{for bacterial resistance}	C12N15/82	C12N15/82		991
C12N15/8282	16	{for fungal resistance}	C12N15/82	C12N15/82		2753
C12N15/8283	16	{for virus resistance}	C12N15/82	C12N15/82		1024
C12N15/8285	16	{for nematode resistance}	C12N15/82	C12N15/82		511
C12N15/8286	16	{for insect resistance}	C12N15/82	C12N15/82		3040
C12N15/8287	14	{for fertility modification, e.g. apomixis}	C12N15/82	C12N15/82		433
C12N15/8289	15	{Male sterility}	C12N15/82	C12N15/82		1947
C12N15/829	15	{Female sterility}	C12N15/82	C12N15/82		93
C12N15/8291	14	{Hormone-influenced development}	C12N15/82	C12N15/82		95
C12N15/8293	15	{Abscisic acid [ABA]}	C12N15/82	C12N15/82		168
C12N15/8294	15	{Auxins}	C12N15/82	C12N15/82		115
C12N15/8295	15	{Cytokinins}	C12N15/82	C12N15/82		96
C12N15/8297	15	{Gibberellins; GA3}	C12N15/82	C12N15/82		122
C12N15/8298	15	{Brassinosteroids}	C12N15/82	C12N15/82		56
C12N15/85	11	for animal cells	C12N15/85	C12N15/85		14192
C12N15/8509	12	{for producing genetically modified animals, e.g. transgenic}<br><br><u>NOTE</u><br><br>Additional aspects of the modified animals are classified in the groups A01K2207/00 - A01K2267/00.	C12N15/85	C12N15/85		5478
C12N2015/8518	13	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}	C12N15/85	C12N15/85		336
C12N2015/8527	13	{for producing animal models, e.g. for tests or diseases}	C12N15/85	C12N15/85		191
C12N2015/8536	14	{Animal models for genetic diseases}	C12N15/85	C12N15/85		76
C12N2015/8545	15	{for Alzheimer&apos;&apos;s disease}	C12N15/85	C12N15/85		13
C12N2015/8554	16	{Invertebrates models for Alzheimer&apos;&apos;s disease}	C12N15/85	C12N15/85		
C12N2015/8563	15	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}	C12N15/85	C12N15/85		13
C12N2015/8572	14	{Animal models for proliferative diseases, e.g. comprising an oncogene}	C12N15/85	C12N15/85		60
C12N2015/8581	14	{Animal models for infectious diseases, e.g. AIDS}	C12N15/85	C12N15/85		17
C12N2015/859	14	{Animal models comprising reporter system for screening tests}	C12N15/85	C12N15/85		60
C12N15/86	12	Viral vectors<br><br><u>WARNING</u><br> From 2012-03-15 groups C12N15/861 - C12N15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N2710/00-C12N2795/00	C12N15/86	C12N15/86		21667
C12N15/861	13	Adenoviral vectors	C12N15/861	C12N15/861		437
C12N15/8613	14	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}	C12N15/861	C12N15/861		18
C12N15/8616	14	{Special methods for targeting systems}	C12N15/861	C12N15/861		21
C12N15/863	13	Poxviral vectors, {e.g. entomopoxvirus}	C12N15/863	C12N15/863		56
C12N15/8633	14	{Avian poxviral vectors}	C12N15/863	C12N15/863		3
C12N15/8636	14	{Vaccina virus vectors}	C12N15/863	C12N15/863		21
C12N15/864	13	Parvoviral vectors {, e.g. parvovirus, densovirus}	C12N15/864	C12N15/864		185
C12N15/8645	14	{Adeno-associated virus}	C12N15/864	C12N15/864		150
C12N15/866	13	Baculoviral vectors	C12N15/866	C12N15/866		109
C12N15/867	13	Retroviral vectors	C12N15/867	C12N15/867		520
C12N15/8673	14	{Special methods for packaging systems}	C12N15/867	C12N15/867		8
C12N15/8676	14	{Special methods for targeting systems}	C12N15/867	C12N15/867		6
C12N15/869	13	Herpesviral vectors	C12N15/869	C12N15/869		51
C12N15/8695	14	{Herpes simplex virus-based vectors}	C12N15/869	C12N15/869		20
C12N15/87	9	Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation	C12N15/87	C12N15/87		4101
C12N15/873	10	Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos	C12N15/873	C12N15/873		439
C12N15/877	11	Techniques for producing new mammalian cloned embryos	C12N15/877	C12N15/877		112
C12N15/8771	12	{Bovine embryos}	C12N15/877	C12N15/877		106
C12N15/8772	12	{Caprine embryos}	C12N15/877	C12N15/877		26
C12N15/8773	12	{Ovine embryos}	C12N15/877	C12N15/877		13
C12N15/8775	12	{Murine embryos}	C12N15/877	C12N15/877		115
C12N15/8776	12	{Primate embryos}	C12N15/877	C12N15/877		32
C12N15/8777	12	{Rabbit embryos}	C12N15/877	C12N15/877		11
C12N15/8778	12	{Swine embryos}	C12N15/877	C12N15/877		201
C12N15/88	10	using microencapsulation, e.g. using {amphiphile} liposome vesicle	C12N15/88	C12N15/88		2952
C12N15/89	10	using microinjection	C12N15/89	C12N15/89		1137
C12N15/895	11	{using biolistic methods}	C12N15/89	C12N15/89		100
C12N15/90	10	Stable introduction of foreign DNA into chromosome	C12N15/90	C12N15/90		1896
C12N15/902	11	{using homologous recombination}	C12N15/90	C12N15/90		1685
C12N15/905	12	{in yeast}	C12N15/90	C12N15/90		396
C12N15/907	12	{in mammalian cells}	C12N15/90	C12N15/90		3981
C12N2300/00	7	Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids<br><br><u>NOTE</u><br><br>Indexing codes of group C12N2300/00 are only used in combination with groups C12N15/11 - C12N15/117. An exception is made for C12N2310/20, which may be applied to CRISPR with any appropriate C12N main trunk symbol.	CPCONLY	C12N2300/00		5
C12N2310/00	7	Structure or type of the nucleic acid<br><br><u>NOTE</u><br><br>In groups C12N2310/00 - C12N2310/533, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N.	CPCONLY	C12N2310/00		27
C12N2310/10	8	Type of nucleic acid	CPCONLY	C12N2310/10		1070
C12N2310/11	9	Antisense	CPCONLY	C12N2310/11		4865
C12N2310/111	10	spanning the whole gene, or a large part of it	CPCONLY	C12N2310/111		1541
C12N2310/113	10	targeting other non-coding nucleic acids, e.g. antagomirs	CPCONLY	C12N2310/113		1201
C12N2310/12	9	catalytic nucleic acids, e.g. ribozymes	CPCONLY	C12N2310/12		608
C12N2310/121	10	Hammerhead	CPCONLY	C12N2310/121		501
C12N2310/122	10	Hairpin	CPCONLY	C12N2310/122		410
C12N2310/123	10	Hepatitis delta	CPCONLY	C12N2310/123		76
C12N2310/124	10	based on group I or II introns	CPCONLY	C12N2310/124		65
C12N2310/1241	11	Tetrahymena	CPCONLY	C12N2310/1241		53
C12N2310/126	10	involving RNAse P	CPCONLY	C12N2310/126		68
C12N2310/127	10	DNAzymes	CPCONLY	C12N2310/127		190
C12N2310/128	10	processing or releasing ribozyme	CPCONLY	C12N2310/128		38
C12N2310/13	9	Decoys	CPCONLY	C12N2310/13		391
C12N2310/14	9	interfering nucleic acids [NA]	CPCONLY	C12N2310/14		11737
C12N2310/141	10	MicroRNAs, miRNAs	CPCONLY	C12N2310/141		3999
C12N2310/15	9	Nucleic acids forming more than 2 strands, e.g. TFOs	CPCONLY	C12N2310/15		204
C12N2310/151	10	more than 3 strands, e.g. tetrads, H-DNA	CPCONLY	C12N2310/151		77
C12N2310/152	10	on a single-stranded target, e.g. fold-back TFOs	CPCONLY	C12N2310/152		66
C12N2310/153	10	with the aid of a protein, e.g. recombinase	CPCONLY	C12N2310/153		12
C12N2310/16	9	Aptamers	CPCONLY	C12N2310/16		3398
C12N2310/17	9	Immunomodulatory nucleic acids	CPCONLY	C12N2310/17		561
C12N2310/18	9	acting by a non-sequence specific mechanism	CPCONLY	C12N2310/18		175
C12N2310/20	9	involving clustered regularly interspaced short palindromic repeats [CRISPR]<br><br><u>WARNING</u><br>Group C12N2310/20 is impacted by reclassification into groups C12N9/22, C12N9/222, C12N9/224 and C12N9/226. <br>All groups listed in this Warning should be considered in order to perform a complete search.	CPCONLY	C12N2310/20		10632
C12N2310/30	8	Chemical structure	CPCONLY	C12N2310/30		26
C12N2310/31	9	of the backbone	CPCONLY	C12N2310/31		253
C12N2310/311	10	Phosphotriesters	CPCONLY	C12N2310/311		55
C12N2310/312	10	Phosphonates	CPCONLY	C12N2310/312		229
C12N2310/3125	11	Methylphosphonates	CPCONLY	C12N2310/3125		291
C12N2310/313	10	Phosphorodithioates	CPCONLY	C12N2310/313		198
C12N2310/314	10	Phosphoramidates	CPCONLY	C12N2310/314		363
C12N2310/3145	11	with the nitrogen in 3&apos; or 5&apos;-position	CPCONLY	C12N2310/3145		100
C12N2310/315	10	Phosphorothioates	CPCONLY	C12N2310/315		5239
C12N2310/316	10	Phosphonothioates	CPCONLY	C12N2310/316		79
C12N2310/317	10	with an inverted bond, e.g. a cap structure	CPCONLY	C12N2310/317		630
C12N2310/318	10	where the PO2 is completely replaced, e.g. MMI or formacetal	CPCONLY	C12N2310/318		326
C12N2310/3181	11	Peptide nucleic acid, PNA	CPCONLY	C12N2310/3181		400
C12N2310/3183	11	Diol linkers, e.g. glycols or propanediols	CPCONLY	C12N2310/3183		154
C12N2310/319	10	linked by 2&apos;-5&apos; linkages, i.e. having a free 3&apos;-position	CPCONLY	C12N2310/319		66
C12N2310/32	9	of the sugar	CPCONLY	C12N2310/32		361
C12N2310/321	10	2&apos;-O-R Modification	CPCONLY	C12N2310/321		4628
C12N2310/322	10	2&apos;-R Modification	CPCONLY	C12N2310/322		2581
C12N2310/323	10	modified ring structure	CPCONLY	C12N2310/323		156
C12N2310/3231	11	having an additional ring, e.g. LNA, ENA	CPCONLY	C12N2310/3231		1519
C12N2310/3233	11	Morpholino-type ring	CPCONLY	C12N2310/3233		636
C12N2310/3235	11	having the O of the ribose replaced by another atom	CPCONLY	C12N2310/3235		22
C12N2310/33	9	of the base	CPCONLY	C12N2310/33		382
C12N2310/331	10	Universal or degenerate base	CPCONLY	C12N2310/331		65
C12N2310/332	10	Abasic residue	CPCONLY	C12N2310/332		357
C12N2310/333	10	Modified A	CPCONLY	C12N2310/333		194
C12N2310/334	10	Modified C	CPCONLY	C12N2310/334		248
C12N2310/3341	11	5-Methylcytosine	CPCONLY	C12N2310/3341		1426
C12N2310/335	10	Modified T or U	CPCONLY	C12N2310/335		445
C12N2310/336	10	Modified G	CPCONLY	C12N2310/336		202
C12N2310/337	10	in alpha-anomeric form	CPCONLY	C12N2310/337		12
C12N2310/34	9	Spatial arrangement of the modifications	CPCONLY	C12N2310/34		36
C12N2310/341	10	Gapmers, i.e. of the type ===---===	CPCONLY	C12N2310/341		1648
C12N2310/342	10	Hemimers, i.e. of the type ====----	CPCONLY	C12N2310/342		13
C12N2310/343	10	having patterns, e.g. ==--==--==--	CPCONLY	C12N2310/343		325
C12N2310/344	10	Position-specific modifications, e.g. on every purine, at the 3&apos;-end	CPCONLY	C12N2310/344		592
C12N2310/345	10	having at least two different backbone modifications	CPCONLY	C12N2310/345		253
C12N2310/346	10	having a combination of backbone and sugar modifications	CPCONLY	C12N2310/346		1771
C12N2310/35	9	Nature of the modification	CPCONLY	C12N2310/35		23
C12N2310/351	10	Conjugate	CPCONLY	C12N2310/351		1508
C12N2310/3511	11	intercalating or cleaving agent	CPCONLY	C12N2310/3511		107
C12N2310/3513	11	Protein; Peptide	CPCONLY	C12N2310/3513		866
C12N2310/3515	11	Lipophilic moiety, e.g. cholesterol	CPCONLY	C12N2310/3515		965
C12N2310/3517	11	Marker; Tag	CPCONLY	C12N2310/3517		424
C12N2310/3519	11	Fusion with another nucleic acid	CPCONLY	C12N2310/3519		850
C12N2310/352	10	linked to the nucleic acid via a carbon atom	CPCONLY	C12N2310/352		43
C12N2310/3521	11	Methyl	CPCONLY	C12N2310/3521		2836
C12N2310/3523	11	Allyl	CPCONLY	C12N2310/3523		103
C12N2310/3525	11	MOE, methoxyethoxy	CPCONLY	C12N2310/3525		1479
C12N2310/3527	11	Other alkyl chain	CPCONLY	C12N2310/3527		281
C12N2310/3529	11	Aromatic substituent	CPCONLY	C12N2310/3529		20
C12N2310/353	10	linked to the nucleic acid via an atom other than carbon	CPCONLY	C12N2310/353		35
C12N2310/3531	11	Hydrogen	CPCONLY	C12N2310/3531		166
C12N2310/3533	11	Halogen	CPCONLY	C12N2310/3533		1428
C12N2310/3535	11	Nitrogen	CPCONLY	C12N2310/3535		97
C12N2310/50	8	Physical structure	CPCONLY	C12N2310/50		68
C12N2310/51	9	in polymeric form, e.g. multimers, concatemers	CPCONLY	C12N2310/51		365
C12N2310/52	9	branched	CPCONLY	C12N2310/52		101
C12N2310/53	9	partially self-complementary or closed	CPCONLY	C12N2310/53		1018
C12N2310/531	10	Stem-loop; Hairpin	CPCONLY	C12N2310/531		2810
C12N2310/532	10	Closed or circular	CPCONLY	C12N2310/532		587
C12N2310/533	10	having a mismatch or nick in at least one of the strands	CPCONLY	C12N2310/533		161
C12N2320/00	7	Applications; Uses	CPCONLY	C12N2320/00		44
C12N2320/10	8	in screening processes	CPCONLY	C12N2320/10		478
C12N2320/11	9	for the determination of target sites, i.e. of active nucleic acids	CPCONLY	C12N2320/11		734
C12N2320/12	9	in functional genomics, i.e. for the determination of gene function	CPCONLY	C12N2320/12		347
C12N2320/13	9	in a process of directed evolution, e.g. SELEX, acquiring a new function	CPCONLY	C12N2320/13		267
C12N2320/30	8	Special therapeutic applications	CPCONLY	C12N2320/30		1708
C12N2320/31	9	Combination therapy	CPCONLY	C12N2320/31		1491
C12N2320/32	9	Special delivery means, e.g. tissue-specific	CPCONLY	C12N2320/32		3099
C12N2320/33	9	Alteration of splicing	CPCONLY	C12N2320/33		790
C12N2320/34	9	Allele or polymorphism specific uses	CPCONLY	C12N2320/34		458
C12N2320/35	9	based on a specific dosage / administration regimen	CPCONLY	C12N2320/35		192
C12N2320/50	8	Methods for regulating/modulating their activity	CPCONLY	C12N2320/50		367
C12N2320/51	9	modulating the chemical stability, e.g. nuclease-resistance	CPCONLY	C12N2320/51		430
C12N2320/52	9	modulating the physical stability, e.g. GC-content	CPCONLY	C12N2320/52		99
C12N2320/53	9	reducing unwanted side-effects	CPCONLY	C12N2320/53		187
C12N2330/00	7	Production	CPCONLY	C12N2330/00		38
C12N2330/10	8	naturally occurring	CPCONLY	C12N2330/10		326
C12N2330/30	8	chemically synthesised	CPCONLY	C12N2330/30		552
C12N2330/31	9	Libraries, arrays	CPCONLY	C12N2330/31		378
C12N2330/50	8	Biochemical production, i.e. in a transformed host cell	CPCONLY	C12N2330/50		284
C12N2330/51	9	Specially adapted vectors	CPCONLY	C12N2330/51		626
C12N2500/00	7	Specific components of cell culture medium	CPCONLY	C12N2500/00		78
C12N2500/02	8	Atmosphere, e.g. low oxygen conditions	CPCONLY	C12N2500/02		1064
C12N2500/05	8	Inorganic components	CPCONLY	C12N2500/05		679
C12N2500/10	9	Metals; Metal chelators	CPCONLY	C12N2500/10		234
C12N2500/12	10	Light metals, i.e. alkali, alkaline earth, Be, Al, Mg	CPCONLY	C12N2500/12		969
C12N2500/14	11	Calcium; Ca chelators; Calcitonin	CPCONLY	C12N2500/14		740
C12N2500/16	11	Magnesium; Mg chelators	CPCONLY	C12N2500/16		464
C12N2500/20	10	Transition metals	CPCONLY	C12N2500/20		396
C12N2500/22	11	Zinc; Zn chelators	CPCONLY	C12N2500/22		323
C12N2500/24	11	Iron; Fe chelators; Transferrin	CPCONLY	C12N2500/24		818
C12N2500/25	12	Insulin-transferrin; Insulin-transferrin-selenium	CPCONLY	C12N2500/25		1685
C12N2500/30	8	Organic components	CPCONLY	C12N2500/30		2670
C12N2500/32	9	Amino acids	CPCONLY	C12N2500/32		3473
C12N2500/33	10	other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine	CPCONLY	C12N2500/33		299
C12N2500/34	9	Sugars	CPCONLY	C12N2500/34		2159
C12N2500/35	9	Polyols, e.g. glycerin, inositol	CPCONLY	C12N2500/35		455
C12N2500/36	9	Lipids	CPCONLY	C12N2500/36		1110
C12N2500/38	9	Vitamins	CPCONLY	C12N2500/38		3594
C12N2500/40	9	Nucleotides, nucleosides or bases	CPCONLY	C12N2500/40		945
C12N2500/42	9	Organic phosphate, e.g. beta glycerophosphate	CPCONLY	C12N2500/42		286
C12N2500/44	9	Thiols, e.g. mercaptoethanol	CPCONLY	C12N2500/44		894
C12N2500/46	9	Amines, e.g. putrescine	CPCONLY	C12N2500/46		777
C12N2500/50	8	Soluble polymers, e.g. polyethyleneglycol [PEG]	CPCONLY	C12N2500/50		365
C12N2500/60	8	Buffer, e.g. pH regulation, osmotic pressure	CPCONLY	C12N2500/60		773
C12N2500/62	9	DMSO	CPCONLY	C12N2500/62		191
C12N2500/70	8	Undefined extracts	CPCONLY	C12N2500/70		63
C12N2500/72	9	from bacteria	CPCONLY	C12N2500/72		180
C12N2500/74	9	from fungi, e.g. yeasts	CPCONLY	C12N2500/74		217
C12N2500/76	9	from plants	CPCONLY	C12N2500/76		728
C12N2500/78	9	from protozoa	CPCONLY	C12N2500/78		5
C12N2500/80	9	from animals	CPCONLY	C12N2500/80		248
C12N2500/82	10	from invertebrates	CPCONLY	C12N2500/82		69
C12N2500/84	10	from mammals	CPCONLY	C12N2500/84		1318
C12N2500/90	8	Serum-free medium, which may still contain naturally-sourced components	CPCONLY	C12N2500/90		2233
C12N2500/92	9	Medium free of human- or animal-derived components	CPCONLY	C12N2500/92		145
C12N2500/95	9	Protein-free medium and culture conditions	CPCONLY	C12N2500/95		104
C12N2500/98	8	Xeno-free medium and culture conditions	CPCONLY	C12N2500/98		158
C12N2500/99	8	Serum-free medium<br><br><u>WARNING</u><br> This group is no longer used for the classification of new documents as from 2012-01-01. The backlog of this group is being continuously reclassified to C12N2500/90&#160;-&#160;C12N2500/98	CPCONLY	C12N2500/99		252
C12N2501/00	7	Active agents used in cell culture processes, e.g. differentation<br><br><u>NOTE</u><br><br>Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K14/00, but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.	CPCONLY	C12N2501/00		139
C12N2501/01	8	Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin	CPCONLY	C12N2501/01		741
C12N2501/02	8	Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes	CPCONLY	C12N2501/02		287
C12N2501/03	8	Compounds acting on the NO pathway, e.g. nitrososarginine	CPCONLY	C12N2501/03		14
C12N2501/04	8	Immunosuppressors, e.g. cyclosporin, tacrolimus	CPCONLY	C12N2501/04		150
C12N2501/05	8	Adjuvants	CPCONLY	C12N2501/05		39
C12N2501/051	9	Lipid A (MPA, MPL)	CPCONLY	C12N2501/051		13
C12N2501/052	9	Lipopolysaccharides [LPS]	CPCONLY	C12N2501/052		226
C12N2501/054	9	Muramyle peptides	CPCONLY	C12N2501/054		6
C12N2501/056	9	Immunostimulating oligonucleotides, e.g. CpG	CPCONLY	C12N2501/056		89
C12N2501/06	8	Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide	CPCONLY	C12N2501/06		395
C12N2501/065	8	Modulators of histone acetylation	CPCONLY	C12N2501/065		292
C12N2501/07	8	Heat shock proteins	CPCONLY	C12N2501/07		37
C12N2501/10	8	Growth factors	CPCONLY	C12N2501/10		506
C12N2501/105	9	Insulin-like growth factors [IGF]	CPCONLY	C12N2501/105		1178
C12N2501/11	9	Epidermal growth factor [EGF]	CPCONLY	C12N2501/11		3511
C12N2501/113	9	Acidic fibroblast growth factor (aFGF, FGF-1)	CPCONLY	C12N2501/113		307
C12N2501/115	9	Basic fibroblast growth factor (bFGF, FGF-2)	CPCONLY	C12N2501/115		4427
C12N2501/117	9	Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)	CPCONLY	C12N2501/117		436
C12N2501/119	9	Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10	CPCONLY	C12N2501/119		1059
C12N2501/12	9	Hepatocyte growth factor [HGF]	CPCONLY	C12N2501/12		777
C12N2501/125	9	Stem cell factor [SCF], c-kit ligand [KL]	CPCONLY	C12N2501/125		1369
C12N2501/13	9	Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins	CPCONLY	C12N2501/13		965
C12N2501/135	9	Platelet-derived growth factor [PDGF]	CPCONLY	C12N2501/135		753
C12N2501/14	9	Erythropoietin [EPO]	CPCONLY	C12N2501/14		300
C12N2501/145	9	Thrombopoietin [TPO]	CPCONLY	C12N2501/145		637
C12N2501/148	9	Transforming growth factor alpha [TGF-a]	CPCONLY	C12N2501/148		190
C12N2501/15	9	Transforming growth factor beta (TGF-&#946;)	CPCONLY	C12N2501/15		2567
C12N2501/155	9	Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor	CPCONLY	C12N2501/155		2289
C12N2501/16	9	Activin; Inhibin; Mullerian inhibiting substance	CPCONLY	C12N2501/16		1090
C12N2501/165	9	Vascular endothelial growth factor [VEGF]	CPCONLY	C12N2501/165		1180
C12N2501/17	9	Angiopoietin	CPCONLY	C12N2501/17		48
C12N2501/175	9	Cardiotrophin	CPCONLY	C12N2501/175		12
C12N2501/18	9	Liver cell growth factor (LCGF, Gly-His-Lys)	CPCONLY	C12N2501/18		59
C12N2501/185	9	Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)	CPCONLY	C12N2501/185		25
C12N2501/19	9	Growth and differentiation factors [GDF]	CPCONLY	C12N2501/19		99
C12N2501/195	9	Heregulin, neu differentiation factor	CPCONLY	C12N2501/195		82
C12N2501/20	8	Cytokines; Chemokines	CPCONLY	C12N2501/20		255
C12N2501/21	9	Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4	CPCONLY	C12N2501/21		248
C12N2501/22	9	Colony stimulating factors (G-CSF, GM-CSF)	CPCONLY	C12N2501/22		1457
C12N2501/23	9	Interleukins [IL]	CPCONLY	C12N2501/23		917
C12N2501/2301	10	Interleukin-1 (IL-1)	CPCONLY	C12N2501/2301		468
C12N2501/2302	10	Interleukin-2 (IL-2)	CPCONLY	C12N2501/2302		2403
C12N2501/2303	10	Interleukin-3 (IL-3)	CPCONLY	C12N2501/2303		546
C12N2501/2304	10	Interleukin-4 (IL-4)	CPCONLY	C12N2501/2304		709
C12N2501/2305	10	Interleukin-5 (IL-5)	CPCONLY	C12N2501/2305		43
C12N2501/2306	10	Interleukin-6 (IL-6)	CPCONLY	C12N2501/2306		803
C12N2501/2307	10	Interleukin-7 (IL-7)	CPCONLY	C12N2501/2307		814
C12N2501/2308	10	Interleukin-8 (IL-8)	CPCONLY	C12N2501/2308		51
C12N2501/2309	10	Interleukin-9 (IL-9)	CPCONLY	C12N2501/2309		29
C12N2501/231	10	Interleukin-10 (IL-10)	CPCONLY	C12N2501/231		163
C12N2501/2311	10	Interleukin-11 (IL-11)	CPCONLY	C12N2501/2311		74
C12N2501/2312	10	Interleukin-12 (IL-12)	CPCONLY	C12N2501/2312		454
C12N2501/2313	10	Interleukin-13 (IL-13)	CPCONLY	C12N2501/2313		61
C12N2501/2314	10	Interleukin-14 (IL-14)	CPCONLY	C12N2501/2314		16
C12N2501/2315	10	Interleukin-15 (IL-15)	CPCONLY	C12N2501/2315		1372
C12N2501/2316	10	Interleukin-16 (IL-16)	CPCONLY	C12N2501/2316		6
C12N2501/2317	10	Interleukin-17 (IL-17)	CPCONLY	C12N2501/2317		53
C12N2501/2318	10	Interleukin-18 (IL-18)	CPCONLY	C12N2501/2318		301
C12N2501/2319	10	Interleukin-19 (IL-19)	CPCONLY	C12N2501/2319		5
C12N2501/232	10	Interleukin-20 (IL-20)	CPCONLY	C12N2501/232		5
C12N2501/2321	10	Interleukin-21 (IL-21)	CPCONLY	C12N2501/2321		679
C12N2501/2322	10	Interleukin-22 (IL-22)	CPCONLY	C12N2501/2322		14
C12N2501/2323	10	Interleukin-23 (IL-23)	CPCONLY	C12N2501/2323		49
C12N2501/2324	10	Interleukin-24 (IL-24)	CPCONLY	C12N2501/2324		4
C12N2501/2325	10	Interleukin-25 (IL-25)	CPCONLY	C12N2501/2325		10
C12N2501/2326	10	Interleukin-26 (IL-26)	CPCONLY	C12N2501/2326		1
C12N2501/2327	10	Interleukin-27 (IL-27)	CPCONLY	C12N2501/2327		35
C12N2501/2328	10	Interleukin-28 (IL-28)	CPCONLY	C12N2501/2328		1
C12N2501/2329	10	Interleukin-29 (IL-29)	CPCONLY	C12N2501/2329		
C12N2501/233	10	Interleukin-30 (IL-30)	CPCONLY	C12N2501/233		
C12N2501/2331	10	Interleukin-31 (IL-31)	CPCONLY	C12N2501/2331		3
C12N2501/2332	10	Interleukin-32 (IL-32)	CPCONLY	C12N2501/2332		3
C12N2501/2333	10	Interleukin-33 (IL-33)	CPCONLY	C12N2501/2333		35
C12N2501/2334	10	Interleukin-34 (IL-34)	CPCONLY	C12N2501/2334		32
C12N2501/2335	10	Interleukin-35 (IL-35)	CPCONLY	C12N2501/2335		6
C12N2501/235	10	Leukemia inhibitory factor [LIF]	CPCONLY	C12N2501/235		668
C12N2501/237	9	Oncostatin M [OSM]	CPCONLY	C12N2501/237		174
C12N2501/24	9	Interferons [IFN]	CPCONLY	C12N2501/24		966
C12N2501/25	9	Tumour necrosing factors [TNF]	CPCONLY	C12N2501/25		797
C12N2501/26	9	Flt-3 ligand (CD135L, flk-2 ligand)	CPCONLY	C12N2501/26		770
C12N2501/30	8	Hormones	CPCONLY	C12N2501/30		726
C12N2501/305	9	Growth hormone [GH], aka. somatotropin	CPCONLY	C12N2501/305		68
C12N2501/31	9	Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins	CPCONLY	C12N2501/31		281
C12N2501/315	9	Prolactin	CPCONLY	C12N2501/315		41
C12N2501/32	9	Angiotensins [AT], angiotensinogen	CPCONLY	C12N2501/32		35
C12N2501/33	9	Insulin	CPCONLY	C12N2501/33		1357
C12N2501/335	9	Glucagon; Glucagon-like peptide [GLP]; Exendin	CPCONLY	C12N2501/335		156
C12N2501/34	9	Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin	CPCONLY	C12N2501/34		11
C12N2501/345	9	Gastrin; Cholecystokinins [CCK]	CPCONLY	C12N2501/345		186
C12N2501/35	9	Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]	CPCONLY	C12N2501/35		25
C12N2501/355	9	Leptin	CPCONLY	C12N2501/355		17
C12N2501/36	9	Somatostatin	CPCONLY	C12N2501/36		13
C12N2501/365	9	Endothelin	CPCONLY	C12N2501/365		35
C12N2501/37	9	Parathyroid hormone [PTH]	CPCONLY	C12N2501/37		41
C12N2501/375	9	Thyroid stimulating hormone [TSH]	CPCONLY	C12N2501/375		37
C12N2501/38	9	with nuclear receptors	CPCONLY	C12N2501/38		47
C12N2501/385	10	of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]	CPCONLY	C12N2501/385		777
C12N2501/39	10	Steroid hormones	CPCONLY	C12N2501/39		1498
C12N2501/392	11	Sexual steroids	CPCONLY	C12N2501/392		491
C12N2501/395	10	Thyroid hormones	CPCONLY	C12N2501/395		337
C12N2501/40	8	Regulators of development	CPCONLY	C12N2501/40		239
C12N2501/405	9	Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases	CPCONLY	C12N2501/405		263
C12N2501/41	9	Hedgehog proteins; Cyclopamine (inhibitor)	CPCONLY	C12N2501/41		471
C12N2501/415	9	Wnt; Frizzeled	CPCONLY	C12N2501/415		1898
C12N2501/42	9	Notch; Delta; Jagged; Serrate	CPCONLY	C12N2501/42		401
C12N2501/48	9	Regulators of apoptosis	CPCONLY	C12N2501/48		224
C12N2501/50	8	Cell markers; Cell surface determinants	CPCONLY	C12N2501/50		312
C12N2501/505	9	CD4; CD8	CPCONLY	C12N2501/505		138
C12N2501/51	9	B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)	CPCONLY	C12N2501/51		865
C12N2501/515	9	CD3, T-cell receptor complex	CPCONLY	C12N2501/515		1581
C12N2501/52	9	CD40, CD40-ligand (CD154)	CPCONLY	C12N2501/52		185
C12N2501/53	9	CD2	CPCONLY	C12N2501/53		66
C12N2501/58	9	Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)	CPCONLY	C12N2501/58		201
C12N2501/585	9	Integrins	CPCONLY	C12N2501/585		63
C12N2501/59	9	Lectins	CPCONLY	C12N2501/59		141
C12N2501/599	9	with CD designations not provided for elsewhere	CPCONLY	C12N2501/599		900
C12N2501/60	8	Transcription factors	CPCONLY	C12N2501/60		869
C12N2501/602	9	Sox-2	CPCONLY	C12N2501/602		602
C12N2501/603	9	Oct-3/4	CPCONLY	C12N2501/603		628
C12N2501/604	9	Klf-4	CPCONLY	C12N2501/604		523
C12N2501/605	9	Nanog	CPCONLY	C12N2501/605		187
C12N2501/606	9	c-Myc	CPCONLY	C12N2501/606		496
C12N2501/608	9	Lin28	CPCONLY	C12N2501/608		161
C12N2501/65	8	MicroRNA	CPCONLY	C12N2501/65		385
C12N2501/70	8	Enzymes	CPCONLY	C12N2501/70		595
C12N2501/71	9	Oxidoreductases (EC 1.)	CPCONLY	C12N2501/71		252
C12N2501/72	9	Transferases [EC 2.]	CPCONLY	C12N2501/72		175
C12N2501/724	10	Glycosyltransferases (EC 2.4.)	CPCONLY	C12N2501/724		63
C12N2501/727	10	Kinases (EC 2.7.)	CPCONLY	C12N2501/727		2882
C12N2501/73	9	Hydrolases (EC 3.)	CPCONLY	C12N2501/73		330
C12N2501/734	10	Proteases (EC 3.4.)	CPCONLY	C12N2501/734		420
C12N2501/80	8	Neurotransmitters; Neurohormones	CPCONLY	C12N2501/80		45
C12N2501/805	9	Acetylcholine	CPCONLY	C12N2501/805		11
C12N2501/81	9	Adrenaline	CPCONLY	C12N2501/81		84
C12N2501/815	9	Dopamine	CPCONLY	C12N2501/815		30
C12N2501/82	9	Histamine	CPCONLY	C12N2501/82		16
C12N2501/825	9	Serotonine (5-HT); Melatonine	CPCONLY	C12N2501/825		51
C12N2501/83	9	Tachykinins, e.g. substance P	CPCONLY	C12N2501/83		8
C12N2501/835	9	Neuropeptide Y [NPY]; Peptide YY [PYY]	CPCONLY	C12N2501/835		10
C12N2501/84	9	Excitatory amino acids	CPCONLY	C12N2501/84		5
C12N2501/845	9	Gamma amino butyric acid [GABA]	CPCONLY	C12N2501/845		33
C12N2501/85	8	Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin	CPCONLY	C12N2501/85		23
C12N2501/855	9	Corticotropin [ACTH]	CPCONLY	C12N2501/855		28
C12N2501/86	9	Melanocyte-stimulating hormone [MSH]	CPCONLY	C12N2501/86		21
C12N2501/90	8	Polysaccharides	CPCONLY	C12N2501/90		498
C12N2501/905	9	Hyaluronic acid	CPCONLY	C12N2501/905		141
C12N2501/91	9	Heparin	CPCONLY	C12N2501/91		615
C12N2501/998	8	Proteins not provided for elsewhere<br><br><u>NOTE</u><br><br>Classification by pathway does not apply.	CPCONLY	C12N2501/998		3316
C12N2501/999	8	Small molecules not provided for elsewhere<br><br><u>NOTE</u><br><br>Classification by pathway does not apply.	CPCONLY	C12N2501/999		3911
C12N2502/00	7	Coculture with; Conditioned medium produced by	CPCONLY	C12N2502/00		297
C12N2502/02	8	embryonic cells	CPCONLY	C12N2502/02		198
C12N2502/025	9	extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton&apos;s jelly	CPCONLY	C12N2502/025		98
C12N2502/03	8	non-embryonic pluripotent stem cells	CPCONLY	C12N2502/03		38
C12N2502/04	8	germ cells	CPCONLY	C12N2502/04		42
C12N2502/07	8	endocrine cells	CPCONLY	C12N2502/07		
C12N2502/072	9	adrenal cells	CPCONLY	C12N2502/072		
C12N2502/074	9	pinealocytes	CPCONLY	C12N2502/074		
C12N2502/076	9	pituitary cells	CPCONLY	C12N2502/076		6
C12N2502/078	9	thyroid, parathyroid cells	CPCONLY	C12N2502/078		2
C12N2502/08	8	cells of the nervous system	CPCONLY	C12N2502/08		123
C12N2502/081	9	neurons	CPCONLY	C12N2502/081		125
C12N2502/083	9	sensory transducers	CPCONLY	C12N2502/083		13
C12N2502/085	9	eye cells	CPCONLY	C12N2502/085		49
C12N2502/086	9	glial cells	CPCONLY	C12N2502/086		128
C12N2502/088	9	neural stem cells	CPCONLY	C12N2502/088		51
C12N2502/09	8	epidermal cells, skin cells, oral mucosa cells	CPCONLY	C12N2502/09		77
C12N2502/091	9	melanocytes	CPCONLY	C12N2502/091		57
C12N2502/092	9	hair cells	CPCONLY	C12N2502/092		34
C12N2502/094	9	keratinocytes	CPCONLY	C12N2502/094		281
C12N2502/095	9	mammary cells	CPCONLY	C12N2502/095		15
C12N2502/097	9	oral mucosa cells	CPCONLY	C12N2502/097		22
C12N2502/098	9	cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands	CPCONLY	C12N2502/098		10
C12N2502/11	8	blood or immune system cells	CPCONLY	C12N2502/11		497
C12N2502/1107	9	B cells	CPCONLY	C12N2502/1107		83
C12N2502/1114	9	T cells	CPCONLY	C12N2502/1114		283
C12N2502/1121	9	Dendritic cells	CPCONLY	C12N2502/1121		324
C12N2502/1128	9	Erythrocytes	CPCONLY	C12N2502/1128		10
C12N2502/1135	9	Granulocytes	CPCONLY	C12N2502/1135		16
C12N2502/1142	9	Osteoclasts	CPCONLY	C12N2502/1142		15
C12N2502/115	9	Platelets, megakaryocytes	CPCONLY	C12N2502/115		110
C12N2502/1157	9	Monocytes, macrophages	CPCONLY	C12N2502/1157		207
C12N2502/1164	9	NK cells	CPCONLY	C12N2502/1164		68
C12N2502/1171	9	Haematopoietic stem cells	CPCONLY	C12N2502/1171		56
C12N2502/1178	9	Spleen cells	CPCONLY	C12N2502/1178		14
C12N2502/1185	9	Thymus cells	CPCONLY	C12N2502/1185		19
C12N2502/1192	9	Lymphatic cells	CPCONLY	C12N2502/1192		29
C12N2502/13	8	connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"	CPCONLY	C12N2502/13		380
C12N2502/1305	9	Adipocytes	CPCONLY	C12N2502/1305		93
C12N2502/1311	9	Osteocytes, osteoblasts, odontoblasts	CPCONLY	C12N2502/1311		66
C12N2502/1317	9	Chondrocytes	CPCONLY	C12N2502/1317		57
C12N2502/1323	9	Adult fibroblasts	CPCONLY	C12N2502/1323		679
C12N2502/1329	9	Cardiomyocytes	CPCONLY	C12N2502/1329		90
C12N2502/1335	9	Skeletal muscle cells, myocytes, myoblasts, myotubes	CPCONLY	C12N2502/1335		81
C12N2502/1341	9	Tenocytes, cells from tendons and ligaments	CPCONLY	C12N2502/1341		15
C12N2502/1347	9	Smooth muscle cells	CPCONLY	C12N2502/1347		71
C12N2502/1352	9	Mesenchymal stem cells	CPCONLY	C12N2502/1352		167
C12N2502/1358	10	Bone marrow mesenchymal stem cells (BM-MSC)	CPCONLY	C12N2502/1358		202
C12N2502/1364	10	Dental pulp stem cells, dental follicle stem cells	CPCONLY	C12N2502/1364		37
C12N2502/137	10	Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood	CPCONLY	C12N2502/137		82
C12N2502/1376	10	Mesenchymal stem cells from hair follicles	CPCONLY	C12N2502/1376		14
C12N2502/1382	10	Adipose-derived stem cells [ADSC], adipose stromal stem cells	CPCONLY	C12N2502/1382		136
C12N2502/1388	10	Mesenchymal stem cells from other natural sources	CPCONLY	C12N2502/1388		105
C12N2502/1394	9	Bone marrow stromal cells; whole marrow	CPCONLY	C12N2502/1394		208
C12N2502/14	8	hepatocytes	CPCONLY	C12N2502/14		184
C12N2502/22	8	pancreatic cells	CPCONLY	C12N2502/22		55
C12N2502/23	8	Gastro-intestinal tract cells	CPCONLY	C12N2502/23		63
C12N2502/24	8	Genital tract cells, non-germinal cells from gonads	CPCONLY	C12N2502/24		
C12N2502/243	9	Cells of the female genital tract, non-germinal ovarian cells	CPCONLY	C12N2502/243		60
C12N2502/246	9	Cells of the male genital tract, non-germinal testis cells	CPCONLY	C12N2502/246		39
C12N2502/25	8	Urinary tract cells, renal cells	CPCONLY	C12N2502/25		8
C12N2502/253	9	Bladder cells	CPCONLY	C12N2502/253		18
C12N2502/256	9	Renal cells	CPCONLY	C12N2502/256		51
C12N2502/27	8	Lung cells, respiratory tract cells	CPCONLY	C12N2502/27		62
C12N2502/28	8	Vascular endothelial cells	CPCONLY	C12N2502/28		539
C12N2502/30	8	tumour cells	CPCONLY	C12N2502/30		523
C12N2502/45	8	Artificially induced pluripotent stem cells	CPCONLY	C12N2502/45		73
C12N2502/50	8	invertebrate cells	CPCONLY	C12N2502/50		10
C12N2502/70	8	Non-animal cells	CPCONLY	C12N2502/70		68
C12N2502/99	8	genetically modified cells<br><br><u>NOTE</u><br><br>Use C12N2501/00 to index the expressed products.	CPCONLY	C12N2502/99		385
C12N2503/00	7	Use of cells in diagnostics	CPCONLY	C12N2503/00		563
C12N2503/02	8	Drug screening	CPCONLY	C12N2503/02		2930
C12N2503/04	8	Screening or testing on artificial tissues	CPCONLY	C12N2503/04		332
C12N2503/06	9	Screening or testing on artificial skin	CPCONLY	C12N2503/06		97
C12N2506/00	7	Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells<br><br><u>NOTE</u><br><br> This scheme indexes the starting point of a differentiation process and is used in combination with classification in C12N5/06 for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed. 	CPCONLY	C12N2506/00		149
C12N2506/02	8	from embryonic cells	CPCONLY	C12N2506/02		2223
C12N2506/025	9	from extra-embryonic cells, e.g. trophoblast, placenta	CPCONLY	C12N2506/025		141
C12N2506/03	8	from non-embryonic pluripotent stem cells	CPCONLY	C12N2506/03		340
C12N2506/04	8	from germ cells	CPCONLY	C12N2506/04		62
C12N2506/07	8	from endocrine cells	CPCONLY	C12N2506/07		5
C12N2506/072	9	from adrenal cells	CPCONLY	C12N2506/072		1
C12N2506/074	9	from pinealocytes	CPCONLY	C12N2506/074		
C12N2506/076	9	from pituitary cells	CPCONLY	C12N2506/076		
C12N2506/078	9	from thyroid, parathyroid cells	CPCONLY	C12N2506/078		2
C12N2506/08	8	from cells of the nervous system	CPCONLY	C12N2506/08		276
C12N2506/09	8	from epidermal cells, from skin cells, from oral mucosa cells	CPCONLY	C12N2506/09		85
C12N2506/091	9	from melanocytes	CPCONLY	C12N2506/091		3
C12N2506/092	9	from hair cells	CPCONLY	C12N2506/092		18
C12N2506/094	9	from keratinocytes	CPCONLY	C12N2506/094		31
C12N2506/095	9	from mammary cells	CPCONLY	C12N2506/095		6
C12N2506/097	9	from oral mucosa cells	CPCONLY	C12N2506/097		8
C12N2506/098	9	from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands	CPCONLY	C12N2506/098		5
C12N2506/11	8	from blood or immune system cells	CPCONLY	C12N2506/11		734
C12N2506/115	9	from monocytes, from macrophages	CPCONLY	C12N2506/115		248
C12N2506/13	8	from connective tissue cells, from mesenchymal cells	CPCONLY	C12N2506/13		145
C12N2506/1307	9	from adult fibroblasts	CPCONLY	C12N2506/1307		626
C12N2506/1315	9	from cardiomyocytes	CPCONLY	C12N2506/1315		25
C12N2506/1323	9	from skeletal muscle cells	CPCONLY	C12N2506/1323		67
C12N2506/133	9	from tenocytes	CPCONLY	C12N2506/133		2
C12N2506/1338	9	from smooth muscle cells	CPCONLY	C12N2506/1338		7
C12N2506/1346	9	from mesenchymal stem cells	CPCONLY	C12N2506/1346		305
C12N2506/1353	10	from bone marrow mesenchymal stem cells (BM-MSC)	CPCONLY	C12N2506/1353		466
C12N2506/1361	10	from dental pulp or dental follicle stem cells	CPCONLY	C12N2506/1361		92
C12N2506/1369	10	from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood	CPCONLY	C12N2506/1369		146
C12N2506/1376	10	from mesenchymal stem cells derived from hair follicles	CPCONLY	C12N2506/1376		11
C12N2506/1384	10	from adipose-derived stem cells [ADSC], from adipose stromal stem cells	CPCONLY	C12N2506/1384		396
C12N2506/1392	10	from mesenchymal stem cells from other natural sources	CPCONLY	C12N2506/1392		245
C12N2506/14	8	from hepatocytes	CPCONLY	C12N2506/14		74
C12N2506/22	8	from pancreatic cells	CPCONLY	C12N2506/22		69
C12N2506/23	8	from cells of the gastro-intestinal tract	CPCONLY	C12N2506/23		39
C12N2506/24	8	from cells of the genital tract, from non-germinal gonad cells	CPCONLY	C12N2506/24		5
C12N2506/243	9	from cells of the female genital tract cells, from non-germinal ovarian cells	CPCONLY	C12N2506/243		10
C12N2506/246	9	from cells of the male genital tract cells, from non-germinal testis cells	CPCONLY	C12N2506/246		6
C12N2506/25	8	from renal cells, from cells of the urinary tract	CPCONLY	C12N2506/25		50
C12N2506/27	8	from lung cells, from cells of the respiratory tract	CPCONLY	C12N2506/27		27
C12N2506/28	8	from vascular endothelial cells	CPCONLY	C12N2506/28		56
C12N2506/30	8	from cancer cells, e.g. reversion of tumour cells<br><br><u>NOTE</u><br><br> Unless the tumourigenic phenotype is totally reversed, the end product is still classified under C12N5/0693. 	CPCONLY	C12N2506/30		123
C12N2506/45	8	from artificially induced pluripotent stem cells	CPCONLY	C12N2506/45		3061
C12N2509/00	7	Methods for the dissociation of cells, e.g. specific use of enzymes	CPCONLY	C12N2509/00		6277
C12N2509/10	8	Mechanical dissociation	CPCONLY	C12N2509/10		2926
C12N2510/00	7	Genetically modified cells	CPCONLY	C12N2510/00		13964
C12N2510/02	8	Cells for production	CPCONLY	C12N2510/02		2105
C12N2510/04	8	Immortalised cells	CPCONLY	C12N2510/04		880
C12N2511/00	7	Cells for large scale production	CPCONLY	C12N2511/00		477
C12N2513/00	7	3D culture	CPCONLY	C12N2513/00		4041
C12N2517/00	7	Cells related to new breeds of animals	CPCONLY	C12N2517/00		44
C12N2517/02	8	Cells from transgenic animals	CPCONLY	C12N2517/02		303
C12N2517/04	8	Cells produced using nuclear transfer	CPCONLY	C12N2517/04		119
C12N2517/10	8	Conditioning of cells for in vitro fecondation or nuclear transfer	CPCONLY	C12N2517/10		209
C12N2521/00	7	Culture process characterised by the use of hydrostatic pressure, flow or shear forces	CPCONLY	C12N2521/00		256
C12N2521/10	8	Sound, e.g. ultrasounds	CPCONLY	C12N2521/10		106
C12N2523/00	7	Culture process characterised by temperature	CPCONLY	C12N2523/00		780
C12N2525/00	7	Culture process characterised by gravity, e.g. microgravity	CPCONLY	C12N2525/00		92
C12N2527/00	7	Culture process characterised by the use of mechanical forces, e.g. strain, vibration	CPCONLY	C12N2527/00		430
C12N2529/00	7	Culture process characterised by the use of electromagnetic stimulation	CPCONLY	C12N2529/00		485
C12N2529/10	8	Stimulation by light	CPCONLY	C12N2529/10		344
C12N2531/00	7	Microcarriers	CPCONLY	C12N2531/00		720
C12N2533/00	7	Supports or coatings for cell culture, characterised by material	CPCONLY	C12N2533/00		250
C12N2533/10	8	Mineral substrates	CPCONLY	C12N2533/10		201
C12N2533/12	9	Glass	CPCONLY	C12N2533/12		153
C12N2533/14	9	Ceramic	CPCONLY	C12N2533/14		71
C12N2533/18	9	Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells	CPCONLY	C12N2533/18		199
C12N2533/20	8	Small organic molecules	CPCONLY	C12N2533/20		216
C12N2533/30	8	Synthetic polymers	CPCONLY	C12N2533/30		2199
C12N2533/32	9	Polylysine, polyornithine	CPCONLY	C12N2533/32		356
C12N2533/40	9	Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers	CPCONLY	C12N2533/40		724
C12N2533/50	8	Proteins	CPCONLY	C12N2533/50		1065
C12N2533/52	9	Fibronectin; Laminin	CPCONLY	C12N2533/52		1386
C12N2533/54	9	Collagen; Gelatin	CPCONLY	C12N2533/54		2817
C12N2533/56	9	Fibrin; Thrombin	CPCONLY	C12N2533/56		459
C12N2533/70	8	Polysaccharides	CPCONLY	C12N2533/70		546
C12N2533/72	9	Chitin, chitosan	CPCONLY	C12N2533/72		387
C12N2533/74	9	Alginate	CPCONLY	C12N2533/74		831
C12N2533/76	9	Agarose, agar-agar	CPCONLY	C12N2533/76		249
C12N2533/78	9	Cellulose	CPCONLY	C12N2533/78		343
C12N2533/80	9	Hyaluronan	CPCONLY	C12N2533/80		458
C12N2533/90	8	Substrates of biological origin, e.g. extracellular matrix, decellularised tissue	CPCONLY	C12N2533/90		2097
C12N2533/92	9	Amnion; Decellularised dermis or mucosa	CPCONLY	C12N2533/92		158
C12N2535/00	7	Supports or coatings for cell culture characterised by topography	CPCONLY	C12N2535/00		676
C12N2535/10	8	Patterned coating	CPCONLY	C12N2535/10		430
C12N2537/00	7	Supports and/or coatings for cell culture characterised by physical or chemical treatment	CPCONLY	C12N2537/00		155
C12N2537/10	8	Cross-linking	CPCONLY	C12N2537/10		552
C12N2539/00	7	Supports and/or coatings for cell culture characterised by properties	CPCONLY	C12N2539/00		215
C12N2539/10	8	Coating allowing for selective detachment of cells, e.g. thermoreactive coating	CPCONLY	C12N2539/10		209
C12N2710/00	7	dsDNA viruses	CPCONLY	C12N2710/00		30
C12N2710/00011	8	Details	CPCONLY	C12N2710/00011		10
C12N2710/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/00021		41
C12N2710/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/00022		73
C12N2710/00023	9	Virus like particles [VLP]	CPCONLY	C12N2710/00023		8
C12N2710/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/00031		6
C12N2710/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/00032		6
C12N2710/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/00033		4
C12N2710/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/00034		98
C12N2710/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/00041		5
C12N2710/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/00042		4
C12N2710/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/00043		24
C12N2710/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/00044		1
C12N2710/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2710/00045		3
C12N2710/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2710/00051		70
C12N2710/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/00052		13
C12N2710/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2710/00061		10
C12N2710/00062	10	by genetic engineering	CPCONLY	C12N2710/00062		6
C12N2710/00063	10	by chemical treatment	CPCONLY	C12N2710/00063		10
C12N2710/00064	10	by serial passage	CPCONLY	C12N2710/00064		2
C12N2710/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2710/00071		6
C12N2710/00088	9	for redistribution	CPCONLY	C12N2710/00088		18
C12N2710/10011	9	Adenoviridae	CPCONLY	C12N2710/10011		27
C12N2710/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/10021		248
C12N2710/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/10022		137
C12N2710/10023	10	Virus like particles [VLP]	CPCONLY	C12N2710/10023		17
C12N2710/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/10031		11
C12N2710/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/10032		131
C12N2710/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/10033		26
C12N2710/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/10034		154
C12N2710/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/10041		150
C12N2710/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/10042		26
C12N2710/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/10043		881
C12N2710/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/10044		12
C12N2710/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/10045		18
C12N2710/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/10051		118
C12N2710/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/10052		55
C12N2710/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/10061		10
C12N2710/10062	11	by genetic engineering	CPCONLY	C12N2710/10062		6
C12N2710/10063	11	by chemical treatment	CPCONLY	C12N2710/10063		2
C12N2710/10064	11	by serial passage	CPCONLY	C12N2710/10064		
C12N2710/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/10071		48
C12N2710/10088	10	for redistribution	CPCONLY	C12N2710/10088		1
C12N2710/10111	10	Atadenovirus, e.g. ovine adenovirus D	CPCONLY	C12N2710/10111		2
C12N2710/10121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/10121		4
C12N2710/10122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/10122		7
C12N2710/10123	11	Virus like particles [VLP]	CPCONLY	C12N2710/10123		2
C12N2710/10131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/10131		
C12N2710/10132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/10132		3
C12N2710/10133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/10133		
C12N2710/10134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/10134		15
C12N2710/10141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/10141		7
C12N2710/10142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/10142		
C12N2710/10143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/10143		17
C12N2710/10144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/10144		1
C12N2710/10145	12	Special targeting system for viral vectors	CPCONLY	C12N2710/10145		
C12N2710/10151	11	Methods of production or purification of viral material	CPCONLY	C12N2710/10151		3
C12N2710/10152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/10152		3
C12N2710/10161	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/10161		
C12N2710/10162	12	by genetic engineering	CPCONLY	C12N2710/10162		
C12N2710/10163	12	by chemical treatment	CPCONLY	C12N2710/10163		
C12N2710/10164	12	by serial passage	CPCONLY	C12N2710/10164		
C12N2710/10171	11	Demonstrated in vivo effect	CPCONLY	C12N2710/10171		1
C12N2710/10188	11	for redistribution	CPCONLY	C12N2710/10188		
C12N2710/10211	10	Aviadenovirus, e.g. fowl adenovirus A	CPCONLY	C12N2710/10211		2
C12N2710/10221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/10221		73
C12N2710/10222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/10222		108
C12N2710/10223	11	Virus like particles [VLP]	CPCONLY	C12N2710/10223		2
C12N2710/10231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/10231		3
C12N2710/10232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/10232		3
C12N2710/10233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/10233		3
C12N2710/10234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/10234		199
C12N2710/10241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/10241		1
C12N2710/10242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/10242		
C12N2710/10243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/10243		52
C12N2710/10244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/10244		1
C12N2710/10245	12	Special targeting system for viral vectors	CPCONLY	C12N2710/10245		1
C12N2710/10251	11	Methods of production or purification of viral material	CPCONLY	C12N2710/10251		54
C12N2710/10252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/10252		24
C12N2710/10261	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/10261		2
C12N2710/10262	12	by genetic engineering	CPCONLY	C12N2710/10262		3
C12N2710/10263	12	by chemical treatment	CPCONLY	C12N2710/10263		13
C12N2710/10264	12	by serial passage	CPCONLY	C12N2710/10264		2
C12N2710/10271	11	Demonstrated in vivo effect	CPCONLY	C12N2710/10271		3
C12N2710/10288	11	for redistribution	CPCONLY	C12N2710/10288		
C12N2710/10311	10	Mastadenovirus, e.g. human or simian adenoviruses	CPCONLY	C12N2710/10311		10
C12N2710/10321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/10321		239
C12N2710/10322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/10322		559
C12N2710/10323	11	Virus like particles [VLP]	CPCONLY	C12N2710/10323		25
C12N2710/10331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/10331		11
C12N2710/10332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/10332		378
C12N2710/10333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/10333		30
C12N2710/10334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/10334		157
C12N2710/10341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/10341		44
C12N2710/10342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/10342		16
C12N2710/10343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/10343		2613
C12N2710/10344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/10344		99
C12N2710/10345	12	Special targeting system for viral vectors	CPCONLY	C12N2710/10345		270
C12N2710/10351	11	Methods of production or purification of viral material	CPCONLY	C12N2710/10351		216
C12N2710/10352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/10352		206
C12N2710/10361	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/10361		21
C12N2710/10362	12	by genetic engineering	CPCONLY	C12N2710/10362		53
C12N2710/10363	12	by chemical treatment	CPCONLY	C12N2710/10363		11
C12N2710/10364	12	by serial passage	CPCONLY	C12N2710/10364		12
C12N2710/10371	11	Demonstrated in vivo effect	CPCONLY	C12N2710/10371		82
C12N2710/10388	11	for redistribution	CPCONLY	C12N2710/10388		
C12N2710/12011	9	Asfarviridae	CPCONLY	C12N2710/12011		4
C12N2710/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/12021		73
C12N2710/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/12022		341
C12N2710/12023	10	Virus like particles [VLP]	CPCONLY	C12N2710/12023		6
C12N2710/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/12031		4
C12N2710/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/12032		1
C12N2710/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/12033		4
C12N2710/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/12034		303
C12N2710/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/12041		1
C12N2710/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/12042		
C12N2710/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/12043		9
C12N2710/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/12044		
C12N2710/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/12045		
C12N2710/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/12051		48
C12N2710/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/12052		18
C12N2710/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/12061		4
C12N2710/12062	11	by genetic engineering	CPCONLY	C12N2710/12062		25
C12N2710/12063	11	by chemical treatment	CPCONLY	C12N2710/12063		2
C12N2710/12064	11	by serial passage	CPCONLY	C12N2710/12064		3
C12N2710/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/12071		16
C12N2710/12088	10	for redistribution	CPCONLY	C12N2710/12088		
C12N2710/14011	9	Baculoviridae	CPCONLY	C12N2710/14011		6
C12N2710/14021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/14021		137
C12N2710/14022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/14022		53
C12N2710/14023	10	Virus like particles [VLP]	CPCONLY	C12N2710/14023		9
C12N2710/14031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/14031		11
C12N2710/14032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/14032		4
C12N2710/14033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/14033		4
C12N2710/14034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/14034		21
C12N2710/14041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/14041		72
C12N2710/14042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/14042		5
C12N2710/14043	11	viral genome or elements thereof as genetic vectore	CPCONLY	C12N2710/14043		774
C12N2710/14044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/14044		38
C12N2710/14045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/14045		4
C12N2710/14051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/14051		50
C12N2710/14052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/14052		36
C12N2710/14061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/14061		1
C12N2710/14062	11	by genetic engineering	CPCONLY	C12N2710/14062		1
C12N2710/14063	11	by chemical treatment	CPCONLY	C12N2710/14063		6
C12N2710/14064	11	by serial passage	CPCONLY	C12N2710/14064		
C12N2710/14071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/14071		3
C12N2710/14088	10	for redistribution	CPCONLY	C12N2710/14088		
C12N2710/14111	10	Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus	CPCONLY	C12N2710/14111		2
C12N2710/14121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/14121		63
C12N2710/14122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/14122		89
C12N2710/14123	11	Virus like particles [VLP]	CPCONLY	C12N2710/14123		3
C12N2710/14131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/14131		29
C12N2710/14132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/14132		10
C12N2710/14133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/14133		
C12N2710/14134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/14134		7
C12N2710/14141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/14141		3
C12N2710/14142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/14142		2
C12N2710/14143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/14143		751
C12N2710/14144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/14144		78
C12N2710/14145	12	Special targeting system for viral vectors	CPCONLY	C12N2710/14145		10
C12N2710/14151	11	Methods of production or purification of viral material	CPCONLY	C12N2710/14151		54
C12N2710/14152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/14152		19
C12N2710/14161	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/14161		1
C12N2710/14162	12	by genetic engineering	CPCONLY	C12N2710/14162		2
C12N2710/14163	12	by chemical treatment	CPCONLY	C12N2710/14163		4
C12N2710/14164	12	by serial passage	CPCONLY	C12N2710/14164		
C12N2710/14171	11	Demonstrated in vivo effect	CPCONLY	C12N2710/14171		5
C12N2710/14188	11	For redistribution	CPCONLY	C12N2710/14188		
C12N2710/16011	9	Herpesviridae	CPCONLY	C12N2710/16011		16
C12N2710/16021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16021		85
C12N2710/16022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16022		169
C12N2710/16023	10	Virus like particles [VLP]	CPCONLY	C12N2710/16023		6
C12N2710/16031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16031		3
C12N2710/16032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16032		11
C12N2710/16033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16033		9
C12N2710/16034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/16034		244
C12N2710/16041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16041		15
C12N2710/16042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16042		1
C12N2710/16043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16043		92
C12N2710/16044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16044		3
C12N2710/16045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/16045		3
C12N2710/16051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/16051		58
C12N2710/16052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16052		25
C12N2710/16061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/16061		13
C12N2710/16062	11	by genetic engineering	CPCONLY	C12N2710/16062		16
C12N2710/16063	11	by chemical treatment	CPCONLY	C12N2710/16063		13
C12N2710/16064	11	by serial passage	CPCONLY	C12N2710/16064		7
C12N2710/16071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/16071		18
C12N2710/16088	10	for redistribution	CPCONLY	C12N2710/16088		
C12N2710/16111	10	Cytomegalovirus, e.g. human herpesvirus 5	CPCONLY	C12N2710/16111		26
C12N2710/16121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16121		30
C12N2710/16122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16122		371
C12N2710/16123	11	Virus like particles [VLP]	CPCONLY	C12N2710/16123		8
C12N2710/16131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16131		5
C12N2710/16132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16132		14
C12N2710/16133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16133		16
C12N2710/16134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/16134		326
C12N2710/16141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16141		11
C12N2710/16142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16142		4
C12N2710/16143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16143		120
C12N2710/16144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16144		2
C12N2710/16145	12	Special targeting system for viral vectors	CPCONLY	C12N2710/16145		7
C12N2710/16151	11	Methods of production or purification of viral material	CPCONLY	C12N2710/16151		38
C12N2710/16152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16152		10
C12N2710/16161	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/16161		14
C12N2710/16162	12	by genetic engineering	CPCONLY	C12N2710/16162		20
C12N2710/16163	12	by chemical treatment	CPCONLY	C12N2710/16163		6
C12N2710/16164	12	by serial passage	CPCONLY	C12N2710/16164		5
C12N2710/16171	11	Demonstrated in vivo effect	CPCONLY	C12N2710/16171		34
C12N2710/16188	11	for redistribution	CPCONLY	C12N2710/16188		
C12N2710/16211	10	Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus	CPCONLY	C12N2710/16211		21
C12N2710/16221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16221		5
C12N2710/16222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16222		350
C12N2710/16223	11	Virus like particles [VLP]	CPCONLY	C12N2710/16223		9
C12N2710/16231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16231		3
C12N2710/16232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16232		6
C12N2710/16233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16233		7
C12N2710/16234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/16234		205
C12N2710/16241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16241		1
C12N2710/16242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16242		1
C12N2710/16243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16243		44
C12N2710/16244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16244		3
C12N2710/16245	12	Special targeting system for viral vectors	CPCONLY	C12N2710/16245		
C12N2710/16251	11	Methods of production or purification of viral material	CPCONLY	C12N2710/16251		6
C12N2710/16252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16252		5
C12N2710/16261	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/16261		2
C12N2710/16262	12	by genetic engineering	CPCONLY	C12N2710/16262		3
C12N2710/16263	12	by chemical treatment	CPCONLY	C12N2710/16263		2
C12N2710/16264	12	by serial passage	CPCONLY	C12N2710/16264		
C12N2710/16271	11	Demonstrated in vivo effect	CPCONLY	C12N2710/16271		14
C12N2710/16288	11	for redistribution	CPCONLY	C12N2710/16288		
C12N2710/16311	10	Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV	CPCONLY	C12N2710/16311		6
C12N2710/16321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16321		96
C12N2710/16322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16322		102
C12N2710/16323	11	Virus like particles [VLP]	CPCONLY	C12N2710/16323		
C12N2710/16331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16331		
C12N2710/16332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16332		3
C12N2710/16333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16333		
C12N2710/16334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/16334		185
C12N2710/16341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16341		1
C12N2710/16342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16342		
C12N2710/16343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16343		97
C12N2710/16344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16344		
C12N2710/16345	12	Special targeting system for viral vectors	CPCONLY	C12N2710/16345		
C12N2710/16351	11	Methods of production or purification of viral material	CPCONLY	C12N2710/16351		33
C12N2710/16352	12	relating to complementin g cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16352		30
C12N2710/16361	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/16361		7
C12N2710/16362	12	by genetic engineering	CPCONLY	C12N2710/16362		15
C12N2710/16363	12	by chemical treatment	CPCONLY	C12N2710/16363		1
C12N2710/16364	12	by serial passage	CPCONLY	C12N2710/16364		2
C12N2710/16371	11	Demonstrated in vivo effect	CPCONLY	C12N2710/16371		4
C12N2710/16388	11	for redistribution	CPCONLY	C12N2710/16388		
C12N2710/16411	10	Rhadinovirus, e.g. human herpesvirus 8	CPCONLY	C12N2710/16411		4
C12N2710/16421	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16421		4
C12N2710/16422	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16422		77
C12N2710/16423	11	Virus like particles [VLP]	CPCONLY	C12N2710/16423		1
C12N2710/16431	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16431		
C12N2710/16432	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16432		1
C12N2710/16433	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16433		6
C12N2710/16434	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/16434		20
C12N2710/16441	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16441		
C12N2710/16442	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16442		1
C12N2710/16443	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16443		15
C12N2710/16444	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16444		
C12N2710/16445	12	Special targeting system for viral vectors	CPCONLY	C12N2710/16445		
C12N2710/16451	11	Methods of production or purification of viral material	CPCONLY	C12N2710/16451		4
C12N2710/16452	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16452		1
C12N2710/16461	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/16461		2
C12N2710/16462	12	by genetic engineering	CPCONLY	C12N2710/16462		1
C12N2710/16463	12	by chemical treatment	CPCONLY	C12N2710/16463		
C12N2710/16464	12	by serial passage	CPCONLY	C12N2710/16464		
C12N2710/16471	11	Demonstrated in vivo effect	CPCONLY	C12N2710/16471		2
C12N2710/16488	11	for redistribution	CPCONLY	C12N2710/16488		
C12N2710/16511	10	Roseolovirus, e.g. human herpesvirus 6, 7	CPCONLY	C12N2710/16511		6
C12N2710/16521	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16521		6
C12N2710/16522	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16522		33
C12N2710/16523	11	Virus like particles [VLP]	CPCONLY	C12N2710/16523		
C12N2710/16531	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16531		
C12N2710/16532	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16532		2
C12N2710/16533	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16533		4
C12N2710/16534	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral	CPCONLY	C12N2710/16534		4
C12N2710/16541	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16541		1
C12N2710/16542	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16542		
C12N2710/16543	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16543		6
C12N2710/16544	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16544		
C12N2710/16545	12	Special targeting system for viral vectors	CPCONLY	C12N2710/16545		1
C12N2710/16551	11	Methods of production or purification of viral material	CPCONLY	C12N2710/16551		5
C12N2710/16552	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16552		
C12N2710/16561	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/16561		
C12N2710/16562	12	by genetic engineering	CPCONLY	C12N2710/16562		1
C12N2710/16563	12	by chemical treatment	CPCONLY	C12N2710/16563		1
C12N2710/16564	12	by serial passage	CPCONLY	C12N2710/16564		
C12N2710/16571	11	Demonstrated in vivo effect	CPCONLY	C12N2710/16571		1
C12N2710/16588	11	for redistribution	CPCONLY	C12N2710/16588		
C12N2710/16611	10	Simplexvirus, e.g. human herpesvirus 1, 2	CPCONLY	C12N2710/16611		43
C12N2710/16621	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16621		154
C12N2710/16622	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16622		655
C12N2710/16623	11	Virus like particles [VLP]	CPCONLY	C12N2710/16623		5
C12N2710/16631	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16631		11
C12N2710/16632	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16632		263
C12N2710/16633	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16633		24
C12N2710/16634	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/16634		407
C12N2710/16641	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16641		20
C12N2710/16642	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16642		7
C12N2710/16643	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16643		433
C12N2710/16644	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16644		16
C12N2710/16645	12	Special targeting system for viral vectors	CPCONLY	C12N2710/16645		20
C12N2710/16651	11	Methods of production or purification of viral material	CPCONLY	C12N2710/16651		68
C12N2710/16652	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16652		41
C12N2710/16661	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/16661		41
C12N2710/16662	12	by genetic engineering	CPCONLY	C12N2710/16662		58
C12N2710/16663	12	by chemical treatment	CPCONLY	C12N2710/16663		23
C12N2710/16664	12	by serial passage	CPCONLY	C12N2710/16664		2
C12N2710/16671	11	Demonstrated in vivo effect	CPCONLY	C12N2710/16671		61
C12N2710/16688	11	for redistribution	CPCONLY	C12N2710/16688		
C12N2710/16711	10	Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies	CPCONLY	C12N2710/16711		15
C12N2710/16721	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/16721		149
C12N2710/16722	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/16722		473
C12N2710/16723	11	Virus like particles [VLP]	CPCONLY	C12N2710/16723		10
C12N2710/16731	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/16731		4
C12N2710/16732	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/16732		16
C12N2710/16733	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/16733		3
C12N2710/16734	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/16734		791
C12N2710/16741	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/16741		4
C12N2710/16742	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/16742		
C12N2710/16743	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/16743		118
C12N2710/16744	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/16744		2
C12N2710/16745	12	Special targeting system for viral vectors	CPCONLY	C12N2710/16745		1
C12N2710/16751	11	Methods of production or purification of viral material	CPCONLY	C12N2710/16751		125
C12N2710/16752	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/16752		27
C12N2710/16761	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/16761		27
C12N2710/16762	12	by genetic engineering	CPCONLY	C12N2710/16762		37
C12N2710/16763	12	by chemical treatment	CPCONLY	C12N2710/16763		28
C12N2710/16764	12	by serial passage	CPCONLY	C12N2710/16764		21
C12N2710/16771	11	Demonstrated in vivo effect	CPCONLY	C12N2710/16771		22
C12N2710/16788	11	for redistribution	CPCONLY	C12N2710/16788		
C12N2710/18011	9	Nimaviridae	CPCONLY	C12N2710/18011		
C12N2710/18021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/18021		
C12N2710/18022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/18022		32
C12N2710/18023	10	Virus like particles [VLP]	CPCONLY	C12N2710/18023		1
C12N2710/18031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/18031		
C12N2710/18032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/18032		
C12N2710/18033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/18033		1
C12N2710/18034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/18034		23
C12N2710/18041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/18041		
C12N2710/18042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/18042		
C12N2710/18043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/18043		1
C12N2710/18044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/18044		
C12N2710/18045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/18045		
C12N2710/18051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/18051		3
C12N2710/18052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/18052		
C12N2710/18061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/18061		
C12N2710/18062	11	by genetic engineering	CPCONLY	C12N2710/18062		
C12N2710/18063	11	by chemical treatment	CPCONLY	C12N2710/18063		
C12N2710/18064	11	by serial passage	CPCONLY	C12N2710/18064		
C12N2710/18071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/18071		1
C12N2710/18088	10	for redistribution	CPCONLY	C12N2710/18088		
C12N2710/20011	9	Papillomaviridae	CPCONLY	C12N2710/20011		23
C12N2710/20021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/20021		20
C12N2710/20022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/20022		837
C12N2710/20023	10	Virus like particles [VLP]	CPCONLY	C12N2710/20023		227
C12N2710/20031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/20031		6
C12N2710/20032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/20032		12
C12N2710/20033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/20033		20
C12N2710/20034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/20034		793
C12N2710/20041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/20041		5
C12N2710/20042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/20042		12
C12N2710/20043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/20043		40
C12N2710/20044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/20044		1
C12N2710/20045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/20045		3
C12N2710/20051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/20051		63
C12N2710/20052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/20052		11
C12N2710/20061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/20061		5
C12N2710/20062	11	by genetic engineering	CPCONLY	C12N2710/20062		
C12N2710/20063	11	by chemical treatment	CPCONLY	C12N2710/20063		5
C12N2710/20064	11	by serial passage	CPCONLY	C12N2710/20064		
C12N2710/20071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/20071		58
C12N2710/20088	10	for redistribution	CPCONLY	C12N2710/20088		
C12N2710/22011	9	Polyomaviridae, e.g. polyoma, SV40, JC	CPCONLY	C12N2710/22011		11
C12N2710/22021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/22021		11
C12N2710/22022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/22022		234
C12N2710/22023	10	Virus like particles [VLP]	CPCONLY	C12N2710/22023		60
C12N2710/22031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/22031		3
C12N2710/22032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/22032		9
C12N2710/22033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/22033		4
C12N2710/22034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/22034		46
C12N2710/22041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/22041		4
C12N2710/22042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/22042		19
C12N2710/22043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/22043		39
C12N2710/22044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/22044		2
C12N2710/22045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/22045		3
C12N2710/22051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/22051		19
C12N2710/22052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/22052		9
C12N2710/22061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/22061		1
C12N2710/22062	11	by genetic engineering	CPCONLY	C12N2710/22062		7
C12N2710/22063	11	by chemical treatment	CPCONLY	C12N2710/22063		2
C12N2710/22064	11	by serial passage	CPCONLY	C12N2710/22064		4
C12N2710/22071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/22071		7
C12N2710/22088	10	for redistribution	CPCONLY	C12N2710/22088		
C12N2710/24011	9	Poxviridae	CPCONLY	C12N2710/24011		7
C12N2710/24021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/24021		94
C12N2710/24022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/24022		127
C12N2710/24023	10	Virus like particles [VLP]	CPCONLY	C12N2710/24023		6
C12N2710/24031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/24031		2
C12N2710/24032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/24032		52
C12N2710/24033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/24033		12
C12N2710/24034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/24034		108
C12N2710/24041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/24041		13
C12N2710/24042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/24042		4
C12N2710/24043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/24043		336
C12N2710/24044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/24044		3
C12N2710/24045	11	Special targeting system for viral vectors	CPCONLY	C12N2710/24045		1
C12N2710/24051	10	Methods of production or purification of viral material	CPCONLY	C12N2710/24051		23
C12N2710/24052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/24052		16
C12N2710/24061	10	Methods of inactivation or attenuation	CPCONLY	C12N2710/24061		3
C12N2710/24062	11	by genetic engineering	CPCONLY	C12N2710/24062		8
C12N2710/24063	11	by chemical treatment	CPCONLY	C12N2710/24063		4
C12N2710/24064	11	by serial passage	CPCONLY	C12N2710/24064		6
C12N2710/24071	10	Demonstrated in vivo effect	CPCONLY	C12N2710/24071		19
C12N2710/24088	10	for redistribution	CPCONLY	C12N2710/24088		
C12N2710/24111	10	Orthopoxvirus, e.g. vaccinia virus, variola	CPCONLY	C12N2710/24111		18
C12N2710/24121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/24121		128
C12N2710/24122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/24122		296
C12N2710/24123	11	Virus like particles [VLP]	CPCONLY	C12N2710/24123		7
C12N2710/24131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/24131		4
C12N2710/24132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/24132		217
C12N2710/24133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/24133		26
C12N2710/24134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/24134		249
C12N2710/24141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/24141		39
C12N2710/24142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/24142		4
C12N2710/24143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/24143		894
C12N2710/24144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/24144		14
C12N2710/24145	12	Special targeting system for viral vectors	CPCONLY	C12N2710/24145		5
C12N2710/24151	11	Methods of production or purification of viral material	CPCONLY	C12N2710/24151		83
C12N2710/24152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/24152		38
C12N2710/24161	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/24161		26
C12N2710/24162	12	by genetic engineering	CPCONLY	C12N2710/24162		37
C12N2710/24163	12	by chemical treatment	CPCONLY	C12N2710/24163		5
C12N2710/24164	12	by serial passage	CPCONLY	C12N2710/24164		11
C12N2710/24171	11	Demonstrated in vivo effect	CPCONLY	C12N2710/24171		57
C12N2710/24188	11	for redistribution	CPCONLY	C12N2710/24188		
C12N2710/24211	10	Parapoxvirus, e.g. Orf virus	CPCONLY	C12N2710/24211		3
C12N2710/24221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2710/24221		35
C12N2710/24222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2710/24222		51
C12N2710/24223	11	Virus like particles [VLP]	CPCONLY	C12N2710/24223		
C12N2710/24231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2710/24231		1
C12N2710/24232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2710/24232		17
C12N2710/24233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2710/24233		4
C12N2710/24234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2710/24234		73
C12N2710/24241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2710/24241		
C12N2710/24242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2710/24242		
C12N2710/24243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2710/24243		31
C12N2710/24244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2710/24244		
C12N2710/24245	12	Special targeting system for viral vectors	CPCONLY	C12N2710/24245		
C12N2710/24251	11	Methods of production or purification of viral material	CPCONLY	C12N2710/24251		25
C12N2710/24252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2710/24252		8
C12N2710/24261	11	Methods of inactivation or attenuation	CPCONLY	C12N2710/24261		4
C12N2710/24262	12	by genetic engineering	CPCONLY	C12N2710/24262		1
C12N2710/24263	12	by chemical treatment	CPCONLY	C12N2710/24263		4
C12N2710/24264	12	by serial passage	CPCONLY	C12N2710/24264		4
C12N2710/24271	11	Demonstrated in vivo effect	CPCONLY	C12N2710/24271		3
C12N2710/24288	11	for redistribution	CPCONLY	C12N2710/24288		
C12N2720/00	7	dsRNA viruses	CPCONLY	C12N2720/00		
C12N2720/00011	8	Details	CPCONLY	C12N2720/00011		2
C12N2720/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2720/00021		19
C12N2720/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2720/00022		35
C12N2720/00023	9	Virus like particles [VLP]	CPCONLY	C12N2720/00023		2
C12N2720/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2720/00031		7
C12N2720/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2720/00032		3
C12N2720/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2720/00033		1
C12N2720/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2720/00034		27
C12N2720/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2720/00041		
C12N2720/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2720/00042		
C12N2720/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2720/00043		2
C12N2720/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2720/00044		1
C12N2720/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2720/00045		
C12N2720/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2720/00051		10
C12N2720/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2720/00052		
C12N2720/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2720/00061		3
C12N2720/00062	10	by genetic engineering	CPCONLY	C12N2720/00062		1
C12N2720/00063	10	by chemical treatment	CPCONLY	C12N2720/00063		4
C12N2720/00064	10	by serial passage	CPCONLY	C12N2720/00064		
C12N2720/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2720/00071		1
C12N2720/00088	9	for redistribution	CPCONLY	C12N2720/00088		
C12N2720/10011	9	Birnaviridae	CPCONLY	C12N2720/10011		6
C12N2720/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2720/10021		32
C12N2720/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2720/10022		181
C12N2720/10023	10	Virus like particles [VLP]	CPCONLY	C12N2720/10023		27
C12N2720/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2720/10031		1
C12N2720/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2720/10032		6
C12N2720/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2720/10033		2
C12N2720/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2720/10034		274
C12N2720/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2720/10041		
C12N2720/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2720/10042		
C12N2720/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2720/10043		6
C12N2720/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2720/10044		1
C12N2720/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2720/10045		1
C12N2720/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2720/10051		46
C12N2720/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2720/10052		4
C12N2720/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2720/10061		14
C12N2720/10062	11	by genetic engineering	CPCONLY	C12N2720/10062		4
C12N2720/10063	11	by chemical treatment	CPCONLY	C12N2720/10063		4
C12N2720/10064	11	by serial passage	CPCONLY	C12N2720/10064		8
C12N2720/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2720/10071		12
C12N2720/10088	10	for redistribution	CPCONLY	C12N2720/10088		
C12N2720/12011	9	Reoviridae	CPCONLY	C12N2720/12011		11
C12N2720/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2720/12021		20
C12N2720/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2720/12022		69
C12N2720/12023	10	Virus like particles [VLP]	CPCONLY	C12N2720/12023		3
C12N2720/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2720/12031		2
C12N2720/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2720/12032		30
C12N2720/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2720/12033		5
C12N2720/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2720/12034		91
C12N2720/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2720/12041		
C12N2720/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2720/12042		
C12N2720/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2720/12043		6
C12N2720/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2720/12044		
C12N2720/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2720/12045		
C12N2720/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2720/12051		41
C12N2720/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2720/12052		10
C12N2720/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2720/12061		3
C12N2720/12062	11	by genetic engineering	CPCONLY	C12N2720/12062		1
C12N2720/12063	11	by chemical treatment	CPCONLY	C12N2720/12063		3
C12N2720/12064	11	by serial passage	CPCONLY	C12N2720/12064		5
C12N2720/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2720/12071		2
C12N2720/12088	10	for redistribution	CPCONLY	C12N2720/12088		
C12N2720/12111	10	Orbivirus, e.g. bluetongue virus	CPCONLY	C12N2720/12111		2
C12N2720/12121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2720/12121		11
C12N2720/12122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2720/12122		40
C12N2720/12123	11	Virus like particles [VLP]	CPCONLY	C12N2720/12123		6
C12N2720/12131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2720/12131		1
C12N2720/12132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2720/12132		1
C12N2720/12133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2720/12133		
C12N2720/12134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2720/12134		49
C12N2720/12141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2720/12141		
C12N2720/12142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2720/12142		1
C12N2720/12143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2720/12143		5
C12N2720/12144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2720/12144		
C12N2720/12145	12	Special targeting system for viral vectors	CPCONLY	C12N2720/12145		
C12N2720/12151	11	Methods of production or purification of viral material	CPCONLY	C12N2720/12151		9
C12N2720/12152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2720/12152		5
C12N2720/12161	11	Methods of inactivation or attenuation	CPCONLY	C12N2720/12161		1
C12N2720/12162	12	by genetic engineering	CPCONLY	C12N2720/12162		4
C12N2720/12163	12	by chemical treatment	CPCONLY	C12N2720/12163		8
C12N2720/12164	12	by serial passage	CPCONLY	C12N2720/12164		1
C12N2720/12171	11	Demonstrated in vivo effect	CPCONLY	C12N2720/12171		5
C12N2720/12188	11	for redistribution	CPCONLY	C12N2720/12188		
C12N2720/12211	10	Orthoreovirus, e.g. mammalian orthoreovirus	CPCONLY	C12N2720/12211		6
C12N2720/12221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2720/12221		38
C12N2720/12222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2720/12222		48
C12N2720/12223	11	Virus like particles [VLP]	CPCONLY	C12N2720/12223		3
C12N2720/12231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2720/12231		
C12N2720/12232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2720/12232		35
C12N2720/12233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2720/12233		1
C12N2720/12234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2720/12234		77
C12N2720/12241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2720/12241		1
C12N2720/12242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2720/12242		
C12N2720/12243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2720/12243		5
C12N2720/12244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2720/12244		
C12N2720/12245	12	Special targeting system for viral vectors	CPCONLY	C12N2720/12245		
C12N2720/12251	11	Methods of production or purification of viral material	CPCONLY	C12N2720/12251		27
C12N2720/12252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2720/12252		5
C12N2720/12261	11	Methods of inactivation or attenuation	CPCONLY	C12N2720/12261		4
C12N2720/12262	12	by genetic engineering	CPCONLY	C12N2720/12262		
C12N2720/12263	12	by chemical treatment	CPCONLY	C12N2720/12263		5
C12N2720/12264	12	by serial passage	CPCONLY	C12N2720/12264		4
C12N2720/12271	11	Demonstrated in vivo effect	CPCONLY	C12N2720/12271		3
C12N2720/12288	11	for redistribution	CPCONLY	C12N2720/12288		
C12N2720/12311	10	Rotavirus, e.g. rotavirus A	CPCONLY	C12N2720/12311		5
C12N2720/12321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2720/12321		52
C12N2720/12322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2720/12322		198
C12N2720/12323	11	Virus like particles [VLP]	CPCONLY	C12N2720/12323		22
C12N2720/12331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2720/12331		1
C12N2720/12332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2720/12332		5
C12N2720/12333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2720/12333		8
C12N2720/12334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2720/12334		282
C12N2720/12341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2720/12341		3
C12N2720/12342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2720/12342		
C12N2720/12343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2720/12343		9
C12N2720/12344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2720/12344		
C12N2720/12345	12	Special targeting system for viral vectors	CPCONLY	C12N2720/12345		1
C12N2720/12351	11	Methods of production or purification of viral material	CPCONLY	C12N2720/12351		66
C12N2720/12352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2720/12352		27
C12N2720/12361	11	Methods of inactivation or attenuation	CPCONLY	C12N2720/12361		4
C12N2720/12362	12	by genetic engineering	CPCONLY	C12N2720/12362		5
C12N2720/12363	12	by chemical treatment	CPCONLY	C12N2720/12363		8
C12N2720/12364	12	by serial passage	CPCONLY	C12N2720/12364		7
C12N2720/12371	11	Demonstrated in vivo effect	CPCONLY	C12N2720/12371		4
C12N2720/12388	11	for redistribution	CPCONLY	C12N2720/12388		
C12N2730/00	7	Reverse transcribing DNA viruses	CPCONLY	C12N2730/00		
C12N2730/00011	8	Details	CPCONLY	C12N2730/00011		
C12N2730/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2730/00021		1
C12N2730/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2730/00022		14
C12N2730/00023	9	Virus like particles [VLP]	CPCONLY	C12N2730/00023		1
C12N2730/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2730/00031		
C12N2730/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2730/00032		
C12N2730/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2730/00033		
C12N2730/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2730/00034		3
C12N2730/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2730/00041		2
C12N2730/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2730/00042		
C12N2730/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2730/00043		17
C12N2730/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2730/00044		
C12N2730/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2730/00045		
C12N2730/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2730/00051		1
C12N2730/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2730/00052		1
C12N2730/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2730/00061		2
C12N2730/00062	10	by genetic engineering	CPCONLY	C12N2730/00062		
C12N2730/00063	10	by chemical treatment	CPCONLY	C12N2730/00063		
C12N2730/00064	10	by serial passage	CPCONLY	C12N2730/00064		
C12N2730/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2730/00071		1
C12N2730/00088	9	for redistribution	CPCONLY	C12N2730/00088		
C12N2730/10011	9	Hepadnaviridae	CPCONLY	C12N2730/10011		5
C12N2730/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2730/10021		1
C12N2730/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2730/10022		9
C12N2730/10023	10	Virus like particles [VLP]	CPCONLY	C12N2730/10023		11
C12N2730/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2730/10031		1
C12N2730/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2730/10032		
C12N2730/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2730/10033		1
C12N2730/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2730/10034		15
C12N2730/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2730/10041		
C12N2730/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2730/10042		
C12N2730/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2730/10043		4
C12N2730/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2730/10044		
C12N2730/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2730/10045		
C12N2730/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2730/10051		3
C12N2730/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2730/10052		1
C12N2730/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2730/10061		
C12N2730/10062	11	by genetic engineering	CPCONLY	C12N2730/10062		
C12N2730/10063	11	by chemical treatment	CPCONLY	C12N2730/10063		1
C12N2730/10064	11	by serial passage	CPCONLY	C12N2730/10064		
C12N2730/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2730/10071		2
C12N2730/10088	10	for redistribution	CPCONLY	C12N2730/10088		
C12N2730/10111	10	Orthohepadnavirus, e.g. hepatitis B virus	CPCONLY	C12N2730/10111		47
C12N2730/10121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2730/10121		36
C12N2730/10122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2730/10122		1161
C12N2730/10123	11	Virus like particles [VLP]	CPCONLY	C12N2730/10123		157
C12N2730/10131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2730/10131		8
C12N2730/10132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2730/10132		6
C12N2730/10133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2730/10133		31
C12N2730/10134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2730/10134		818
C12N2730/10141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2730/10141		6
C12N2730/10142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2730/10142		19
C12N2730/10143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2730/10143		42
C12N2730/10144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2730/10144		3
C12N2730/10145	12	Special targeting system for viral vectors	CPCONLY	C12N2730/10145		4
C12N2730/10151	11	Methods of production or purification of viral material	CPCONLY	C12N2730/10151		87
C12N2730/10152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2730/10152		16
C12N2730/10161	11	Methods of inactivation or attenuation	CPCONLY	C12N2730/10161		10
C12N2730/10162	12	by genetic engineering	CPCONLY	C12N2730/10162		7
C12N2730/10163	12	by chemical treatment	CPCONLY	C12N2730/10163		11
C12N2730/10164	12	by serial passage	CPCONLY	C12N2730/10164		
C12N2730/10171	11	Demonstrated in vivo effect	CPCONLY	C12N2730/10171		36
C12N2730/10188	11	for redistribution	CPCONLY	C12N2730/10188		
C12N2740/00	7	Reverse transcribing RNA viruses	CPCONLY	C12N2740/00		
C12N2740/00011	8	Details	CPCONLY	C12N2740/00011		2
C12N2740/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/00021		4
C12N2740/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/00022		8
C12N2740/00023	9	Virus like particles [VLP]	CPCONLY	C12N2740/00023		
C12N2740/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/00031		
C12N2740/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/00032		
C12N2740/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/00033		1
C12N2740/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/00034		5
C12N2740/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/00041		1
C12N2740/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/00042		1
C12N2740/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/00043		29
C12N2740/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/00044		
C12N2740/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2740/00045		
C12N2740/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2740/00051		6
C12N2740/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/00052		2
C12N2740/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2740/00061		1
C12N2740/00062	10	by genetic engineering	CPCONLY	C12N2740/00062		
C12N2740/00063	10	by chemical treatment	CPCONLY	C12N2740/00063		
C12N2740/00064	10	by serial passage	CPCONLY	C12N2740/00064		
C12N2740/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2740/00071		1
C12N2740/00088	9	for redistribution	CPCONLY	C12N2740/00088		
C12N2740/10011	9	Retroviridae	CPCONLY	C12N2740/10011		23
C12N2740/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/10021		78
C12N2740/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/10022		229
C12N2740/10023	10	Virus like particles [VLP]	CPCONLY	C12N2740/10023		34
C12N2740/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/10031		
C12N2740/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/10032		5
C12N2740/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/10033		13
C12N2740/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/10034		39
C12N2740/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/10041		55
C12N2740/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/10042		21
C12N2740/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/10043		649
C12N2740/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/10044		1
C12N2740/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2740/10045		14
C12N2740/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2740/10051		56
C12N2740/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/10052		47
C12N2740/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2740/10061		1
C12N2740/10062	11	by genetic engineering	CPCONLY	C12N2740/10062		2
C12N2740/10063	11	by chemical treatment	CPCONLY	C12N2740/10063		5
C12N2740/10064	11	by serial passage	CPCONLY	C12N2740/10064		1
C12N2740/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2740/10071		8
C12N2740/10088	10	for redistribution	CPCONLY	C12N2740/10088		
C12N2740/11011	10	Alpharetrovirus, e.g. avian leucosis virus	CPCONLY	C12N2740/11011		6
C12N2740/11021	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/11021		3
C12N2740/11022	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/11022		71
C12N2740/11023	11	Virus like particles [VLP]	CPCONLY	C12N2740/11023		9
C12N2740/11031	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/11031		1
C12N2740/11032	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/11032		1
C12N2740/11033	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/11033		
C12N2740/11034	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/11034		19
C12N2740/11041	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/11041		
C12N2740/11042	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/11042		4
C12N2740/11043	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/11043		38
C12N2740/11044	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/11044		1
C12N2740/11045	12	Special targeting system for viral vectors	CPCONLY	C12N2740/11045		8
C12N2740/11051	11	Methods of production or purification of viral material	CPCONLY	C12N2740/11051		10
C12N2740/11052	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/11052		4
C12N2740/11061	11	Methods of inactivation or attenuation	CPCONLY	C12N2740/11061		1
C12N2740/11062	12	by genetic engineering	CPCONLY	C12N2740/11062		
C12N2740/11063	12	by chemical treatment	CPCONLY	C12N2740/11063		3
C12N2740/11064	12	by serial passage	CPCONLY	C12N2740/11064		
C12N2740/11071	11	Demonstrated in vivo effect	CPCONLY	C12N2740/11071		
C12N2740/11088	11	for redistribution	CPCONLY	C12N2740/11088		
C12N2740/12011	10	Betaretrovirus, e.g. mouse mammary tumour virus	CPCONLY	C12N2740/12011		3
C12N2740/12021	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/12021		4
C12N2740/12022	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/12022		32
C12N2740/12023	11	Virus like particles [VLP]	CPCONLY	C12N2740/12023		6
C12N2740/12031	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/12031		
C12N2740/12032	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/12032		1
C12N2740/12033	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/12033		
C12N2740/12034	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/12034		9
C12N2740/12041	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/12041		
C12N2740/12042	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/12042		
C12N2740/12043	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/12043		15
C12N2740/12044	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/12044		
C12N2740/12045	12	Special targeting system for viral vectors	CPCONLY	C12N2740/12045		3
C12N2740/12051	11	Methods of production or purification of viral material	CPCONLY	C12N2740/12051		1
C12N2740/12052	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/12052		
C12N2740/12061	11	Methods of inactivation or attenuation	CPCONLY	C12N2740/12061		
C12N2740/12062	12	by genetic engineering	CPCONLY	C12N2740/12062		
C12N2740/12063	12	by chemical treatment	CPCONLY	C12N2740/12063		1
C12N2740/12064	12	by serial passage	CPCONLY	C12N2740/12064		
C12N2740/12071	11	Demonstrated in vivo effect	CPCONLY	C12N2740/12071		
C12N2740/12088	11	for redistribution	CPCONLY	C12N2740/12088		
C12N2740/13011	10	Gammaretrovirus, e.g. murine leukeamia virus	CPCONLY	C12N2740/13011		11
C12N2740/13021	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/13021		21
C12N2740/13022	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/13022		328
C12N2740/13023	11	Virus like particles [VLP]	CPCONLY	C12N2740/13023		77
C12N2740/13031	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/13031		2
C12N2740/13032	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/13032		15
C12N2740/13033	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/13033		3
C12N2740/13034	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/13034		62
C12N2740/13041	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/13041		8
C12N2740/13042	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/13042		15
C12N2740/13043	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/13043		870
C12N2740/13044	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/13044		7
C12N2740/13045	12	Special targeting system for viral vectors	CPCONLY	C12N2740/13045		159
C12N2740/13051	11	Methods of production or purification of viral material	CPCONLY	C12N2740/13051		56
C12N2740/13052	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/13052		136
C12N2740/13061	11	Methods of inactivation or attenuation	CPCONLY	C12N2740/13061		7
C12N2740/13062	12	by genetic engineering	CPCONLY	C12N2740/13062		27
C12N2740/13063	12	by chemical treatment	CPCONLY	C12N2740/13063		10
C12N2740/13064	12	by serial passage	CPCONLY	C12N2740/13064		2
C12N2740/13071	11	Demonstrated in vivo effect	CPCONLY	C12N2740/13071		9
C12N2740/13088	11	for redistribution	CPCONLY	C12N2740/13088		
C12N2740/14011	10	Deltaretrovirus, e.g. bovine leukeamia virus	CPCONLY	C12N2740/14011		8
C12N2740/14021	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/14021		13
C12N2740/14022	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/14022		171
C12N2740/14023	11	Virus like particles [VLP]	CPCONLY	C12N2740/14023		5
C12N2740/14031	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/14031		1
C12N2740/14032	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/14032		
C12N2740/14033	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/14033		1
C12N2740/14034	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/14034		35
C12N2740/14041	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/14041		
C12N2740/14042	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/14042		1
C12N2740/14043	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/14043		20
C12N2740/14044	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/14044		
C12N2740/14045	12	Special targeting system for viral vectors	CPCONLY	C12N2740/14045		
C12N2740/14051	11	Methods of production or purification of viral material	CPCONLY	C12N2740/14051		9
C12N2740/14052	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/14052		2
C12N2740/14061	11	Methods of inactivation or attenuation	CPCONLY	C12N2740/14061		
C12N2740/14062	12	by genetic engineering	CPCONLY	C12N2740/14062		1
C12N2740/14063	12	by chemical treatment	CPCONLY	C12N2740/14063		2
C12N2740/14064	12	by serial passage	CPCONLY	C12N2740/14064		1
C12N2740/14071	11	Demonstrated in vivo effect	CPCONLY	C12N2740/14071		3
C12N2740/14088	11	for redistribution	CPCONLY	C12N2740/14088		
C12N2740/15011	10	Lentivirus, not HIV, e.g. FIV, SIV	CPCONLY	C12N2740/15011		57
C12N2740/15021	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/15021		446
C12N2740/15022	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/15022		478
C12N2740/15023	11	Virus like particles [VLP]	CPCONLY	C12N2740/15023		76
C12N2740/15031	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/15031		7
C12N2740/15032	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/15032		33
C12N2740/15033	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/15033		19
C12N2740/15034	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/15034		250
C12N2740/15041	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/15041		257
C12N2740/15042	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/15042		50
C12N2740/15043	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/15043		5647
C12N2740/15044	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/15044		9
C12N2740/15045	12	Special targeting system for viral vectors	CPCONLY	C12N2740/15045		103
C12N2740/15051	11	Methods of production or purification of viral material	CPCONLY	C12N2740/15051		135
C12N2740/15052	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/15052		248
C12N2740/15061	11	Methods of inactivation or attenuation	CPCONLY	C12N2740/15061		8
C12N2740/15062	12	by genetic engineering	CPCONLY	C12N2740/15062		15
C12N2740/15063	12	by chemical treatment	CPCONLY	C12N2740/15063		6
C12N2740/15064	12	by serial passage	CPCONLY	C12N2740/15064		1
C12N2740/15071	11	Demonstrated in vivo effect	CPCONLY	C12N2740/15071		63
C12N2740/15088	11	for redistribution	CPCONLY	C12N2740/15088		
C12N2740/16011	10	Human Immunodeficiency Virus, HIV	CPCONLY	C12N2740/16011		144
C12N2740/16021	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/16021		135
C12N2740/16022	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/16022		432
C12N2740/16023	11	Virus like particles [VLP]	CPCONLY	C12N2740/16023		197
C12N2740/16031	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/16031		7
C12N2740/16032	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/16032		28
C12N2740/16033	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/16033		65
C12N2740/16034	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/16034		579
C12N2740/16041	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/16041		27
C12N2740/16042	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/16042		27
C12N2740/16043	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/16043		2580
C12N2740/16044	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/16044		16
C12N2740/16045	12	Special targeting system for viral vectors	CPCONLY	C12N2740/16045		226
C12N2740/16051	11	Methods of production or purification of viral material	CPCONLY	C12N2740/16051		196
C12N2740/16052	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/16052		221
C12N2740/16061	11	Methods of inactivation or attenuation	CPCONLY	C12N2740/16061		45
C12N2740/16062	12	by genetic engineering	CPCONLY	C12N2740/16062		49
C12N2740/16063	12	by chemical treatment	CPCONLY	C12N2740/16063		58
C12N2740/16064	12	by serial passage	CPCONLY	C12N2740/16064		1
C12N2740/16071	11	Demonstrated in vivo effect	CPCONLY	C12N2740/16071		51
C12N2740/16088	11	for redistribution	CPCONLY	C12N2740/16088		2
C12N2740/16111	11	concerning HIV env	CPCONLY	C12N2740/16111		66
C12N2740/16122	12	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/16122		1637
C12N2740/16134	12	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/16134		815
C12N2740/16171	12	Demonstrated in vivo effect	CPCONLY	C12N2740/16171		53
C12N2740/16188	12	for redistribution	CPCONLY	C12N2740/16188		
C12N2740/16211	11	concerning HIV gagpol	CPCONLY	C12N2740/16211		31
C12N2740/16222	12	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/16222		848
C12N2740/16234	12	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/16234		400
C12N2740/16271	12	Demonstrated in vivo effect	CPCONLY	C12N2740/16271		22
C12N2740/16288	12	for redistribution	CPCONLY	C12N2740/16288		
C12N2740/16311	11	concerning HIV regulatory proteins	CPCONLY	C12N2740/16311		28
C12N2740/16322	12	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/16322		647
C12N2740/16334	12	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/16334		153
C12N2740/16371	12	Demonstrated in vivo effect	CPCONLY	C12N2740/16371		12
C12N2740/16388	12	for redistribution	CPCONLY	C12N2740/16388		
C12N2740/17011	10	Spumavirus, e.g. chimpanzee foamy virus	CPCONLY	C12N2740/17011		
C12N2740/17021	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2740/17021		10
C12N2740/17022	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2740/17022		29
C12N2740/17023	11	Virus like particles [VLP]	CPCONLY	C12N2740/17023		3
C12N2740/17031	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2740/17031		
C12N2740/17032	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2740/17032		5
C12N2740/17033	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2740/17033		1
C12N2740/17034	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2740/17034		1
C12N2740/17041	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2740/17041		1
C12N2740/17042	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2740/17042		
C12N2740/17043	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2740/17043		24
C12N2740/17044	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2740/17044		
C12N2740/17045	12	Special targeting system for viral vectors	CPCONLY	C12N2740/17045		2
C12N2740/17051	11	Methods of production or purification of viral material	CPCONLY	C12N2740/17051		2
C12N2740/17052	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2740/17052		12
C12N2740/17061	11	Methods of inactivation or attenuation	CPCONLY	C12N2740/17061		
C12N2740/17062	12	by genetic engineering	CPCONLY	C12N2740/17062		
C12N2740/17063	12	by chemical treatment	CPCONLY	C12N2740/17063		
C12N2740/17064	12	by serial passage	CPCONLY	C12N2740/17064		
C12N2740/17071	11	Demonstrated in vivo effect	CPCONLY	C12N2740/17071		
C12N2740/17088	11	for redistribution	CPCONLY	C12N2740/17088		
C12N2750/00	7	ssDNA viruses	CPCONLY	C12N2750/00		
C12N2750/00011	8	Details	CPCONLY	C12N2750/00011		2
C12N2750/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2750/00021		31
C12N2750/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2750/00022		60
C12N2750/00023	9	Virus like particles [VLP]	CPCONLY	C12N2750/00023		12
C12N2750/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2750/00031		3
C12N2750/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2750/00032		3
C12N2750/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2750/00033		4
C12N2750/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2750/00034		20
C12N2750/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2750/00041		2
C12N2750/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2750/00042		6
C12N2750/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2750/00043		46
C12N2750/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2750/00044		2
C12N2750/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2750/00045		2
C12N2750/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2750/00051		10
C12N2750/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2750/00052		9
C12N2750/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2750/00061		1
C12N2750/00062	10	by genetic engineering	CPCONLY	C12N2750/00062		
C12N2750/00063	10	by chemical treatment	CPCONLY	C12N2750/00063		1
C12N2750/00064	10	by serial passage	CPCONLY	C12N2750/00064		1
C12N2750/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2750/00071		6
C12N2750/00088	9	for redistribution	CPCONLY	C12N2750/00088		
C12N2750/10011	9	Circoviridae	CPCONLY	C12N2750/10011		14
C12N2750/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2750/10021		63
C12N2750/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2750/10022		358
C12N2750/10023	10	Virus like particles [VLP]	CPCONLY	C12N2750/10023		77
C12N2750/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2750/10031		5
C12N2750/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2750/10032		1
C12N2750/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2750/10033		9
C12N2750/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2750/10034		441
C12N2750/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2750/10041		5
C12N2750/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2750/10042		
C12N2750/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2750/10043		21
C12N2750/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2750/10044		2
C12N2750/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2750/10045		
C12N2750/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2750/10051		131
C12N2750/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2750/10052		22
C12N2750/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2750/10061		7
C12N2750/10062	11	by genetic engineering	CPCONLY	C12N2750/10062		9
C12N2750/10063	11	by chemical treatment	CPCONLY	C12N2750/10063		7
C12N2750/10064	11	by serial passage	CPCONLY	C12N2750/10064		8
C12N2750/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2750/10071		18
C12N2750/10088	10	for redistribution	CPCONLY	C12N2750/10088		
C12N2750/12011	9	Geminiviridae	CPCONLY	C12N2750/12011		9
C12N2750/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2750/12021		16
C12N2750/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2750/12022		58
C12N2750/12023	10	Virus like particles [VLP]	CPCONLY	C12N2750/12023		2
C12N2750/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2750/12031		
C12N2750/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2750/12032		
C12N2750/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2750/12033		
C12N2750/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2750/12034		2
C12N2750/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2750/12041		2
C12N2750/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2750/12042		
C12N2750/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2750/12043		31
C12N2750/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2750/12044		2
C12N2750/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2750/12045		
C12N2750/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2750/12051		3
C12N2750/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2750/12052		
C12N2750/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2750/12061		1
C12N2750/12062	11	by genetic engineering	CPCONLY	C12N2750/12062		1
C12N2750/12063	11	by chemical treatment	CPCONLY	C12N2750/12063		1
C12N2750/12064	11	by serial passage	CPCONLY	C12N2750/12064		
C12N2750/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2750/12071		1
C12N2750/12088	10	for redistribution	CPCONLY	C12N2750/12088		
C12N2750/14011	9	Parvoviridae	CPCONLY	C12N2750/14011		7
C12N2750/14021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2750/14021		29
C12N2750/14022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2750/14022		62
C12N2750/14023	10	Virus like particles [VLP]	CPCONLY	C12N2750/14023		24
C12N2750/14031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2750/14031		2
C12N2750/14032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2750/14032		10
C12N2750/14033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2750/14033		5
C12N2750/14034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2750/14034		95
C12N2750/14041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2750/14041		9
C12N2750/14042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2750/14042		3
C12N2750/14043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2750/14043		61
C12N2750/14044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2750/14044		1
C12N2750/14045	11	Special targeting system for viral vectors	CPCONLY	C12N2750/14045		5
C12N2750/14051	10	Methods of production or purification of viral material	CPCONLY	C12N2750/14051		45
C12N2750/14052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2750/14052		11
C12N2750/14061	10	Methods of inactivation or attenuation	CPCONLY	C12N2750/14061		5
C12N2750/14062	11	by genetic engineering	CPCONLY	C12N2750/14062		
C12N2750/14063	11	by chemical treatment	CPCONLY	C12N2750/14063		6
C12N2750/14064	11	by serial passage	CPCONLY	C12N2750/14064		1
C12N2750/14071	10	Demonstrated in vivo effect	CPCONLY	C12N2750/14071		16
C12N2750/14088	10	for redistribution	CPCONLY	C12N2750/14088		
C12N2750/14111	10	Dependovirus, e.g. adenoassociated viruses	CPCONLY	C12N2750/14111		36
C12N2750/14121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2750/14121		462
C12N2750/14122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2750/14122		1315
C12N2750/14123	11	Virus like particles [VLP]	CPCONLY	C12N2750/14123		151
C12N2750/14131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2750/14131		8
C12N2750/14132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2750/14132		147
C12N2750/14133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2750/14133		55
C12N2750/14134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2750/14134		55
C12N2750/14141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2750/14141		252
C12N2750/14142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2750/14142		119
C12N2750/14143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2750/14143		6853
C12N2750/14144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2750/14144		28
C12N2750/14145	12	Special targeting system for viral vectors	CPCONLY	C12N2750/14145		629
C12N2750/14151	11	Methods of production or purification of viral material	CPCONLY	C12N2750/14151		584
C12N2750/14152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2750/14152		550
C12N2750/14161	11	Methods of inactivation or attenuation	CPCONLY	C12N2750/14161		4
C12N2750/14162	12	by genetic engineering	CPCONLY	C12N2750/14162		16
C12N2750/14163	12	by chemical treatment	CPCONLY	C12N2750/14163		1
C12N2750/14164	12	by serial passage	CPCONLY	C12N2750/14164		
C12N2750/14171	11	Demonstrated in vivo effect	CPCONLY	C12N2750/14171		412
C12N2750/14188	11	for redistribution	CPCONLY	C12N2750/14188		
C12N2750/14211	10	Erythrovirus, e.g. B19 virus	CPCONLY	C12N2750/14211		1
C12N2750/14221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2750/14221		4
C12N2750/14222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2750/14222		32
C12N2750/14223	11	Virus like particles [VLP]	CPCONLY	C12N2750/14223		6
C12N2750/14231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2750/14231		
C12N2750/14232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2750/14232		
C12N2750/14233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2750/14233		
C12N2750/14234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2750/14234		6
C12N2750/14241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2750/14241		
C12N2750/14242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2750/14242		1
C12N2750/14243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2750/14243		18
C12N2750/14244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2750/14244		
C12N2750/14245	12	Special targeting system for viral vectors	CPCONLY	C12N2750/14245		2
C12N2750/14251	11	Methods of production or purification of viral material	CPCONLY	C12N2750/14251		4
C12N2750/14252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2750/14252		1
C12N2750/14261	11	Methods of inactivation or attenuation	CPCONLY	C12N2750/14261		1
C12N2750/14262	12	by genetic engineering	CPCONLY	C12N2750/14262		
C12N2750/14263	12	by chemical treatment	CPCONLY	C12N2750/14263		1
C12N2750/14264	12	by serial passage	CPCONLY	C12N2750/14264		
C12N2750/14271	11	Demonstrated in vivo effect	CPCONLY	C12N2750/14271		
C12N2750/14288	11	for redistribution	CPCONLY	C12N2750/14288		
C12N2750/14311	10	Parvovirus, e.g. minute virus of mice	CPCONLY	C12N2750/14311		5
C12N2750/14321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2750/14321		50
C12N2750/14322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2750/14322		199
C12N2750/14323	11	Virus like particles [VLP]	CPCONLY	C12N2750/14323		35
C12N2750/14331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2750/14331		
C12N2750/14332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2750/14332		29
C12N2750/14333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2750/14333		5
C12N2750/14334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2750/14334		226
C12N2750/14341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2750/14341		
C12N2750/14342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2750/14342		1
C12N2750/14343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2750/14343		54
C12N2750/14344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2750/14344		3
C12N2750/14345	12	Special targeting system for viral vectors	CPCONLY	C12N2750/14345		6
C12N2750/14351	11	Methods of production or purification of viral material	CPCONLY	C12N2750/14351		60
C12N2750/14352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2750/14352		16
C12N2750/14361	11	Methods of inactivation or attenuation	CPCONLY	C12N2750/14361		9
C12N2750/14362	12	by genetic engineering	CPCONLY	C12N2750/14362		6
C12N2750/14363	12	by chemical treatment	CPCONLY	C12N2750/14363		18
C12N2750/14364	12	by serial passage	CPCONLY	C12N2750/14364		6
C12N2750/14371	11	Demonstrated in vivo effect	CPCONLY	C12N2750/14371		7
C12N2750/14388	11	for redistribution	CPCONLY	C12N2750/14388		
C12N2760/00	7	ssRNA viruses negative-sense	CPCONLY	C12N2760/00		3
C12N2760/00011	8	Details	CPCONLY	C12N2760/00011		3
C12N2760/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/00021		13
C12N2760/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/00022		40
C12N2760/00023	9	Virus like particles [VLP]	CPCONLY	C12N2760/00023		4
C12N2760/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/00031		1
C12N2760/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/00032		4
C12N2760/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/00033		3
C12N2760/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/00034		32
C12N2760/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/00041		1
C12N2760/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/00042		1
C12N2760/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/00043		12
C12N2760/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/00044		2
C12N2760/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2760/00045		1
C12N2760/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2760/00051		21
C12N2760/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/00052		5
C12N2760/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2760/00061		3
C12N2760/00062	10	by genetic engineering	CPCONLY	C12N2760/00062		5
C12N2760/00063	10	by chemical treatment	CPCONLY	C12N2760/00063		3
C12N2760/00064	10	by serial passage	CPCONLY	C12N2760/00064		1
C12N2760/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2760/00071		5
C12N2760/00088	9	for redistribution	CPCONLY	C12N2760/00088		
C12N2760/10011	9	Arenaviridae	CPCONLY	C12N2760/10011		12
C12N2760/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/10021		17
C12N2760/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/10022		72
C12N2760/10023	10	Virus like particles [VLP]	CPCONLY	C12N2760/10023		11
C12N2760/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/10031		2
C12N2760/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/10032		9
C12N2760/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/10033		5
C12N2760/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/10034		84
C12N2760/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/10041		6
C12N2760/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/10042		
C12N2760/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/10043		25
C12N2760/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/10044		1
C12N2760/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2760/10045		2
C12N2760/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2760/10051		10
C12N2760/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/10052		7
C12N2760/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2760/10061		2
C12N2760/10062	11	by genetic engineering	CPCONLY	C12N2760/10062		7
C12N2760/10063	11	by chemical treatment	CPCONLY	C12N2760/10063		2
C12N2760/10064	11	by serial passage	CPCONLY	C12N2760/10064		1
C12N2760/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2760/10071		5
C12N2760/10088	10	for redistribution	CPCONLY	C12N2760/10088		
C12N2760/10111	10	Deltavirus, e.g. hepatitis delta virus	CPCONLY	C12N2760/10111		3
C12N2760/10121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/10121		3
C12N2760/10122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/10122		38
C12N2760/10123	11	Virus like particles [VLP]	CPCONLY	C12N2760/10123		2
C12N2760/10131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/10131		1
C12N2760/10132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/10132		
C12N2760/10133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/10133		2
C12N2760/10134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/10134		16
C12N2760/10141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/10141		
C12N2760/10142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/10142		
C12N2760/10143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/10143		1
C12N2760/10144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/10144		
C12N2760/10145	12	Special targeting system for viral vectors	CPCONLY	C12N2760/10145		
C12N2760/10151	11	Methods of production or purification of viral material	CPCONLY	C12N2760/10151		2
C12N2760/10152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/10152		2
C12N2760/10161	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/10161		
C12N2760/10162	12	by genetic engineering	CPCONLY	C12N2760/10162		1
C12N2760/10163	12	by chemical treatment	CPCONLY	C12N2760/10163		4
C12N2760/10164	12	by serial passage	CPCONLY	C12N2760/10164		
C12N2760/10171	11	Demonstrated in vivo effect	CPCONLY	C12N2760/10171		2
C12N2760/10188	11	for redistribution	CPCONLY	C12N2760/10188		
C12N2760/12011	9	Bunyaviridae	CPCONLY	C12N2760/12011		4
C12N2760/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/12021		20
C12N2760/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/12022		98
C12N2760/12023	10	Virus like particles [VLP]	CPCONLY	C12N2760/12023		7
C12N2760/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/12031		1
C12N2760/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/12032		1
C12N2760/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/12033		2
C12N2760/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/12034		79
C12N2760/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/12041		1
C12N2760/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/12042		
C12N2760/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/12043		7
C12N2760/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/12044		
C12N2760/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2760/12045		
C12N2760/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2760/12051		4
C12N2760/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/12052		2
C12N2760/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2760/12061		4
C12N2760/12062	11	by genetic engineering	CPCONLY	C12N2760/12062		3
C12N2760/12063	11	by chemical treatment	CPCONLY	C12N2760/12063		2
C12N2760/12064	11	by serial passage	CPCONLY	C12N2760/12064		
C12N2760/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2760/12071		4
C12N2760/12088	10	for redistribution	CPCONLY	C12N2760/12088		
C12N2760/12111	10	Hantavirus, e.g. Hantaan virus	CPCONLY	C12N2760/12111		5
C12N2760/12121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/12121		8
C12N2760/12122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/12122		49
C12N2760/12123	11	Virus like particles [VLP]	CPCONLY	C12N2760/12123		3
C12N2760/12131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/12131		2
C12N2760/12132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/12132		
C12N2760/12133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/12133		2
C12N2760/12134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/12134		33
C12N2760/12141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/12141		
C12N2760/12142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/12142		
C12N2760/12143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/12143		1
C12N2760/12144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/12144		
C12N2760/12145	12	Special targeting system for viral vectors	CPCONLY	C12N2760/12145		
C12N2760/12151	11	Methods of production or purification of viral material	CPCONLY	C12N2760/12151		14
C12N2760/12152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/12152		
C12N2760/12161	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/12161		
C12N2760/12162	12	by genetic engineering	CPCONLY	C12N2760/12162		2
C12N2760/12163	12	by chemical treatment	CPCONLY	C12N2760/12163		
C12N2760/12164	12	by serial passage	CPCONLY	C12N2760/12164		
C12N2760/12171	11	Demonstrated in vivo effect	CPCONLY	C12N2760/12171		3
C12N2760/12188	11	for redistribution	CPCONLY	C12N2760/12188		
C12N2760/12211	10	Phlebovirus, e.g. Rift Valley fever virus	CPCONLY	C12N2760/12211		13
C12N2760/12221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/12221		18
C12N2760/12222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/12222		34
C12N2760/12223	11	Virus like particles [VLP]	CPCONLY	C12N2760/12223		6
C12N2760/12231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/12231		
C12N2760/12232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/12232		1
C12N2760/12233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/12233		4
C12N2760/12234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/12234		45
C12N2760/12241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/12241		
C12N2760/12242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/12242		
C12N2760/12243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/12243		3
C12N2760/12244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/12244		
C12N2760/12245	12	Special targeting system for viral vectors	CPCONLY	C12N2760/12245		
C12N2760/12251	11	Methods of production or purification of viral material	CPCONLY	C12N2760/12251		6
C12N2760/12252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/12252		4
C12N2760/12261	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/12261		1
C12N2760/12262	12	by genetic engineering	CPCONLY	C12N2760/12262		5
C12N2760/12263	12	by chemical treatment	CPCONLY	C12N2760/12263		1
C12N2760/12264	12	by serial passage	CPCONLY	C12N2760/12264		1
C12N2760/12271	11	Demonstrated in vivo effect	CPCONLY	C12N2760/12271		4
C12N2760/12288	11	for redistribution	CPCONLY	C12N2760/12288		
C12N2760/14011	9	Filoviridae	CPCONLY	C12N2760/14011		5
C12N2760/14021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/14021		1
C12N2760/14022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/14022		17
C12N2760/14023	10	Virus like particles [VLP]	CPCONLY	C12N2760/14023		3
C12N2760/14031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/14031		
C12N2760/14032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/14032		
C12N2760/14033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/14033		3
C12N2760/14034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/14034		21
C12N2760/14041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/14041		
C12N2760/14042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/14042		
C12N2760/14043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/14043		
C12N2760/14044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/14044		
C12N2760/14045	11	Special targeting system for viral vectors	CPCONLY	C12N2760/14045		
C12N2760/14051	10	Methods of production or purification of viral material	CPCONLY	C12N2760/14051		2
C12N2760/14052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/14052		1
C12N2760/14061	10	Methods of inactivation or attenuation	CPCONLY	C12N2760/14061		
C12N2760/14062	11	by genetic engineering	CPCONLY	C12N2760/14062		
C12N2760/14063	11	by chemical treatment	CPCONLY	C12N2760/14063		
C12N2760/14064	11	by serial passage	CPCONLY	C12N2760/14064		
C12N2760/14071	10	Demonstrated in vivo effect	CPCONLY	C12N2760/14071		2
C12N2760/14088	10	for redistribution	CPCONLY	C12N2760/14088		
C12N2760/14111	10	Ebolavirus, e.g. Zaire ebolavirus	CPCONLY	C12N2760/14111		17
C12N2760/14121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/14121		7
C12N2760/14122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/14122		122
C12N2760/14123	11	Virus like particles [VLP]	CPCONLY	C12N2760/14123		22
C12N2760/14131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/14131		1
C12N2760/14132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/14132		1
C12N2760/14133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/14133		8
C12N2760/14134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/14134		167
C12N2760/14141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/14141		
C12N2760/14142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/14142		1
C12N2760/14143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/14143		4
C12N2760/14144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/14144		
C12N2760/14145	12	Special targeting system for viral vectors	CPCONLY	C12N2760/14145		5
C12N2760/14151	11	Methods of production or purification of viral material	CPCONLY	C12N2760/14151		6
C12N2760/14152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/14152		4
C12N2760/14161	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/14161		
C12N2760/14162	12	by genetic engineering	CPCONLY	C12N2760/14162		2
C12N2760/14163	12	by chemical treatment	CPCONLY	C12N2760/14163		6
C12N2760/14164	12	by serial passage	CPCONLY	C12N2760/14164		
C12N2760/14171	11	Demonstrated in vivo effect	CPCONLY	C12N2760/14171		21
C12N2760/14188	11	for redistribution	CPCONLY	C12N2760/14188		
C12N2760/14211	10	Marburgvirus, e.g. lake Victoria marburgvirus	CPCONLY	C12N2760/14211		4
C12N2760/14221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/14221		4
C12N2760/14222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/14222		34
C12N2760/14223	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/14223		7
C12N2760/14231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/14231		
C12N2760/14232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/14232		
C12N2760/14233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/14233		2
C12N2760/14234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/14234		47
C12N2760/14241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/14241		
C12N2760/14242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/14242		
C12N2760/14243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/14243		
C12N2760/14244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/14244		1
C12N2760/14245	12	Special targeting system for viral vectors	CPCONLY	C12N2760/14245		3
C12N2760/14251	11	Methods of production or purification of viral material	CPCONLY	C12N2760/14251		1
C12N2760/14252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/14252		2
C12N2760/14261	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/14261		
C12N2760/14262	12	by genetic engineering	CPCONLY	C12N2760/14262		
C12N2760/14263	12	by chemical treatment	CPCONLY	C12N2760/14263		
C12N2760/14264	12	by serial passage	CPCONLY	C12N2760/14264		
C12N2760/14271	11	Demonstrated in vivo effect	CPCONLY	C12N2760/14271		3
C12N2760/14288	11	for redistribution	CPCONLY	C12N2760/14288		
C12N2760/16011	9	Orthomyxoviridae	CPCONLY	C12N2760/16011		31
C12N2760/16021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/16021		35
C12N2760/16022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/16022		245
C12N2760/16023	10	Virus like particles [VLP]	CPCONLY	C12N2760/16023		35
C12N2760/16031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/16031		3
C12N2760/16032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/16032		7
C12N2760/16033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/16033		11
C12N2760/16034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/16034		417
C12N2760/16041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/16041		5
C12N2760/16042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/16042		4
C12N2760/16043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/16043		16
C12N2760/16044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/16044		
C12N2760/16045	11	Special targeting system for viral vectors	CPCONLY	C12N2760/16045		2
C12N2760/16051	10	Methods of production or purification of viral material	CPCONLY	C12N2760/16051		112
C12N2760/16052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/16052		21
C12N2760/16061	10	Methods of inactivation or attenuation	CPCONLY	C12N2760/16061		17
C12N2760/16062	11	by genetic engineering	CPCONLY	C12N2760/16062		13
C12N2760/16063	11	by chemical treatment	CPCONLY	C12N2760/16063		15
C12N2760/16064	11	by serial passage	CPCONLY	C12N2760/16064		4
C12N2760/16071	10	Demonstrated in vivo effect	CPCONLY	C12N2760/16071		42
C12N2760/16088	10	for redistribution	CPCONLY	C12N2760/16088		
C12N2760/16111	10	Influenzavirus A, i.e. influenza A virus	CPCONLY	C12N2760/16111		110
C12N2760/16121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/16121		267
C12N2760/16122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/16122		1381
C12N2760/16123	11	Virus like particles [VLP]	CPCONLY	C12N2760/16123		175
C12N2760/16131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/16131		14
C12N2760/16132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/16132		30
C12N2760/16133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/16133		31
C12N2760/16134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/16134		2732
C12N2760/16141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/16141		14
C12N2760/16142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/16142		12
C12N2760/16143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/16143		106
C12N2760/16144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/16144		1
C12N2760/16145	12	Special targeting system for viral vectors	CPCONLY	C12N2760/16145		3
C12N2760/16151	11	Methods of production or purification of viral material	CPCONLY	C12N2760/16151		461
C12N2760/16152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/16152		129
C12N2760/16161	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/16161		84
C12N2760/16162	12	by genetic engineering	CPCONLY	C12N2760/16162		93
C12N2760/16163	12	by chemical treatment	CPCONLY	C12N2760/16163		85
C12N2760/16164	12	by serial passage	CPCONLY	C12N2760/16164		14
C12N2760/16171	11	Demonstrated in vivo effect	CPCONLY	C12N2760/16171		150
C12N2760/16188	11	for redistribution	CPCONLY	C12N2760/16188		
C12N2760/16211	10	Influenzavirus B, i.e. influenza B virus	CPCONLY	C12N2760/16211		13
C12N2760/16221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/16221		32
C12N2760/16222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/16222		210
C12N2760/16223	11	Virus like particles [VLP]	CPCONLY	C12N2760/16223		34
C12N2760/16231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/16231		
C12N2760/16232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/16232		7
C12N2760/16233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/16233		5
C12N2760/16234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/16234		621
C12N2760/16241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/16241		1
C12N2760/16242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/16242		
C12N2760/16243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/16243		19
C12N2760/16244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/16244		
C12N2760/16245	12	Special targeting system for viral vectors	CPCONLY	C12N2760/16245		
C12N2760/16251	11	Methods of production or purification of viral material	CPCONLY	C12N2760/16251		111
C12N2760/16252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/16252		33
C12N2760/16261	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/16261		19
C12N2760/16262	12	by genetic engineering	CPCONLY	C12N2760/16262		16
C12N2760/16263	12	by chemical treatment	CPCONLY	C12N2760/16263		22
C12N2760/16264	12	by serial passage	CPCONLY	C12N2760/16264		4
C12N2760/16271	11	Demonstrated in vivo effect	CPCONLY	C12N2760/16271		23
C12N2760/16288	11	for redistribution	CPCONLY	C12N2760/16288		
C12N2760/16311	10	Influenzavirus C, i.e. influenza C virus	CPCONLY	C12N2760/16311		3
C12N2760/16321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/16321		4
C12N2760/16322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/16322		26
C12N2760/16323	11	Virus like particles [VLP]	CPCONLY	C12N2760/16323		3
C12N2760/16331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/16331		
C12N2760/16332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/16332		3
C12N2760/16333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/16333		1
C12N2760/16334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/16334		40
C12N2760/16341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/16341		
C12N2760/16342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/16342		
C12N2760/16343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/16343		3
C12N2760/16344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/16344		
C12N2760/16345	12	Special targeting system for viral vectors	CPCONLY	C12N2760/16345		1
C12N2760/16351	11	Methods of production or purification of viral material	CPCONLY	C12N2760/16351		11
C12N2760/16352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/16352		2
C12N2760/16361	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/16361		2
C12N2760/16362	12	by genetic engineering	CPCONLY	C12N2760/16362		1
C12N2760/16363	12	by chemical treatment	CPCONLY	C12N2760/16363		3
C12N2760/16364	12	by serial passage	CPCONLY	C12N2760/16364		
C12N2760/16371	11	Demonstrated in vivo effect	CPCONLY	C12N2760/16371		
C12N2760/16388	11	for redistribution	CPCONLY	C12N2760/16388		
C12N2760/18011	9	Paramyxoviridae	CPCONLY	C12N2760/18011		14
C12N2760/18021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18021		14
C12N2760/18022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18022		67
C12N2760/18023	10	Virus like particles [VLP]	CPCONLY	C12N2760/18023		7
C12N2760/18031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18031		2
C12N2760/18032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18032		5
C12N2760/18033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18033		2
C12N2760/18034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18034		75
C12N2760/18041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18041		1
C12N2760/18042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18042		
C12N2760/18043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18043		14
C12N2760/18044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18044		
C12N2760/18045	11	Special targeting system for viral vectors	CPCONLY	C12N2760/18045		1
C12N2760/18051	10	Methods of production or purification of viral material	CPCONLY	C12N2760/18051		16
C12N2760/18052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18052		9
C12N2760/18061	10	Methods of inactivation or attenuation	CPCONLY	C12N2760/18061		3
C12N2760/18062	11	by genetic engineering	CPCONLY	C12N2760/18062		1
C12N2760/18063	11	by chemical treatment	CPCONLY	C12N2760/18063		3
C12N2760/18064	11	by serial passage	CPCONLY	C12N2760/18064		
C12N2760/18071	10	Demonstrated in vivo effect	CPCONLY	C12N2760/18071		7
C12N2760/18088	10	for redistribution	CPCONLY	C12N2760/18088		
C12N2760/18111	10	Avulavirus, e.g. Newcastle disease virus	CPCONLY	C12N2760/18111		12
C12N2760/18121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18121		156
C12N2760/18122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18122		249
C12N2760/18123	11	Virus like particles [VLP]	CPCONLY	C12N2760/18123		15
C12N2760/18131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18131		
C12N2760/18132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18132		64
C12N2760/18133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18133		9
C12N2760/18134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18134		472
C12N2760/18141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18141		10
C12N2760/18142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18142		1
C12N2760/18143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18143		111
C12N2760/18144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18144		3
C12N2760/18145	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18145		1
C12N2760/18151	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18151		69
C12N2760/18152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18152		50
C12N2760/18161	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18161		10
C12N2760/18162	12	by genetic engineering	CPCONLY	C12N2760/18162		17
C12N2760/18163	12	by chemical treatment	CPCONLY	C12N2760/18163		13
C12N2760/18164	12	by serial passage	CPCONLY	C12N2760/18164		2
C12N2760/18171	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18171		24
C12N2760/18188	11	for redistribution	CPCONLY	C12N2760/18188		
C12N2760/18211	10	Henipavirus, e.g. hendra virus	CPCONLY	C12N2760/18211		4
C12N2760/18221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18221		3
C12N2760/18222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18222		79
C12N2760/18223	11	Virus like particles [VLP]	CPCONLY	C12N2760/18223		8
C12N2760/18231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18231		1
C12N2760/18232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18232		1
C12N2760/18233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18233		6
C12N2760/18234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18234		46
C12N2760/18241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18241		1
C12N2760/18242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18242		1
C12N2760/18243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18243		2
C12N2760/18244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18244		1
C12N2760/18245	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18245		2
C12N2760/18251	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18251		3
C12N2760/18252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18252		3
C12N2760/18261	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18261		1
C12N2760/18262	12	by genetic engineering	CPCONLY	C12N2760/18262		2
C12N2760/18263	12	by chemical treatment	CPCONLY	C12N2760/18263		
C12N2760/18264	12	by serial passage	CPCONLY	C12N2760/18264		
C12N2760/18271	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18271		11
C12N2760/18288	11	for redistribution	CPCONLY	C12N2760/18288		
C12N2760/18311	10	Metapneumovirus, e.g. avian pneumovirus	CPCONLY	C12N2760/18311		2
C12N2760/18321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18321		20
C12N2760/18322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18322		63
C12N2760/18323	11	Virus like particles [VLP]	CPCONLY	C12N2760/18323		5
C12N2760/18331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18331		
C12N2760/18332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18332		1
C12N2760/18333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18333		1
C12N2760/18334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18334		115
C12N2760/18341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18341		
C12N2760/18342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18342		
C12N2760/18343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18343		9
C12N2760/18344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18344		
C12N2760/18345	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18345		
C12N2760/18351	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18351		10
C12N2760/18352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18352		4
C12N2760/18361	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18361		4
C12N2760/18362	12	by genetic engineering	CPCONLY	C12N2760/18362		9
C12N2760/18363	12	by chemical treatment	CPCONLY	C12N2760/18363		
C12N2760/18364	12	by serial passage	CPCONLY	C12N2760/18364		7
C12N2760/18371	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18371		6
C12N2760/18388	11	for redistribution	CPCONLY	C12N2760/18388		
C12N2760/18411	10	Morbillivirus, e.g. Measles virus, canine distemper	CPCONLY	C12N2760/18411		12
C12N2760/18421	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18421		64
C12N2760/18422	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18422		233
C12N2760/18423	11	Virus like particles [VLP]	CPCONLY	C12N2760/18423		13
C12N2760/18431	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18431		
C12N2760/18432	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18432		29
C12N2760/18433	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18433		11
C12N2760/18434	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18434		393
C12N2760/18441	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18441		8
C12N2760/18442	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18442		3
C12N2760/18443	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18443		70
C12N2760/18444	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18444		6
C12N2760/18445	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18445		5
C12N2760/18451	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18451		71
C12N2760/18452	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18452		22
C12N2760/18461	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18461		7
C12N2760/18462	12	by genetic engineering	CPCONLY	C12N2760/18462		4
C12N2760/18463	12	by chemical treatment	CPCONLY	C12N2760/18463		11
C12N2760/18464	12	by serial passage	CPCONLY	C12N2760/18464		9
C12N2760/18471	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18471		13
C12N2760/18488	11	For redistribution	CPCONLY	C12N2760/18488		
C12N2760/18511	10	Pneumovirus, e.g. human respiratory syncytial virus	CPCONLY	C12N2760/18511		33
C12N2760/18521	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18521		44
C12N2760/18522	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18522		505
C12N2760/18523	11	Virus like particles [VLP]	CPCONLY	C12N2760/18523		47
C12N2760/18531	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18531		4
C12N2760/18532	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18532		11
C12N2760/18533	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18533		14
C12N2760/18534	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18534		672
C12N2760/18541	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18541		7
C12N2760/18542	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18542		
C12N2760/18543	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18543		44
C12N2760/18544	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18544		1
C12N2760/18545	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18545		3
C12N2760/18551	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18551		43
C12N2760/18552	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18552		12
C12N2760/18561	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18561		35
C12N2760/18562	12	by genetic engineering	CPCONLY	C12N2760/18562		27
C12N2760/18563	12	by chemical treatment	CPCONLY	C12N2760/18563		5
C12N2760/18564	12	by serial passage	CPCONLY	C12N2760/18564		6
C12N2760/18571	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18571		67
C12N2760/18588	11	for redistribution	CPCONLY	C12N2760/18588		
C12N2760/18611	10	Respirovirus, e.g. Bovine, human parainfluenza 1,3	CPCONLY	C12N2760/18611		5
C12N2760/18621	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18621		19
C12N2760/18622	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18622		112
C12N2760/18623	11	Virus like particles [VLP]	CPCONLY	C12N2760/18623		2
C12N2760/18631	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18631		
C12N2760/18632	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18632		2
C12N2760/18633	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18633		5
C12N2760/18634	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18634		161
C12N2760/18641	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18641		6
C12N2760/18642	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18642		
C12N2760/18643	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18643		32
C12N2760/18644	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18644		1
C12N2760/18645	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18645		2
C12N2760/18651	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18651		34
C12N2760/18652	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18652		6
C12N2760/18661	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18661		14
C12N2760/18662	12	by genetic engineering	CPCONLY	C12N2760/18662		3
C12N2760/18663	12	by chemical treatment	CPCONLY	C12N2760/18663		4
C12N2760/18664	12	by serial passage	CPCONLY	C12N2760/18664		3
C12N2760/18671	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18671		8
C12N2760/18688	11	for redistribution	CPCONLY	C12N2760/18688		
C12N2760/18711	10	Rubulavirus, e.g. mumps virus, parainfluenza 2,4	CPCONLY	C12N2760/18711		4
C12N2760/18721	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18721		24
C12N2760/18722	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18722		74
C12N2760/18723	11	Virus like particles [VLP]	CPCONLY	C12N2760/18723		5
C12N2760/18731	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18731		
C12N2760/18732	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18732		7
C12N2760/18733	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18733		1
C12N2760/18734	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18734		131
C12N2760/18741	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18741		2
C12N2760/18742	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18742		2
C12N2760/18743	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18743		27
C12N2760/18744	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/18744		
C12N2760/18745	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18745		1
C12N2760/18751	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18751		22
C12N2760/18752	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18752		13
C12N2760/18761	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18761		4
C12N2760/18762	12	by genetic engineering	CPCONLY	C12N2760/18762		5
C12N2760/18763	12	by chemical treatment	CPCONLY	C12N2760/18763		3
C12N2760/18764	12	by serial passage	CPCONLY	C12N2760/18764		6
C12N2760/18771	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18771		3
C12N2760/18788	11	for redistribution	CPCONLY	C12N2760/18788		
C12N2760/18811	10	Sendai virus	CPCONLY	C12N2760/18811		7
C12N2760/18821	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/18821		13
C12N2760/18822	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/18822		44
C12N2760/18823	11	Virus like particles [VLP]	CPCONLY	C12N2760/18823		11
C12N2760/18831	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/18831		3
C12N2760/18832	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/18832		10
C12N2760/18833	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/18833		4
C12N2760/18834	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/18834		28
C12N2760/18841	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/18841		10
C12N2760/18842	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/18842		5
C12N2760/18843	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/18843		146
C12N2760/18845	12	Special targeting system for viral vectors	CPCONLY	C12N2760/18845		12
C12N2760/18851	11	Methods of production or purification of viral material	CPCONLY	C12N2760/18851		16
C12N2760/18852	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/18852		12
C12N2760/18861	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/18861		11
C12N2760/18862	12	by genetic engineering	CPCONLY	C12N2760/18862		6
C12N2760/18863	12	by chemical treatment	CPCONLY	C12N2760/18863		8
C12N2760/18864	12	by serial passage	CPCONLY	C12N2760/18864		1
C12N2760/18871	11	Demonstrated in vivo effect	CPCONLY	C12N2760/18871		12
C12N2760/18888	11	for redistribution	CPCONLY	C12N2760/18888		
C12N2760/20011	9	Rhabdoviridae	CPCONLY	C12N2760/20011		10
C12N2760/20021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/20021		34
C12N2760/20022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/20022		111
C12N2760/20023	10	Virus like particles [VLP]	CPCONLY	C12N2760/20023		10
C12N2760/20031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/20031		3
C12N2760/20032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/20032		19
C12N2760/20033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/20033		3
C12N2760/20034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/20034		102
C12N2760/20041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/20041		6
C12N2760/20042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/20042		3
C12N2760/20043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/20043		41
C12N2760/20044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/20044		2
C12N2760/20045	11	Special targeting system for viral vectors	CPCONLY	C12N2760/20045		4
C12N2760/20051	10	Methods of production or purification of viral material	CPCONLY	C12N2760/20051		32
C12N2760/20052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/20052		11
C12N2760/20061	10	Methods of inactivation or attenuation	CPCONLY	C12N2760/20061		4
C12N2760/20062	11	by genetic engineering	CPCONLY	C12N2760/20062		3
C12N2760/20063	11	by chemical treatment	CPCONLY	C12N2760/20063		5
C12N2760/20064	11	by serial passage	CPCONLY	C12N2760/20064		2
C12N2760/20071	10	Demonstrated in vivo effect	CPCONLY	C12N2760/20071		8
C12N2760/20088	10	for redistribution	CPCONLY	C12N2760/20088		
C12N2760/20111	10	Lyssavirus, e.g. rabies virus	CPCONLY	C12N2760/20111		6
C12N2760/20121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/20121		50
C12N2760/20122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/20122		262
C12N2760/20123	11	Virus like particles [VLP]	CPCONLY	C12N2760/20123		10
C12N2760/20131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/20131		1
C12N2760/20132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/20132		
C12N2760/20133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/20133		6
C12N2760/20134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/20134		430
C12N2760/20141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/20141		2
C12N2760/20142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/20142		2
C12N2760/20143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/20143		48
C12N2760/20144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/20144		
C12N2760/20145	12	Special targeting system for viral vectors	CPCONLY	C12N2760/20145		8
C12N2760/20151	11	Methods of production or purification of viral material	CPCONLY	C12N2760/20151		96
C12N2760/20152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/20152		29
C12N2760/20161	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/20161		11
C12N2760/20162	12	by genetic engineering	CPCONLY	C12N2760/20162		6
C12N2760/20163	12	by chemical treatment	CPCONLY	C12N2760/20163		14
C12N2760/20164	12	by serial passage	CPCONLY	C12N2760/20164		5
C12N2760/20171	11	Demonstrated in vivo effect	CPCONLY	C12N2760/20171		16
C12N2760/20188	11	for redistribution	CPCONLY	C12N2760/20188		
C12N2760/20211	10	Vesiculovirus, e.g. vesicular stomatitis Indiana virus	CPCONLY	C12N2760/20211		8
C12N2760/20221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2760/20221		75
C12N2760/20222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2760/20222		299
C12N2760/20223	11	Virus like particles [VLP]	CPCONLY	C12N2760/20223		30
C12N2760/20231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2760/20231		2
C12N2760/20232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2760/20232		103
C12N2760/20233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2760/20233		14
C12N2760/20234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2760/20234		95
C12N2760/20241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2760/20241		11
C12N2760/20242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2760/20242		13
C12N2760/20243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2760/20243		196
C12N2760/20244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2760/20244		9
C12N2760/20245	12	Special targeting system for viral vectors	CPCONLY	C12N2760/20245		19
C12N2760/20251	11	Methods of production or purification of viral material	CPCONLY	C12N2760/20251		36
C12N2760/20252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2760/20252		38
C12N2760/20261	11	Methods of inactivation or attenuation	CPCONLY	C12N2760/20261		14
C12N2760/20262	12	by genetic engineering	CPCONLY	C12N2760/20262		18
C12N2760/20263	12	by chemical treatment	CPCONLY	C12N2760/20263		26
C12N2760/20264	12	by serial passage	CPCONLY	C12N2760/20264		6
C12N2760/20271	11	Demonstrated in vivo effect	CPCONLY	C12N2760/20271		17
C12N2760/20288	11	for redistribution	CPCONLY	C12N2760/20288		
C12N2770/00	7	ssRNA viruses positive-sense	CPCONLY	C12N2770/00		5
C12N2770/00011	8	Details	CPCONLY	C12N2770/00011		16
C12N2770/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/00021		63
C12N2770/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/00022		216
C12N2770/00023	9	Virus like particles [VLP]	CPCONLY	C12N2770/00023		47
C12N2770/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/00031		17
C12N2770/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/00032		5
C12N2770/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/00033		8
C12N2770/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/00034		45
C12N2770/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/00041		7
C12N2770/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/00042		20
C12N2770/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/00043		63
C12N2770/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/00044		2
C12N2770/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2770/00045		
C12N2770/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2770/00051		27
C12N2770/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/00052		3
C12N2770/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2770/00061		5
C12N2770/00062	10	by genetic engineering	CPCONLY	C12N2770/00062		6
C12N2770/00063	10	by chemical treatment	CPCONLY	C12N2770/00063		4
C12N2770/00064	10	by serial passage	CPCONLY	C12N2770/00064		
C12N2770/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2770/00071		3
C12N2770/00088	9	for redistribution	CPCONLY	C12N2770/00088		
C12N2770/10011	9	Arteriviridae	CPCONLY	C12N2770/10011		19
C12N2770/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/10021		121
C12N2770/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/10022		230
C12N2770/10023	10	Virus like particles [VLP]	CPCONLY	C12N2770/10023		15
C12N2770/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/10031		4
C12N2770/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/10032		2
C12N2770/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/10033		3
C12N2770/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/10034		391
C12N2770/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/10041		1
C12N2770/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/10042		
C12N2770/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/10043		25
C12N2770/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/10044		2
C12N2770/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/10045		
C12N2770/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/10051		74
C12N2770/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/10052		29
C12N2770/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/10061		24
C12N2770/10062	11	by genetic engineering	CPCONLY	C12N2770/10062		27
C12N2770/10063	11	by chemical treatment	CPCONLY	C12N2770/10063		5
C12N2770/10064	11	by serial passage	CPCONLY	C12N2770/10064		20
C12N2770/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/10071		16
C12N2770/10088	10	for redistribution	CPCONLY	C12N2770/10088		
C12N2770/12011	9	Astroviridae	CPCONLY	C12N2770/12011		3
C12N2770/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/12021		18
C12N2770/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/12022		49
C12N2770/12023	10	Virus like particles [VLP]	CPCONLY	C12N2770/12023		2
C12N2770/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/12031		
C12N2770/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/12032		1
C12N2770/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/12033		5
C12N2770/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/12034		47
C12N2770/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/12041		
C12N2770/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/12042		
C12N2770/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/12043		1
C12N2770/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/12044		
C12N2770/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/12045		
C12N2770/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/12051		14
C12N2770/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/12052		2
C12N2770/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/12061		
C12N2770/12062	11	by genetic engineering	CPCONLY	C12N2770/12062		
C12N2770/12063	11	by chemical treatment	CPCONLY	C12N2770/12063		3
C12N2770/12064	11	by serial passage	CPCONLY	C12N2770/12064		2
C12N2770/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/12071		2
C12N2770/12088	10	for redistribution	CPCONLY	C12N2770/12088		
C12N2770/14011	9	Bromoviridae	CPCONLY	C12N2770/14011		4
C12N2770/14021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/14021		11
C12N2770/14022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/14022		67
C12N2770/14023	10	Virus like particles [VLP]	CPCONLY	C12N2770/14023		42
C12N2770/14031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/14031		3
C12N2770/14032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/14032		
C12N2770/14033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/14033		1
C12N2770/14034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/14034		16
C12N2770/14041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/14041		5
C12N2770/14042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/14042		17
C12N2770/14043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/14043		8
C12N2770/14044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/14044		
C12N2770/14045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/14045		1
C12N2770/14051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/14051		2
C12N2770/14052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/14052		4
C12N2770/14061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/14061		1
C12N2770/14062	11	by genetic engineering	CPCONLY	C12N2770/14062		3
C12N2770/14063	11	by chemical treatment	CPCONLY	C12N2770/14063		
C12N2770/14064	11	by serial passage	CPCONLY	C12N2770/14064		
C12N2770/14071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/14071		1
C12N2770/14088	10	for redistribution	CPCONLY	C12N2770/14088		
C12N2770/16011	9	Caliciviridae	CPCONLY	C12N2770/16011		11
C12N2770/16021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/16021		38
C12N2770/16022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/16022		169
C12N2770/16023	10	Virus like particles [VLP]	CPCONLY	C12N2770/16023		92
C12N2770/16031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/16031		1
C12N2770/16032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/16032		1
C12N2770/16033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/16033		3
C12N2770/16034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/16034		228
C12N2770/16041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/16041		
C12N2770/16042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/16042		7
C12N2770/16043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/16043		13
C12N2770/16044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/16044		
C12N2770/16045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/16045		1
C12N2770/16051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/16051		57
C12N2770/16052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/16052		10
C12N2770/16061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/16061		10
C12N2770/16062	11	by genetic engineering	CPCONLY	C12N2770/16062		2
C12N2770/16063	11	by chemical treatment	CPCONLY	C12N2770/16063		16
C12N2770/16064	11	by serial passage	CPCONLY	C12N2770/16064		1
C12N2770/16071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/16071		11
C12N2770/16088	10	for redistribution	CPCONLY	C12N2770/16088		
C12N2770/18011	9	Comoviridae	CPCONLY	C12N2770/18011		3
C12N2770/18021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/18021		5
C12N2770/18022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/18022		32
C12N2770/18023	10	Virus like particles [VLP]	CPCONLY	C12N2770/18023		28
C12N2770/18031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/18031		2
C12N2770/18032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/18032		3
C12N2770/18033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/18033		2
C12N2770/18034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/18034		28
C12N2770/18041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/18041		2
C12N2770/18042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/18042		9
C12N2770/18043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/18043		5
C12N2770/18044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/18044		
C12N2770/18045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/18045		3
C12N2770/18051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/18051		3
C12N2770/18052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/18052		2
C12N2770/18061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/18061		
C12N2770/18062	11	by genetic engineering	CPCONLY	C12N2770/18062		
C12N2770/18063	11	by chemical treatment	CPCONLY	C12N2770/18063		2
C12N2770/18064	11	by serial passage	CPCONLY	C12N2770/18064		
C12N2770/18071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/18071		11
C12N2770/18088	10	for redistribution	CPCONLY	C12N2770/18088		
C12N2770/20011	9	Coronaviridae	CPCONLY	C12N2770/20011		90
C12N2770/20021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/20021		350
C12N2770/20022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/20022		2606
C12N2770/20023	10	Virus like particles [VLP]	CPCONLY	C12N2770/20023		145
C12N2770/20031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/20031		30
C12N2770/20032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/20032		15
C12N2770/20033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/20033		72
C12N2770/20034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/20034		3307
C12N2770/20041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/20041		7
C12N2770/20042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/20042		7
C12N2770/20043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/20043		56
C12N2770/20044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/20044		5
C12N2770/20045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/20045		3
C12N2770/20051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/20051		304
C12N2770/20052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/20052		125
C12N2770/20061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/20061		38
C12N2770/20062	11	by genetic engineering	CPCONLY	C12N2770/20062		46
C12N2770/20063	11	by chemical treatment	CPCONLY	C12N2770/20063		55
C12N2770/20064	11	by serial passage	CPCONLY	C12N2770/20064		40
C12N2770/20071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/20071		227
C12N2770/20088	10	for redistribution	CPCONLY	C12N2770/20088		
C12N2770/22011	9	Dicistroviridae	CPCONLY	C12N2770/22011		
C12N2770/22021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/22021		2
C12N2770/22022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/22022		16
C12N2770/22023	10	Virus like particles [VLP]	CPCONLY	C12N2770/22023		4
C12N2770/22031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/22031		1
C12N2770/22032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/22032		
C12N2770/22033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/22033		
C12N2770/22034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/22034		5
C12N2770/22041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/22041		
C12N2770/22042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/22042		2
C12N2770/22043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/22043		5
C12N2770/22044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/22044		
C12N2770/22045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/22045		
C12N2770/22051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/22051		
C12N2770/22052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/22052		2
C12N2770/22061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/22061		
C12N2770/22062	11	by genetic engineering	CPCONLY	C12N2770/22062		
C12N2770/22063	11	by chemical treatment	CPCONLY	C12N2770/22063		
C12N2770/22064	11	by serial passage	CPCONLY	C12N2770/22064		
C12N2770/22071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/22071		
C12N2770/22088	10	for redistribution	CPCONLY	C12N2770/22088		
C12N2770/24011	9	Flaviviridae	CPCONLY	C12N2770/24011		18
C12N2770/24021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/24021		18
C12N2770/24022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/24022		89
C12N2770/24023	10	Virus like particles [VLP]	CPCONLY	C12N2770/24023		6
C12N2770/24031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/24031		1
C12N2770/24032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/24032		5
C12N2770/24033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/24033		8
C12N2770/24034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/24034		72
C12N2770/24041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/24041		2
C12N2770/24042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/24042		
C12N2770/24043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/24043		12
C12N2770/24044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/24044		3
C12N2770/24045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/24045		
C12N2770/24051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/24051		24
C12N2770/24052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/24052		1
C12N2770/24061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/24061		2
C12N2770/24062	11	by genetic engineering	CPCONLY	C12N2770/24062		2
C12N2770/24063	11	by chemical treatment	CPCONLY	C12N2770/24063		6
C12N2770/24064	11	by serial passage	CPCONLY	C12N2770/24064		3
C12N2770/24071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/24071		3
C12N2770/24088	10	for redistribution	CPCONLY	C12N2770/24088		
C12N2770/24111	10	Flavivirus, e.g. yellow fever virus, dengue, JEV	CPCONLY	C12N2770/24111		49
C12N2770/24121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/24121		150
C12N2770/24122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/24122		625
C12N2770/24123	11	Virus like particles [VLP]	CPCONLY	C12N2770/24123		77
C12N2770/24131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/24131		8
C12N2770/24132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/24132		27
C12N2770/24133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/24133		15
C12N2770/24134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/24134		762
C12N2770/24141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/24141		10
C12N2770/24142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/24142		1
C12N2770/24143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/24143		85
C12N2770/24144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/24144		14
C12N2770/24145	12	Special targeting system for viral vectors	CPCONLY	C12N2770/24145		2
C12N2770/24151	11	Methods of production or purification of viral material	CPCONLY	C12N2770/24151		147
C12N2770/24152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/24152		44
C12N2770/24161	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/24161		51
C12N2770/24162	12	by genetic engineering	CPCONLY	C12N2770/24162		71
C12N2770/24163	12	by chemical treatment	CPCONLY	C12N2770/24163		39
C12N2770/24164	12	by serial passage	CPCONLY	C12N2770/24164		25
C12N2770/24171	11	Demonstrated in vivo effect	CPCONLY	C12N2770/24171		81
C12N2770/24188	11	for redistribution	CPCONLY	C12N2770/24188		
C12N2770/24211	10	Hepacivirus, e.g. hepatitis C virus, hepatitis G virus	CPCONLY	C12N2770/24211		99
C12N2770/24221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/24221		92
C12N2770/24222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/24222		938
C12N2770/24223	11	Virus like particles [VLP]	CPCONLY	C12N2770/24223		38
C12N2770/24231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/24231		9
C12N2770/24232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/24232		6
C12N2770/24233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/24233		15
C12N2770/24234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/24234		365
C12N2770/24241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/24241		
C12N2770/24242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/24242		2
C12N2770/24243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/24243		61
C12N2770/24244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/24244		2
C12N2770/24245	12	Special targeting system for viral vectors	CPCONLY	C12N2770/24245		5
C12N2770/24251	11	Methods of production or purification of viral material	CPCONLY	C12N2770/24251		108
C12N2770/24252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/24252		17
C12N2770/24261	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/24261		11
C12N2770/24262	12	by genetic engineering	CPCONLY	C12N2770/24262		7
C12N2770/24263	12	by chemical treatment	CPCONLY	C12N2770/24263		10
C12N2770/24264	12	by serial passage	CPCONLY	C12N2770/24264		1
C12N2770/24271	11	Demonstrated in vivo effect	CPCONLY	C12N2770/24271		19
C12N2770/24288	11	for redistribution	CPCONLY	C12N2770/24288		
C12N2770/24311	10	Pestivirus, e.g. bovine viral diarrhea virus	CPCONLY	C12N2770/24311		6
C12N2770/24321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/24321		31
C12N2770/24322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/24322		257
C12N2770/24323	11	Virus like particles [VLP]	CPCONLY	C12N2770/24323		11
C12N2770/24331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/24331		2
C12N2770/24332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/24332		
C12N2770/24333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/24333		2
C12N2770/24334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/24334		358
C12N2770/24341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/24341		1
C12N2770/24342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/24342		1
C12N2770/24343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/24343		5
C12N2770/24344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/24344		1
C12N2770/24345	12	Special targeting system for viral vectors	CPCONLY	C12N2770/24345		1
C12N2770/24351	11	Methods of production or purification of viral material	CPCONLY	C12N2770/24351		61
C12N2770/24352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/24352		16
C12N2770/24361	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/24361		20
C12N2770/24362	12	by genetic engineering	CPCONLY	C12N2770/24362		15
C12N2770/24363	12	by chemical treatment	CPCONLY	C12N2770/24363		20
C12N2770/24364	12	by serial passage	CPCONLY	C12N2770/24364		8
C12N2770/24371	11	Demonstrated in vivo effect	CPCONLY	C12N2770/24371		10
C12N2770/24388	11	for redistribution	CPCONLY	C12N2770/24388		
C12N2770/26011	9	Flexiviridae	CPCONLY	C12N2770/26011		5
C12N2770/26021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/26021		4
C12N2770/26022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/26022		14
C12N2770/26023	10	Virus like particles [VLP]	CPCONLY	C12N2770/26023		16
C12N2770/26031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/26031		1
C12N2770/26032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/26032		
C12N2770/26033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/26033		3
C12N2770/26034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/26034		6
C12N2770/26041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/26041		
C12N2770/26042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/26042		7
C12N2770/26043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/26043		5
C12N2770/26044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/26044		
C12N2770/26045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/26045		
C12N2770/26051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/26051		2
C12N2770/26052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/26052		
C12N2770/26061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/26061		
C12N2770/26062	11	by genetic engineering	CPCONLY	C12N2770/26062		2
C12N2770/26063	11	by chemical treatment	CPCONLY	C12N2770/26063		
C12N2770/26064	11	by serial passage	CPCONLY	C12N2770/26064		
C12N2770/26071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/26071		2
C12N2770/26088	10	for redistribution	CPCONLY	C12N2770/26088		
C12N2770/28011	9	Hepeviridae	CPCONLY	C12N2770/28011		1
C12N2770/28021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/28021		3
C12N2770/28022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/28022		7
C12N2770/28023	10	Virus like particles [VLP]	CPCONLY	C12N2770/28023		3
C12N2770/28031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/28031		
C12N2770/28032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/28032		
C12N2770/28033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/28033		1
C12N2770/28034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/28034		5
C12N2770/28041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/28041		1
C12N2770/28042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/28042		
C12N2770/28043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/28043		
C12N2770/28044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/28044		
C12N2770/28045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/28045		1
C12N2770/28051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/28051		1
C12N2770/28052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/28052		
C12N2770/28061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/28061		1
C12N2770/28062	11	by genetic engineering	CPCONLY	C12N2770/28062		
C12N2770/28063	11	by chemical treatment	CPCONLY	C12N2770/28063		
C12N2770/28064	11	by serial passage	CPCONLY	C12N2770/28064		
C12N2770/28071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/28071		
C12N2770/28088	10	for redistribution	CPCONLY	C12N2770/28088		
C12N2770/28111	10	Hepevirus, e.g. hepatitis E virus	CPCONLY	C12N2770/28111		1
C12N2770/28121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/28121		6
C12N2770/28122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/28122		76
C12N2770/28123	11	Virus like particles [VLP]	CPCONLY	C12N2770/28123		30
C12N2770/28131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/28131		2
C12N2770/28132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/28132		
C12N2770/28133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/28133		1
C12N2770/28134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/28134		39
C12N2770/28141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/28141		1
C12N2770/28142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/28142		4
C12N2770/28143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/28143		4
C12N2770/28144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/28144		
C12N2770/28145	12	Special targeting system for viral vectors	CPCONLY	C12N2770/28145		1
C12N2770/28151	11	Methods of production or purification of viral material	CPCONLY	C12N2770/28151		14
C12N2770/28152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/28152		4
C12N2770/28161	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/28161		1
C12N2770/28162	12	by genetic engineering	CPCONLY	C12N2770/28162		1
C12N2770/28163	12	by chemical treatment	CPCONLY	C12N2770/28163		
C12N2770/28164	12	by serial passage	CPCONLY	C12N2770/28164		
C12N2770/28171	11	Demonstrated in vivo effect	CPCONLY	C12N2770/28171		3
C12N2770/28188	11	for redistribution	CPCONLY	C12N2770/28188		
C12N2770/30011	9	Nodaviridae	CPCONLY	C12N2770/30011		2
C12N2770/30021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/30021		4
C12N2770/30022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/30022		31
C12N2770/30023	10	Virus like particles [VLP]	CPCONLY	C12N2770/30023		11
C12N2770/30031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/30031		
C12N2770/30032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/30032		1
C12N2770/30033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/30033		
C12N2770/30034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/30034		28
C12N2770/30041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/30041		1
C12N2770/30042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/30042		1
C12N2770/30043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/30043		7
C12N2770/30044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/30044		
C12N2770/30045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/30045		1
C12N2770/30051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/30051		16
C12N2770/30052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/30052		3
C12N2770/30061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/30061		
C12N2770/30062	11	by genetic engineering	CPCONLY	C12N2770/30062		1
C12N2770/30063	11	by chemical treatment	CPCONLY	C12N2770/30063		3
C12N2770/30064	11	by serial passage	CPCONLY	C12N2770/30064		
C12N2770/30071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/30071		1
C12N2770/30088	10	for redistribution	CPCONLY	C12N2770/30088		
C12N2770/32011	9	Picornaviridae	CPCONLY	C12N2770/32011		10
C12N2770/32021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32021		91
C12N2770/32022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32022		149
C12N2770/32023	10	Virus like particles [VLP]	CPCONLY	C12N2770/32023		36
C12N2770/32031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32031		5
C12N2770/32032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32032		20
C12N2770/32033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32033		6
C12N2770/32034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32034		169
C12N2770/32041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32041		1
C12N2770/32042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32042		3
C12N2770/32043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32043		28
C12N2770/32044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32044		2
C12N2770/32045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/32045		2
C12N2770/32051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/32051		73
C12N2770/32052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32052		21
C12N2770/32061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/32061		6
C12N2770/32062	11	by genetic engineering	CPCONLY	C12N2770/32062		4
C12N2770/32063	11	by chemical treatment	CPCONLY	C12N2770/32063		6
C12N2770/32064	11	by serial passage	CPCONLY	C12N2770/32064		3
C12N2770/32071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/32071		7
C12N2770/32088	10	for redistribution	CPCONLY	C12N2770/32088		
C12N2770/32111	10	Aphthovirus, e.g. footandmouth disease virus	CPCONLY	C12N2770/32111		15
C12N2770/32121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32121		49
C12N2770/32122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32122		289
C12N2770/32123	11	Virus like particles [VLP]	CPCONLY	C12N2770/32123		79
C12N2770/32131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32131		6
C12N2770/32132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32132		1
C12N2770/32133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32133		5
C12N2770/32134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32134		453
C12N2770/32141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32141		3
C12N2770/32142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32142		1
C12N2770/32143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32143		9
C12N2770/32144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32144		
C12N2770/32145	12	Special targeting system for viral vectors	CPCONLY	C12N2770/32145		
C12N2770/32151	11	Methods of production or purification of viral material	CPCONLY	C12N2770/32151		129
C12N2770/32152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32152		41
C12N2770/32161	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/32161		10
C12N2770/32162	12	by genetic engineering	CPCONLY	C12N2770/32162		10
C12N2770/32163	12	by chemical treatment	CPCONLY	C12N2770/32163		16
C12N2770/32164	12	by serial passage	CPCONLY	C12N2770/32164		8
C12N2770/32171	11	Demonstrated in vivo effect	CPCONLY	C12N2770/32171		14
C12N2770/32188	11	for redistribution	CPCONLY	C12N2770/32188		
C12N2770/32211	10	Cardiovirus, e.g. encephalomyocarditis virus	CPCONLY	C12N2770/32211		4
C12N2770/32221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32221		5
C12N2770/32222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32222		15
C12N2770/32223	11	Virus like particles [VLP]	CPCONLY	C12N2770/32223		1
C12N2770/32231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32231		
C12N2770/32232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32232		3
C12N2770/32233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32233		
C12N2770/32234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32234		12
C12N2770/32241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32241		
C12N2770/32242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32242		1
C12N2770/32243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32243		11
C12N2770/32244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32244		
C12N2770/32245	12	Special targeting system for viral vectors	CPCONLY	C12N2770/32245		
C12N2770/32251	11	Methods of production or purification of viral material	CPCONLY	C12N2770/32251		2
C12N2770/32252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32252		
C12N2770/32261	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/32261		2
C12N2770/32262	12	by genetic engineering	CPCONLY	C12N2770/32262		1
C12N2770/32263	12	by chemical treatment	CPCONLY	C12N2770/32263		6
C12N2770/32264	12	by serial passage	CPCONLY	C12N2770/32264		
C12N2770/32271	11	Demonstrated in vivo effect	CPCONLY	C12N2770/32271		2
C12N2770/32288	11	for redistribution	CPCONLY	C12N2770/32288		
C12N2770/32311	10	Enterovirus	CPCONLY	C12N2770/32311		21
C12N2770/32321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32321		98
C12N2770/32322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32322		118
C12N2770/32323	11	Virus like particles [VLP]	CPCONLY	C12N2770/32323		35
C12N2770/32331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32331		2
C12N2770/32332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32332		45
C12N2770/32333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32333		10
C12N2770/32334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32334		220
C12N2770/32341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32341		5
C12N2770/32342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32342		
C12N2770/32343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32343		38
C12N2770/32344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32344		2
C12N2770/32345	12	Special targeting system for viral vectors	CPCONLY	C12N2770/32345		1
C12N2770/32351	11	Methods of production or purification of viral material	CPCONLY	C12N2770/32351		68
C12N2770/32352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32352		18
C12N2770/32361	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/32361		13
C12N2770/32362	12	by genetic engineering	CPCONLY	C12N2770/32362		6
C12N2770/32363	12	by chemical treatment	CPCONLY	C12N2770/32363		18
C12N2770/32364	12	by serial passage	CPCONLY	C12N2770/32364		5
C12N2770/32371	11	Demonstrated in vivo effect	CPCONLY	C12N2770/32371		19
C12N2770/32388	11	for redistribution	CPCONLY	C12N2770/32388		
C12N2770/32411	10	Hepatovirus, i.e. hepatitis A virus	CPCONLY	C12N2770/32411		15
C12N2770/32421	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32421		25
C12N2770/32422	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32422		84
C12N2770/32423	11	Virus like particles [VLP]	CPCONLY	C12N2770/32423		5
C12N2770/32431	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32431		1
C12N2770/32432	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32432		7
C12N2770/32433	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32433		
C12N2770/32434	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32434		156
C12N2770/32441	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32441		
C12N2770/32442	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32442		
C12N2770/32443	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32443		5
C12N2770/32444	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32444		
C12N2770/32445	12	Special targeting system for viral vectors	CPCONLY	C12N2770/32445		
C12N2770/32451	11	Methods of production or purification of viral material	CPCONLY	C12N2770/32451		63
C12N2770/32452	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32452		6
C12N2770/32461	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/32461		10
C12N2770/32462	12	by genetic engineering	CPCONLY	C12N2770/32462		3
C12N2770/32463	12	by chemical treatment	CPCONLY	C12N2770/32463		10
C12N2770/32464	12	by serial passage	CPCONLY	C12N2770/32464		11
C12N2770/32471	11	Demonstrated in vivo effect	CPCONLY	C12N2770/32471		2
C12N2770/32488	11	for redistribution	CPCONLY	C12N2770/32488		
C12N2770/32511	10	Parechovirus, e.g. human parechovirus	CPCONLY	C12N2770/32511		2
C12N2770/32521	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32521		2
C12N2770/32522	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32522		4
C12N2770/32523	11	Virus like particles [VLP]	CPCONLY	C12N2770/32523		
C12N2770/32531	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32531		
C12N2770/32532	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32532		
C12N2770/32533	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32533		
C12N2770/32534	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32534		3
C12N2770/32541	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32541		
C12N2770/32542	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32542		
C12N2770/32543	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32543		
C12N2770/32544	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32544		
C12N2770/32545	12	Special targeting system for viral vectors	CPCONLY	C12N2770/32545		
C12N2770/32551	11	Methods of production or purification of viral material	CPCONLY	C12N2770/32551		1
C12N2770/32552	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32552		
C12N2770/32561	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/32561		
C12N2770/32562	12	by genetic engineering	CPCONLY	C12N2770/32562		
C12N2770/32563	12	by chemical treatment	CPCONLY	C12N2770/32563		
C12N2770/32564	12	by serial passage	CPCONLY	C12N2770/32564		
C12N2770/32571	11	Demonstrated in vivo effect	CPCONLY	C12N2770/32571		
C12N2770/32588	11	for redistribution	CPCONLY	C12N2770/32588		
C12N2770/32611	10	Poliovirus	CPCONLY	C12N2770/32611		11
C12N2770/32621	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32621		15
C12N2770/32622	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32622		98
C12N2770/32623	11	Virus like particles [VLP]	CPCONLY	C12N2770/32623		12
C12N2770/32631	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32631		
C12N2770/32632	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32632		14
C12N2770/32633	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32633		1
C12N2770/32634	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32634		284
C12N2770/32641	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32641		1
C12N2770/32642	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32642		
C12N2770/32643	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32643		23
C12N2770/32644	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32644		3
C12N2770/32645	12	Special targeting system for viral vectors	CPCONLY	C12N2770/32645		2
C12N2770/32651	11	Methods of production or purification of viral material	CPCONLY	C12N2770/32651		85
C12N2770/32652	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32652		6
C12N2770/32661	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/32661		21
C12N2770/32662	12	by genetic engineering	CPCONLY	C12N2770/32662		9
C12N2770/32663	12	by chemical treatment	CPCONLY	C12N2770/32663		24
C12N2770/32664	12	by serial passage	CPCONLY	C12N2770/32664		3
C12N2770/32671	11	Demonstrated in vivo effect	CPCONLY	C12N2770/32671		11
C12N2770/32688	11	for redistribution	CPCONLY	C12N2770/32688		
C12N2770/32711	10	Rhinovirus	CPCONLY	C12N2770/32711		5
C12N2770/32721	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/32721		10
C12N2770/32722	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/32722		73
C12N2770/32723	11	Virus like particles [VLP]	CPCONLY	C12N2770/32723		5
C12N2770/32731	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/32731		
C12N2770/32732	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/32732		2
C12N2770/32733	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/32733		1
C12N2770/32734	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/32734		36
C12N2770/32741	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/32741		
C12N2770/32742	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/32742		
C12N2770/32743	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/32743		8
C12N2770/32744	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/32744		1
C12N2770/32745	12	Special targeting system for viral vectors	CPCONLY	C12N2770/32745		
C12N2770/32751	11	Methods of production or purification of viral material	CPCONLY	C12N2770/32751		6
C12N2770/32752	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/32752		
C12N2770/32761	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/32761		3
C12N2770/32762	12	by genetic engineering	CPCONLY	C12N2770/32762		6
C12N2770/32763	12	by chemical treatment	CPCONLY	C12N2770/32763		2
C12N2770/32764	12	by serial passage	CPCONLY	C12N2770/32764		1
C12N2770/32771	11	Demonstrated in vivo effect	CPCONLY	C12N2770/32771		1
C12N2770/32788	11	for redistribution	CPCONLY	C12N2770/32788		
C12N2770/34011	9	Potyviridae	CPCONLY	C12N2770/34011		7
C12N2770/34021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/34021		20
C12N2770/34022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/34022		91
C12N2770/34023	10	Virus like particles [VLP]	CPCONLY	C12N2770/34023		6
C12N2770/34031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/34031		2
C12N2770/34032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/34032		1
C12N2770/34033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/34033		4
C12N2770/34034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/34034		11
C12N2770/34041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/34041		2
C12N2770/34042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/34042		3
C12N2770/34043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/34043		8
C12N2770/34044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/34044		1
C12N2770/34045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/34045		
C12N2770/34051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/34051		7
C12N2770/34052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/34052		5
C12N2770/34061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/34061		2
C12N2770/34062	11	by genetic engineering	CPCONLY	C12N2770/34062		4
C12N2770/34063	11	by chemical treatment	CPCONLY	C12N2770/34063		
C12N2770/34064	11	by serial passage	CPCONLY	C12N2770/34064		
C12N2770/34071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/34071		1
C12N2770/34088	10	for redistribution	CPCONLY	C12N2770/34088		
C12N2770/36011	9	Togaviridae	CPCONLY	C12N2770/36011		5
C12N2770/36021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/36021		3
C12N2770/36022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/36022		11
C12N2770/36023	10	Virus like particles [VLP]	CPCONLY	C12N2770/36023		1
C12N2770/36031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/36031		
C12N2770/36032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/36032		2
C12N2770/36033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/36033		
C12N2770/36034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/36034		23
C12N2770/36041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/36041		
C12N2770/36042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/36042		
C12N2770/36043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/36043		3
C12N2770/36044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/36044		
C12N2770/36045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/36045		
C12N2770/36051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/36051		10
C12N2770/36052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/36052		1
C12N2770/36061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/36061		4
C12N2770/36062	11	by genetic engineering	CPCONLY	C12N2770/36062		1
C12N2770/36063	11	by chemical treatment	CPCONLY	C12N2770/36063		1
C12N2770/36064	11	by serial passage	CPCONLY	C12N2770/36064		1
C12N2770/36071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/36071		1
C12N2770/36088	10	for redistribution	CPCONLY	C12N2770/36088		
C12N2770/36111	10	Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki	CPCONLY	C12N2770/36111		28
C12N2770/36121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/36121		78
C12N2770/36122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/36122		239
C12N2770/36123	11	Virus like particles [VLP]	CPCONLY	C12N2770/36123		61
C12N2770/36131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/36131		4
C12N2770/36132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/36132		28
C12N2770/36133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/36133		7
C12N2770/36134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/36134		206
C12N2770/36141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/36141		16
C12N2770/36142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/36142		5
C12N2770/36143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/36143		422
C12N2770/36144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/36144		9
C12N2770/36145	12	Special targeting system for viral vectors	CPCONLY	C12N2770/36145		17
C12N2770/36151	11	Methods of production or purification of viral material	CPCONLY	C12N2770/36151		41
C12N2770/36152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/36152		41
C12N2770/36161	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/36161		20
C12N2770/36162	12	by genetic engineering	CPCONLY	C12N2770/36162		35
C12N2770/36163	12	by chemical treatment	CPCONLY	C12N2770/36163		18
C12N2770/36164	12	by serial passage	CPCONLY	C12N2770/36164		3
C12N2770/36171	11	Demonstrated in vivo effect	CPCONLY	C12N2770/36171		32
C12N2770/36188	11	for redistribution	CPCONLY	C12N2770/36188		
C12N2770/36211	10	Rubivirus, e.g. rubella virus	CPCONLY	C12N2770/36211		1
C12N2770/36221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/36221		4
C12N2770/36222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/36222		38
C12N2770/36223	11	Virus like particles [VLP]	CPCONLY	C12N2770/36223		3
C12N2770/36231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/36231		
C12N2770/36232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/36232		1
C12N2770/36233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/36233		
C12N2770/36234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/36234		94
C12N2770/36241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/36241		
C12N2770/36242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/36242		
C12N2770/36243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/36243		4
C12N2770/36244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/36244		1
C12N2770/36245	12	Special targeting system for viral vectors	CPCONLY	C12N2770/36245		
C12N2770/36251	11	Methods of production or purification of viral material	CPCONLY	C12N2770/36251		20
C12N2770/36252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/36252		4
C12N2770/36261	11	Methods of inactivation or attenuation	CPCONLY	C12N2770/36261		3
C12N2770/36262	12	by genetic engineering	CPCONLY	C12N2770/36262		1
C12N2770/36263	12	by chemical treatment	CPCONLY	C12N2770/36263		2
C12N2770/36264	12	by serial passage	CPCONLY	C12N2770/36264		1
C12N2770/36271	11	Demonstrated in vivo effect	CPCONLY	C12N2770/36271		2
C12N2770/36288	11	for redistribution	CPCONLY	C12N2770/36288		
C12N2770/38011	9	Tombusviridae	CPCONLY	C12N2770/38011		4
C12N2770/38021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/38021		3
C12N2770/38022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/38022		22
C12N2770/38023	10	Virus like particles [VLP]	CPCONLY	C12N2770/38023		3
C12N2770/38031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/38031		2
C12N2770/38032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/38032		
C12N2770/38033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/38033		
C12N2770/38034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/38034		4
C12N2770/38041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/38041		2
C12N2770/38042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/38042		
C12N2770/38043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/38043		11
C12N2770/38044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/38044		1
C12N2770/38045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/38045		
C12N2770/38051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/38051		1
C12N2770/38052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/38052		
C12N2770/38061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/38061		
C12N2770/38062	11	by genetic engineering	CPCONLY	C12N2770/38062		
C12N2770/38063	11	by chemical treatment	CPCONLY	C12N2770/38063		1
C12N2770/38064	11	by serial passage	CPCONLY	C12N2770/38064		
C12N2770/38071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/38071		
C12N2770/38088	10	for redistribution	CPCONLY	C12N2770/38088		
C12N2770/40011	9	Tymoviridae	CPCONLY	C12N2770/40011		1
C12N2770/40021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2770/40021		1
C12N2770/40022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2770/40022		22
C12N2770/40023	10	Virus like particles [VLP]	CPCONLY	C12N2770/40023		11
C12N2770/40031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2770/40031		3
C12N2770/40032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2770/40032		1
C12N2770/40033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2770/40033		1
C12N2770/40034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2770/40034		6
C12N2770/40041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2770/40041		2
C12N2770/40042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2770/40042		4
C12N2770/40043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2770/40043		7
C12N2770/40044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2770/40044		
C12N2770/40045	11	Special targeting system for viral vectors	CPCONLY	C12N2770/40045		
C12N2770/40051	10	Methods of production or purification of viral material	CPCONLY	C12N2770/40051		3
C12N2770/40052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2770/40052		
C12N2770/40061	10	Methods of inactivation or attenuation	CPCONLY	C12N2770/40061		1
C12N2770/40062	11	by genetic engineering	CPCONLY	C12N2770/40062		1
C12N2770/40063	11	by chemical treatment	CPCONLY	C12N2770/40063		1
C12N2770/40064	11	by serial passage	CPCONLY	C12N2770/40064		
C12N2770/40071	10	Demonstrated in vivo effect	CPCONLY	C12N2770/40071		
C12N2770/40088	10	for redistribution	CPCONLY	C12N2770/40088		
C12N2780/00	7	Naked RNA viruses	CPCONLY	C12N2780/00		
C12N2780/00011	8	Details	CPCONLY	C12N2780/00011		
C12N2780/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2780/00021		1
C12N2780/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2780/00022		
C12N2780/00023	9	Virus like particles [VLP]	CPCONLY	C12N2780/00023		
C12N2780/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2780/00031		
C12N2780/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2780/00032		
C12N2780/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2780/00033		
C12N2780/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2780/00034		1
C12N2780/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2780/00041		
C12N2780/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2780/00042		
C12N2780/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2780/00043		2
C12N2780/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2780/00044		
C12N2780/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2780/00045		
C12N2780/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2780/00051		
C12N2780/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2780/00052		
C12N2780/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2780/00061		1
C12N2780/00062	10	by genetic engineering	CPCONLY	C12N2780/00062		1
C12N2780/00063	10	by chemical treatment	CPCONLY	C12N2780/00063		
C12N2780/00064	10	by serial passage	CPCONLY	C12N2780/00064		
C12N2780/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2780/00071		1
C12N2780/00088	9	for redistribution	CPCONLY	C12N2780/00088		
C12N2780/10011	9	Narnaviridae	CPCONLY	C12N2780/10011		
C12N2780/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2780/10021		
C12N2780/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2780/10022		
C12N2780/10023	10	Virus like particles [VLP]	CPCONLY	C12N2780/10023		
C12N2780/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2780/10031		
C12N2780/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2780/10032		
C12N2780/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2780/10033		
C12N2780/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2780/10034		
C12N2780/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2780/10041		
C12N2780/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2780/10042		
C12N2780/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2780/10043		
C12N2780/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2780/10044		
C12N2780/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2780/10045		
C12N2780/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2780/10051		
C12N2780/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2780/10052		
C12N2780/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2780/10061		
C12N2780/10062	11	by genetic engineering	CPCONLY	C12N2780/10062		
C12N2780/10063	11	by chemical treatment	CPCONLY	C12N2780/10063		
C12N2780/10064	11	by serial passage	CPCONLY	C12N2780/10064		
C12N2780/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2780/10071		
C12N2780/10088	10	for redistribution	CPCONLY	C12N2780/10088		
C12N2790/00	7	Viroids or subviral agents	CPCONLY	C12N2790/00		1
C12N2790/00011	8	Details	CPCONLY	C12N2790/00011		
C12N2790/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2790/00021		
C12N2790/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2790/00022		
C12N2790/00023	9	Virus like particles [VLP]	CPCONLY	C12N2790/00023		2
C12N2790/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2790/00031		
C12N2790/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2790/00032		
C12N2790/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2790/00033		
C12N2790/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2790/00034		2
C12N2790/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2790/00041		
C12N2790/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2790/00042		2
C12N2790/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2790/00043		
C12N2790/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2790/00044		1
C12N2790/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2790/00045		
C12N2790/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2790/00051		
C12N2790/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2790/00052		
C12N2790/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2790/00061		
C12N2790/00062	10	by genetic engineering	CPCONLY	C12N2790/00062		
C12N2790/00063	10	by chemical treatment	CPCONLY	C12N2790/00063		
C12N2790/00064	10	by serial passage	CPCONLY	C12N2790/00064		
C12N2790/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2790/00071		
C12N2790/00088	9	for redistribution	CPCONLY	C12N2790/00088		
C12N2790/10011	9	Prions	CPCONLY	C12N2790/10011		2
C12N2790/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2790/10021		
C12N2790/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2790/10022		6
C12N2790/10023	10	Virus like particles [VLP]	CPCONLY	C12N2790/10023		
C12N2790/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2790/10031		
C12N2790/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2790/10032		
C12N2790/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2790/10033		
C12N2790/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2790/10034		
C12N2790/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2790/10041		
C12N2790/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2790/10042		
C12N2790/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2790/10043		1
C12N2790/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2790/10044		
C12N2790/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2790/10045		
C12N2790/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2790/10051		1
C12N2790/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2790/10052		
C12N2790/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2790/10061		
C12N2790/10062	11	by genetic engineering	CPCONLY	C12N2790/10062		
C12N2790/10063	11	by chemical treatment	CPCONLY	C12N2790/10063		
C12N2790/10064	11	by serial passage	CPCONLY	C12N2790/10064		
C12N2790/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2790/10071		
C12N2790/10088	10	for redistribution	CPCONLY	C12N2790/10088		
C12N2790/12011	9	Satellite viruses	CPCONLY	C12N2790/12011		
C12N2790/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2790/12021		
C12N2790/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2790/12022		
C12N2790/12023	10	Virus like particles [VLP]	CPCONLY	C12N2790/12023		
C12N2790/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2790/12031		
C12N2790/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2790/12032		
C12N2790/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2790/12033		
C12N2790/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2790/12034		
C12N2790/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2790/12041		
C12N2790/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2790/12042		
C12N2790/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2790/12043		
C12N2790/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2790/12044		
C12N2790/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2790/12045		
C12N2790/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2790/12051		
C12N2790/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2790/12052		
C12N2790/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2790/12061		
C12N2790/12062	11	by genetic engineering	CPCONLY	C12N2790/12062		
C12N2790/12063	11	by chemical treatment	CPCONLY	C12N2790/12063		
C12N2790/12064	11	by serial passage	CPCONLY	C12N2790/12064		
C12N2790/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2790/12071		
C12N2790/12088	10	for redistribution	CPCONLY	C12N2790/12088		
C12N2790/14011	9	Viroids	CPCONLY	C12N2790/14011		
C12N2790/14021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2790/14021		
C12N2790/14022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2790/14022		1
C12N2790/14023	10	Virus like particles [VLP]	CPCONLY	C12N2790/14023		
C12N2790/14031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2790/14031		
C12N2790/14032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2790/14032		
C12N2790/14033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2790/14033		
C12N2790/14034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2790/14034		1
C12N2790/14041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2790/14041		
C12N2790/14042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2790/14042		
C12N2790/14043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2790/14043		1
C12N2790/14044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2790/14044		
C12N2790/14045	11	Special targeting system for viral vectors	CPCONLY	C12N2790/14045		
C12N2790/14051	10	Methods of production or purification of viral material	CPCONLY	C12N2790/14051		
C12N2790/14052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2790/14052		
C12N2790/14061	10	Methods of inactivation or attenuation	CPCONLY	C12N2790/14061		
C12N2790/14062	11	by genetic engineering	CPCONLY	C12N2790/14062		
C12N2790/14063	11	by chemical treatment	CPCONLY	C12N2790/14063		
C12N2790/14064	11	by serial passage	CPCONLY	C12N2790/14064		
C12N2790/14071	10	Demonstrated in vivo effect	CPCONLY	C12N2790/14071		
C12N2790/14088	10	for redistribution	CPCONLY	C12N2790/14088		
C12N2792/00	7	Archaeabacteria viruses	CPCONLY	C12N2792/00		
C12N2792/00011	8	Details	CPCONLY	C12N2792/00011		
C12N2792/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2792/00021		2
C12N2792/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2792/00022		2
C12N2792/00023	9	Virus like particles [VLP]	CPCONLY	C12N2792/00023		1
C12N2792/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2792/00031		1
C12N2792/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2792/00032		
C12N2792/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2792/00033		
C12N2792/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2792/00034		
C12N2792/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2792/00041		
C12N2792/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2792/00042		
C12N2792/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2792/00043		
C12N2792/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2792/00044		
C12N2792/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2792/00045		
C12N2792/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2792/00051		
C12N2792/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2792/00052		
C12N2792/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2792/00061		
C12N2792/00062	10	by genetic engineering	CPCONLY	C12N2792/00062		
C12N2792/00063	10	by chemical treatment	CPCONLY	C12N2792/00063		
C12N2792/00064	10	by serial passage	CPCONLY	C12N2792/00064		
C12N2792/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2792/00071		
C12N2792/00088	9	for redistribution	CPCONLY	C12N2792/00088		
C12N2792/10011	9	Fuselloviridae	CPCONLY	C12N2792/10011		
C12N2792/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2792/10021		
C12N2792/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2792/10022		1
C12N2792/10023	10	Virus like particles [VLP]	CPCONLY	C12N2792/10023		
C12N2792/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2792/10031		
C12N2792/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2792/10032		
C12N2792/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2792/10033		
C12N2792/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2792/10034		
C12N2792/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2792/10041		
C12N2792/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2792/10042		
C12N2792/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2792/10043		
C12N2792/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2792/10044		
C12N2792/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2792/10045		
C12N2792/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2792/10051		
C12N2792/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2792/10052		
C12N2792/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2792/10061		
C12N2792/10062	11	by genetic engineering	CPCONLY	C12N2792/10062		
C12N2792/10063	11	by chemical treatment	CPCONLY	C12N2792/10063		
C12N2792/10064	11	by serial passage	CPCONLY	C12N2792/10064		
C12N2792/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2792/10071		
C12N2792/10088	10	for redistribution	CPCONLY	C12N2792/10088		
C12N2792/12011	9	Guttaviridae	CPCONLY	C12N2792/12011		
C12N2792/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2792/12021		
C12N2792/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2792/12022		
C12N2792/12023	10	Virus like particles [VLP]	CPCONLY	C12N2792/12023		
C12N2792/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2792/12031		
C12N2792/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2792/12032		
C12N2792/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2792/12033		
C12N2792/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2792/12034		
C12N2792/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2792/12041		
C12N2792/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2792/12042		
C12N2792/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2792/12043		
C12N2792/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2792/12044		
C12N2792/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2792/12045		
C12N2792/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2792/12051		
C12N2792/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2792/12052		
C12N2792/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2792/12061		
C12N2792/12062	11	by genetic engineering	CPCONLY	C12N2792/12062		
C12N2792/12063	11	by chemical treatment	CPCONLY	C12N2792/12063		
C12N2792/12064	11	by serial passage	CPCONLY	C12N2792/12064		
C12N2792/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2792/12071		
C12N2792/12088	10	for redistribution	CPCONLY	C12N2792/12088		
C12N2795/00	7	Bacteriophages	CPCONLY	C12N2795/00		4
C12N2795/00011	8	Details	CPCONLY	C12N2795/00011		67
C12N2795/00021	9	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/00021		407
C12N2795/00022	9	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/00022		207
C12N2795/00023	9	Virus like particles [VLP]	CPCONLY	C12N2795/00023		29
C12N2795/00031	9	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/00031		257
C12N2795/00032	9	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/00032		362
C12N2795/00033	9	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/00033		32
C12N2795/00034	9	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/00034		30
C12N2795/00041	9	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/00041		16
C12N2795/00042	10	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/00042		17
C12N2795/00043	10	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/00043		62
C12N2795/00044	10	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/00044		3
C12N2795/00045	10	Special targeting system for viral vectors	CPCONLY	C12N2795/00045		10
C12N2795/00051	9	Methods of production or purification of viral material	CPCONLY	C12N2795/00051		166
C12N2795/00052	10	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/00052		24
C12N2795/00061	9	Methods of inactivation or attenuation	CPCONLY	C12N2795/00061		5
C12N2795/00062	10	by genetic engineering	CPCONLY	C12N2795/00062		3
C12N2795/00063	10	by chemical treatment	CPCONLY	C12N2795/00063		5
C12N2795/00064	10	by serial passage	CPCONLY	C12N2795/00064		1
C12N2795/00071	9	Demonstrated in vivo effect	CPCONLY	C12N2795/00071		13
C12N2795/00088	9	for redistribution	CPCONLY	C12N2795/00088		
C12N2795/10011	9	dsDNA Bacteriophages	CPCONLY	C12N2795/10011		4
C12N2795/10021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/10021		95
C12N2795/10022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/10022		103
C12N2795/10023	10	Virus like particles [VLP]	CPCONLY	C12N2795/10023		6
C12N2795/10031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/10031		45
C12N2795/10032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/10032		71
C12N2795/10033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/10033		11
C12N2795/10034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/10034		4
C12N2795/10041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/10041		6
C12N2795/10042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/10042		7
C12N2795/10043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/10043		36
C12N2795/10044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/10044		
C12N2795/10045	11	Special targeting system for viral vectors	CPCONLY	C12N2795/10045		7
C12N2795/10051	10	Methods of production or purification of viral material	CPCONLY	C12N2795/10051		20
C12N2795/10052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/10052		4
C12N2795/10061	10	Methods of inactivation or attenuation	CPCONLY	C12N2795/10061		3
C12N2795/10062	11	by genetic engineering	CPCONLY	C12N2795/10062		
C12N2795/10063	11	by chemical treatment	CPCONLY	C12N2795/10063		
C12N2795/10064	11	by serial passage	CPCONLY	C12N2795/10064		
C12N2795/10071	10	Demonstrated in vivo effect	CPCONLY	C12N2795/10071		5
C12N2795/10088	10	for redistribution	CPCONLY	C12N2795/10088		
C12N2795/10111	10	Myoviridae	CPCONLY	C12N2795/10111		13
C12N2795/10121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/10121		332
C12N2795/10122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/10122		115
C12N2795/10123	11	Virus like particles [VLP]	CPCONLY	C12N2795/10123		7
C12N2795/10131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/10131		186
C12N2795/10132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/10132		268
C12N2795/10133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/10133		18
C12N2795/10134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/10134		6
C12N2795/10141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/10141		3
C12N2795/10142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/10142		15
C12N2795/10143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/10143		43
C12N2795/10144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/10144		2
C12N2795/10145	12	Special targeting system for viral vectors	CPCONLY	C12N2795/10145		6
C12N2795/10151	11	Methods of production or purification of viral material	CPCONLY	C12N2795/10151		62
C12N2795/10152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/10152		14
C12N2795/10161	11	Methods of inactivation or attenuation	CPCONLY	C12N2795/10161		2
C12N2795/10162	12	by genetic engineering	CPCONLY	C12N2795/10162		3
C12N2795/10163	12	by chemical treatment	CPCONLY	C12N2795/10163		4
C12N2795/10164	12	by serial passage	CPCONLY	C12N2795/10164		
C12N2795/10171	11	Demonstrated in vivo effect	CPCONLY	C12N2795/10171		13
C12N2795/10188	11	for redistribution	CPCONLY	C12N2795/10188		
C12N2795/10211	10	Podoviridae	CPCONLY	C12N2795/10211		10
C12N2795/10221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/10221		204
C12N2795/10222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/10222		87
C12N2795/10223	11	Virus like particles [VLP]	CPCONLY	C12N2795/10223		10
C12N2795/10231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/10231		126
C12N2795/10232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/10232		150
C12N2795/10233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/10233		15
C12N2795/10234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/10234		5
C12N2795/10241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/10241		
C12N2795/10242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/10242		4
C12N2795/10243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/10243		32
C12N2795/10244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/10244		1
C12N2795/10245	12	Special targeting system for viral vectors	CPCONLY	C12N2795/10245		3
C12N2795/10251	11	Methods of production or purification of viral material	CPCONLY	C12N2795/10251		38
C12N2795/10252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/10252		6
C12N2795/10261	11	Methods of inactivation or attenuation	CPCONLY	C12N2795/10261		
C12N2795/10262	12	by genetic engineering	CPCONLY	C12N2795/10262		
C12N2795/10263	12	by chemical treatment	CPCONLY	C12N2795/10263		1
C12N2795/10264	12	by serial passage	CPCONLY	C12N2795/10264		
C12N2795/10271	11	Demonstrated in vivo effect	CPCONLY	C12N2795/10271		9
C12N2795/10288	11	for redistribution	CPCONLY	C12N2795/10288		
C12N2795/10311	10	Siphoviridae	CPCONLY	C12N2795/10311		17
C12N2795/10321	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/10321		268
C12N2795/10322	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/10322		116
C12N2795/10323	11	Virus like particles [VLP]	CPCONLY	C12N2795/10323		1
C12N2795/10331	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/10331		147
C12N2795/10332	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/10332		202
C12N2795/10333	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/10333		18
C12N2795/10334	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/10334		8
C12N2795/10341	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/10341		
C12N2795/10342	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/10342		12
C12N2795/10343	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/10343		49
C12N2795/10344	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/10344		3
C12N2795/10345	12	Special targeting system for viral vectors	CPCONLY	C12N2795/10345		6
C12N2795/10351	11	Methods of production or purification of viral material	CPCONLY	C12N2795/10351		49
C12N2795/10352	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/10352		12
C12N2795/10361	11	Methods of inactivation or attenuation	CPCONLY	C12N2795/10361		
C12N2795/10362	12	by genetic engineering	CPCONLY	C12N2795/10362		5
C12N2795/10363	12	by chemical treatment	CPCONLY	C12N2795/10363		6
C12N2795/10364	12	by serial passage	CPCONLY	C12N2795/10364		2
C12N2795/10371	11	Demonstrated in vivo effect	CPCONLY	C12N2795/10371		12
C12N2795/10388	11	for redistribution	CPCONLY	C12N2795/10388		
C12N2795/12011	9	dsRNA Bacteriophages	CPCONLY	C12N2795/12011		
C12N2795/12021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/12021		5
C12N2795/12022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/12022		5
C12N2795/12023	10	Virus like particles [VLP]	CPCONLY	C12N2795/12023		2
C12N2795/12031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/12031		4
C12N2795/12032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/12032		5
C12N2795/12033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/12033		
C12N2795/12034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/12034		
C12N2795/12041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/12041		
C12N2795/12042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/12042		1
C12N2795/12043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/12043		4
C12N2795/12044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/12044		
C12N2795/12045	11	Special targeting system for viral vectors	CPCONLY	C12N2795/12045		
C12N2795/12051	10	Methods of production or purification of viral material	CPCONLY	C12N2795/12051		1
C12N2795/12052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/12052		
C12N2795/12061	10	Methods of inactivation or attenuation	CPCONLY	C12N2795/12061		
C12N2795/12062	11	by genetic engineering	CPCONLY	C12N2795/12062		
C12N2795/12063	11	by chemical treatment	CPCONLY	C12N2795/12063		1
C12N2795/12064	11	by serial passage	CPCONLY	C12N2795/12064		
C12N2795/12071	10	Demonstrated in vivo effect	CPCONLY	C12N2795/12071		1
C12N2795/12088	10	for redistribution	CPCONLY	C12N2795/12088		
C12N2795/14011	9	ssDNA Bacteriophages	CPCONLY	C12N2795/14011		4
C12N2795/14021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/14021		9
C12N2795/14022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/14022		22
C12N2795/14023	10	Virus like particles [VLP]	CPCONLY	C12N2795/14023		1
C12N2795/14031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/14031		5
C12N2795/14032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/14032		2
C12N2795/14033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/14033		1
C12N2795/14034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/14034		2
C12N2795/14041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/14041		1
C12N2795/14042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/14042		3
C12N2795/14043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/14043		9
C12N2795/14044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/14044		
C12N2795/14045	11	Special targeting system for viral vectors	CPCONLY	C12N2795/14045		4
C12N2795/14051	10	Methods of production or purification of viral material	CPCONLY	C12N2795/14051		3
C12N2795/14052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/14052		2
C12N2795/14061	10	Methods of inactivation or attenuation	CPCONLY	C12N2795/14061		
C12N2795/14062	11	by genetic engineering	CPCONLY	C12N2795/14062		
C12N2795/14063	11	by chemical treatment	CPCONLY	C12N2795/14063		
C12N2795/14064	11	by serial passage	CPCONLY	C12N2795/14064		
C12N2795/14071	10	Demonstrated in vivo effect	CPCONLY	C12N2795/14071		1
C12N2795/14088	10	for redistribution	CPCONLY	C12N2795/14088		
C12N2795/14111	10	Inoviridae	CPCONLY	C12N2795/14111		13
C12N2795/14121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/14121		49
C12N2795/14122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/14122		68
C12N2795/14123	11	Virus like particles [VLP]	CPCONLY	C12N2795/14123		3
C12N2795/14131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/14131		29
C12N2795/14132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/14132		34
C12N2795/14133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/14133		7
C12N2795/14134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/14134		4
C12N2795/14141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/14141		8
C12N2795/14142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/14142		17
C12N2795/14143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/14143		57
C12N2795/14144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/14144		4
C12N2795/14145	12	Special targeting system for viral vectors	CPCONLY	C12N2795/14145		14
C12N2795/14151	11	Methods of production or purification of viral material	CPCONLY	C12N2795/14151		26
C12N2795/14152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/14152		13
C12N2795/14161	11	Methods of inactivation or attenuation	CPCONLY	C12N2795/14161		1
C12N2795/14162	12	by genetic engineering	CPCONLY	C12N2795/14162		1
C12N2795/14163	12	by chemical treatment	CPCONLY	C12N2795/14163		1
C12N2795/14164	12	by serial passage	CPCONLY	C12N2795/14164		
C12N2795/14171	11	Demonstrated in vivo effect	CPCONLY	C12N2795/14171		10
C12N2795/14188	11	for redistribution	CPCONLY	C12N2795/14188		
C12N2795/14211	10	Microviridae	CPCONLY	C12N2795/14211		2
C12N2795/14221	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/14221		5
C12N2795/14222	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/14222		18
C12N2795/14223	11	Virus like particles [VLP]	CPCONLY	C12N2795/14223		
C12N2795/14231	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/14231		5
C12N2795/14232	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/14232		4
C12N2795/14233	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/14233		4
C12N2795/14234	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/14234		2
C12N2795/14241	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/14241		
C12N2795/14242	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/14242		
C12N2795/14243	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/14243		
C12N2795/14244	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/14244		
C12N2795/14245	12	Special targeting system for viral vectors	CPCONLY	C12N2795/14245		
C12N2795/14251	11	Methods of production or purification of viral material	CPCONLY	C12N2795/14251		8
C12N2795/14252	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/14252		
C12N2795/14261	11	Methods of inactivation or attenuation	CPCONLY	C12N2795/14261		1
C12N2795/14262	12	by genetic engineering	CPCONLY	C12N2795/14262		
C12N2795/14263	12	by chemical treatment	CPCONLY	C12N2795/14263		
C12N2795/14264	12	by serial passage	CPCONLY	C12N2795/14264		
C12N2795/14271	11	Demonstrated in vivo effect	CPCONLY	C12N2795/14271		
C12N2795/14288	11	for redistribution	CPCONLY	C12N2795/14288		
C12N2795/16011	9	ssRNA Bacteriophages negative-sense	CPCONLY	C12N2795/16011		
C12N2795/16021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/16021		1
C12N2795/16022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/16022		1
C12N2795/16023	10	Virus like particles [VLP]	CPCONLY	C12N2795/16023		3
C12N2795/16031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/16031		
C12N2795/16032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/16032		
C12N2795/16033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/16033		
C12N2795/16034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/16034		1
C12N2795/16041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/16041		
C12N2795/16042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/16042		1
C12N2795/16043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/16043		
C12N2795/16044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/16044		
C12N2795/16045	11	Special targeting system for viral vectors	CPCONLY	C12N2795/16045		
C12N2795/16051	10	Methods of production or purification of viral material	CPCONLY	C12N2795/16051		
C12N2795/16052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/16052		
C12N2795/16061	10	Methods of inactivation or attenuation	CPCONLY	C12N2795/16061		1
C12N2795/16062	11	by genetic engineering	CPCONLY	C12N2795/16062		
C12N2795/16063	11	by chemical treatment	CPCONLY	C12N2795/16063		
C12N2795/16064	11	by serial passage	CPCONLY	C12N2795/16064		
C12N2795/16071	10	Demonstrated in vivo effect	CPCONLY	C12N2795/16071		
C12N2795/16088	10	for redistribution	CPCONLY	C12N2795/16088		
C12N2795/18011	9	ssRNA Bacteriophages positive-sense	CPCONLY	C12N2795/18011		1
C12N2795/18021	10	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/18021		2
C12N2795/18022	10	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/18022		23
C12N2795/18023	10	Virus like particles [VLP]	CPCONLY	C12N2795/18023		19
C12N2795/18031	10	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/18031		1
C12N2795/18032	10	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/18032		1
C12N2795/18033	10	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/18033		1
C12N2795/18034	10	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/18034		
C12N2795/18041	10	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/18041		
C12N2795/18042	11	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/18042		3
C12N2795/18043	11	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/18043		2
C12N2795/18044	11	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/18044		
C12N2795/18045	11	Special targeting system for viral vectors	CPCONLY	C12N2795/18045		
C12N2795/18051	10	Methods of production or purification of viral material	CPCONLY	C12N2795/18051		
C12N2795/18052	11	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/18052		5
C12N2795/18061	10	Methods of inactivation or attenuation	CPCONLY	C12N2795/18061		1
C12N2795/18062	11	by genetic engineering	CPCONLY	C12N2795/18062		
C12N2795/18063	11	by chemical treatment	CPCONLY	C12N2795/18063		
C12N2795/18064	11	by serial passage	CPCONLY	C12N2795/18064		
C12N2795/18071	10	Demonstrated in vivo effect	CPCONLY	C12N2795/18071		1
C12N2795/18088	10	for redistribution	CPCONLY	C12N2795/18088		
C12N2795/18111	10	Leviviridae	CPCONLY	C12N2795/18111		3
C12N2795/18121	11	Viruses as such, e.g. new isolates, mutants or their genomic sequences	CPCONLY	C12N2795/18121		4
C12N2795/18122	11	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	CPCONLY	C12N2795/18122		94
C12N2795/18123	11	Virus like particles [VLP]	CPCONLY	C12N2795/18123		83
C12N2795/18131	11	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	CPCONLY	C12N2795/18131		4
C12N2795/18132	11	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	CPCONLY	C12N2795/18132		4
C12N2795/18133	11	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	CPCONLY	C12N2795/18133		2
C12N2795/18134	11	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	CPCONLY	C12N2795/18134		14
C12N2795/18141	11	Use of virus, viral particle or viral elements as a vector	CPCONLY	C12N2795/18141		4
C12N2795/18142	12	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	CPCONLY	C12N2795/18142		17
C12N2795/18143	12	viral genome or elements thereof as genetic vector	CPCONLY	C12N2795/18143		8
C12N2795/18144	12	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	CPCONLY	C12N2795/18144		
C12N2795/18145	12	Special targeting system for viral vectors	CPCONLY	C12N2795/18145		
C12N2795/18151	11	Methods of production or purification of viral material	CPCONLY	C12N2795/18151		11
C12N2795/18152	12	relating to complementing cells and packaging systems for producing virus or viral particles	CPCONLY	C12N2795/18152		5
C12N2795/18161	11	Methods of inactivation or attenuation	CPCONLY	C12N2795/18161		1
C12N2795/18162	12	by genetic engineering	CPCONLY	C12N2795/18162		
C12N2795/18163	12	by chemical treatment	CPCONLY	C12N2795/18163		3
C12N2795/18164	12	by serial passage	CPCONLY	C12N2795/18164		
C12N2795/18171	11	Demonstrated in vivo effect	CPCONLY	C12N2795/18171		3
C12N2795/18188	11	for redistribution	CPCONLY	C12N2795/18188		
C12N2796/00	7	Viruses not covered by groups C12N2710/00 - C12N2795/00	CPCONLY	C12N2796/00		31
C12N2799/00	7	Uses of viruses<br><br><u>WARNING</u><br> From 2012-03-15 codes in the range C12N2799/00 - C12N2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N2710/00-C12N2795/00	CPCONLY	C12N2799/00		4
C12N2799/02	8	as vector	CPCONLY	C12N2799/02		20
C12N2799/021	9	for the expression of a heterologous nucleic acid	CPCONLY	C12N2799/021		545
C12N2799/022	10	where the vector is derived from an adenovirus	CPCONLY	C12N2799/022		665
C12N2799/023	10	where the vector is derived from a poxvirus	CPCONLY	C12N2799/023		120
C12N2799/025	10	where the vector is derived from a parvovirus	CPCONLY	C12N2799/025		182
C12N2799/026	10	where the vector is derived from a baculovirus	CPCONLY	C12N2799/026		827
C12N2799/027	10	where the vector is derived from a retrovirus	CPCONLY	C12N2799/027		658
C12N2799/028	10	where the vector is derived from a herpesvirus	CPCONLY	C12N2799/028		57
C12N2799/04	9	in vivo	CPCONLY	C12N2799/04		77
C12N2799/06	9	in vitro	CPCONLY	C12N2799/06		42
C12N2800/00	7	Nucleic acids vectors	CPCONLY	C12N2800/00		72
C12N2800/10	8	Plasmid DNA	CPCONLY	C12N2800/10		170
C12N2800/101	9	for bacteria	CPCONLY	C12N2800/101		2281
C12N2800/102	9	for yeast	CPCONLY	C12N2800/102		645
C12N2800/103	9	for invertebrates	CPCONLY	C12N2800/103		22
C12N2800/105	10	for insects	CPCONLY	C12N2800/105		442
C12N2800/106	9	for vertebrates	CPCONLY	C12N2800/106		258
C12N2800/107	10	for mammalian	CPCONLY	C12N2800/107		6987
C12N2800/108	9	episomal vectors	CPCONLY	C12N2800/108		442
C12N2800/20	8	Pseudochromosomes, minichrosomosomes	CPCONLY	C12N2800/20		22
C12N2800/202	9	of bacteriophage origin	CPCONLY	C12N2800/202		24
C12N2800/204	9	of bacterial origin, e.g. BAC	CPCONLY	C12N2800/204		181
C12N2800/206	9	of yeast origin, e.g. YAC, 2u	CPCONLY	C12N2800/206		59
C12N2800/208	9	of mammalian origin, e.g. minichromosome	CPCONLY	C12N2800/208		44
C12N2800/22	8	Vectors comprising a coding region that has been codon optimised for expression in a respective host	CPCONLY	C12N2800/22		4082
C12N2800/24	8	Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication	CPCONLY	C12N2800/24		118
C12N2800/30	8	Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT	CPCONLY	C12N2800/30		1586
C12N2800/40	8	Systems of functionally co-operating vectors	CPCONLY	C12N2800/40		339
C12N2800/50	8	Vectors for producing vectors	CPCONLY	C12N2800/50		111
C12N2800/60	8	Vectors containing traps for, e.g. exons, promoters	CPCONLY	C12N2800/60		352
C12N2800/70	8	Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites	CPCONLY	C12N2800/70		79
C12N2800/80	8	Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites	CPCONLY	C12N2800/80		1831
C12N2800/90	8	Vectors containing a transposable element	CPCONLY	C12N2800/90		656
C12N2800/95	8	Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers	CPCONLY	C12N2800/95		18
C12N2810/00	7	Vectors comprising a targeting moiety	CPCONLY	C12N2810/00		49
C12N2810/10	8	Vectors comprising a non-peptidic targeting moiety	CPCONLY	C12N2810/10		511
C12N2810/40	8	Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source	CPCONLY	C12N2810/40		243
C12N2810/405	9	Vectors comprising RGD peptide	CPCONLY	C12N2810/405		90
C12N2810/50	8	Vectors comprising as targeting moiety peptide derived from defined protein	CPCONLY	C12N2810/50		79
C12N2810/55	9	from bacteria	CPCONLY	C12N2810/55		31
C12N2810/60	9	from viruses	CPCONLY	C12N2810/60		134
C12N2810/6009	10	dsDNA viruses	CPCONLY	C12N2810/6009		18
C12N2810/6018	11	Adenoviridae	CPCONLY	C12N2810/6018		132
C12N2810/6027	10	ssDNA viruses	CPCONLY	C12N2810/6027		45
C12N2810/6036	10	DNA rev transcr viruses	CPCONLY	C12N2810/6036		3
C12N2810/6045	10	RNA rev transcr viruses	CPCONLY	C12N2810/6045		3
C12N2810/6054	11	Retroviridae	CPCONLY	C12N2810/6054		121
C12N2810/6063	10	ds RNA viruses	CPCONLY	C12N2810/6063		3
C12N2810/6072	10	negative strand RNA viruses	CPCONLY	C12N2810/6072		59
C12N2810/6081	11	rhabdoviridae, e.g. VSV	CPCONLY	C12N2810/6081		160
C12N2810/609	10	positive strand RNA viruses	CPCONLY	C12N2810/609		37
C12N2810/65	9	from plants	CPCONLY	C12N2810/65		10
C12N2810/70	9	from fungi	CPCONLY	C12N2810/70		3
C12N2810/75	9	from invertebrates	CPCONLY	C12N2810/75		2
C12N2810/80	9	from vertebrates	CPCONLY	C12N2810/80		58
C12N2810/85	10	mammalian	CPCONLY	C12N2810/85		57
C12N2810/851	11	from growth factors; from growth regulators	CPCONLY	C12N2810/851		54
C12N2810/852	11	from cytokines; from lymphokines; from interferons	CPCONLY	C12N2810/852		23
C12N2810/853	12	from tumor necrosis factor, TNF	CPCONLY	C12N2810/853		2
C12N2810/854	11	from hormones	CPCONLY	C12N2810/854		28
C12N2810/855	11	from receptors; from cell surface antigens; from cell surface determinants	CPCONLY	C12N2810/855		92
C12N2810/856	12	from integrins	CPCONLY	C12N2810/856		9
C12N2810/857	11	from blood coagulation or fibrinolysis factors	CPCONLY	C12N2810/857		11
C12N2810/858	11	from apolipopeptides	CPCONLY	C12N2810/858		6
C12N2810/859	11	from immunoglobulins	CPCONLY	C12N2810/859		189
C12N2810/90	10	avian	CPCONLY	C12N2810/90		
C12N2820/00	7	Vectors comprising a special origin of replication system	CPCONLY	C12N2820/00		17
C12N2820/002	8	inducible or controllable	CPCONLY	C12N2820/002		58
C12N2820/005	8	cell-cycle regulated	CPCONLY	C12N2820/005		2
C12N2820/007	8	tissue or cell-specific	CPCONLY	C12N2820/007		31
C12N2820/10	8	multiple origins of replication	CPCONLY	C12N2820/10		24
C12N2820/55	8	from bacteria	CPCONLY	C12N2820/55		73
C12N2820/60	8	from viruses	CPCONLY	C12N2820/60		115
C12N2820/65	8	from plants	CPCONLY	C12N2820/65		3
C12N2820/70	8	from fungi	CPCONLY	C12N2820/70		2
C12N2820/702	9	yeast	CPCONLY	C12N2820/702		5
C12N2820/704	10	S. cerevisae	CPCONLY	C12N2820/704		4
C12N2820/706	10	S. pombe	CPCONLY	C12N2820/706		1
C12N2820/708	10	C. albicans	CPCONLY	C12N2820/708		
C12N2820/75	8	from invertebrates	CPCONLY	C12N2820/75		
C12N2820/80	8	from vertebrates	CPCONLY	C12N2820/80		2
C12N2820/85	9	mammalian	CPCONLY	C12N2820/85		12
C12N2820/90	9	avian	CPCONLY	C12N2820/90		
C12N2830/00	7	Vector systems having a special element relevant for transcription	CPCONLY	C12N2830/00		778
C12N2830/001	8	controllable enhancer/promoter combination	CPCONLY	C12N2830/001		259
C12N2830/002	9	inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor	CPCONLY	C12N2830/002		1136
C12N2830/003	10	tet inducible	CPCONLY	C12N2830/003		429
C12N2830/005	9	repressible enhancer/promoter combination, e.g. KRAB	CPCONLY	C12N2830/005		106
C12N2830/006	10	tet repressible	CPCONLY	C12N2830/006		197
C12N2830/007	8	cell cycle specific enhancer/promoter combination	CPCONLY	C12N2830/007		70
C12N2830/008	8	cell type or tissue specific enhancer/promoter combination	CPCONLY	C12N2830/008		2539
C12N2830/15	8	chimeric enhancer/promoter combination	CPCONLY	C12N2830/15		540
C12N2830/20	8	transcription of more than one cistron	CPCONLY	C12N2830/20		165
C12N2830/205	9	bidirectional	CPCONLY	C12N2830/205		112
C12N2830/30	8	being an enhancer not forming part of the promoter region	CPCONLY	C12N2830/30		192
C12N2830/32	8	being an silencer not forming part of the promoter region	CPCONLY	C12N2830/32		35
C12N2830/34	8	being a transcription initiation element	CPCONLY	C12N2830/34		392
C12N2830/36	8	being a transcription termination element	CPCONLY	C12N2830/36		166
C12N2830/38	8	being a stuffer	CPCONLY	C12N2830/38		113
C12N2830/40	8	being an insulator	CPCONLY	C12N2830/40		126
C12N2830/42	8	being an intron or intervening sequence for splicing and/or stability of RNA	CPCONLY	C12N2830/42		870
C12N2830/46	8	elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island	CPCONLY	C12N2830/46		160
C12N2830/48	8	regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE	CPCONLY	C12N2830/48		639
C12N2830/50	8	regulating RNA stability, not being an intron, e.g. poly A signal	CPCONLY	C12N2830/50		1114
C12N2830/52	8	encoding ribozyme for self-inactivation	CPCONLY	C12N2830/52		24
C12N2830/55	8	from bacteria	CPCONLY	C12N2830/55		139
C12N2830/60	8	from viruses	CPCONLY	C12N2830/60		456
C12N2830/65	8	from plants	CPCONLY	C12N2830/65		9
C12N2830/70	8	from fungi	CPCONLY	C12N2830/70		4
C12N2830/702	9	yeast	CPCONLY	C12N2830/702		46
C12N2830/704	10	S. cerevisiae	CPCONLY	C12N2830/704		11
C12N2830/706	10	S. pombe	CPCONLY	C12N2830/706		2
C12N2830/708	10	C. albicans	CPCONLY	C12N2830/708		1
C12N2830/75	8	from invertebrates	CPCONLY	C12N2830/75		49
C12N2830/80	8	from vertebrates	CPCONLY	C12N2830/80		27
C12N2830/85	9	mammalian	CPCONLY	C12N2830/85		816
C12N2830/90	9	avian	CPCONLY	C12N2830/90		64
C12N2840/00	7	Vectors comprising a special translation-regulating system	CPCONLY	C12N2840/00		36
C12N2840/002	8	controllable or inducible	CPCONLY	C12N2840/002		118
C12N2840/005	8	cell cycle specific	CPCONLY	C12N2840/005		5
C12N2840/007	8	cell or tissue specific	CPCONLY	C12N2840/007		123
C12N2840/10	8	regulates levels of translation	CPCONLY	C12N2840/10		54
C12N2840/102	9	inhibiting translation	CPCONLY	C12N2840/102		69
C12N2840/105	9	enhancing translation	CPCONLY	C12N2840/105		175
C12N2840/107	9	inhibiting translational read-through	CPCONLY	C12N2840/107		9
C12N2840/20	8	translation of more than one cistron	CPCONLY	C12N2840/20		597
C12N2840/203	9	having an IRES	CPCONLY	C12N2840/203		1379
C12N2840/206	10	having multiple IRES	CPCONLY	C12N2840/206		131
C12N2840/44	8	being a specific part of the splice mechanism, e.g. donor, acceptor	CPCONLY	C12N2840/44		407
C12N2840/445	9	for trans-splicing, e.g. polypyrimidine tract, branch point splicing	CPCONLY	C12N2840/445		79
C12N2840/50	8	utilisation of non-ATG initiation codon<br><br><u>NOTE</u><br><br>This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here	CPCONLY	C12N2840/50		9
C12N2840/55	8	from bacteria	CPCONLY	C12N2840/55		26
C12N2840/60	8	from viruses	CPCONLY	C12N2840/60		58
C12N2840/65	8	from plants	CPCONLY	C12N2840/65		2
C12N2840/70	8	from fungi	CPCONLY	C12N2840/70		1
C12N2840/702	9	yeast	CPCONLY	C12N2840/702		1
C12N2840/704	10	S. cerevisiae	CPCONLY	C12N2840/704		1
C12N2840/706	10	S. pombe	CPCONLY	C12N2840/706		
C12N2840/708	10	C. albicans	CPCONLY	C12N2840/708		
C12N2840/75	8	from invertebrates	CPCONLY	C12N2840/75		3
C12N2840/80	8	from vertebrates	CPCONLY	C12N2840/80		1
C12N2840/85	9	mammalian	CPCONLY	C12N2840/85		41
C12N2840/90	9	avian	CPCONLY	C12N2840/90		
C12N2999/00	7	Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00<br><br><u>NOTE</u><br><br>This group is for classification of patent and non-patent literature documents.<br>When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.	CPCONLY	C12N2999/00		2
C12N2999/002	8	Adverse teaching	CPCONLY	C12N2999/002		4
C12N2999/005	8	Biological teaching, e.g. a link between protein and disease, new virus causing pandemic	CPCONLY	C12N2999/005		16
C12N2999/007	8	Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals	CPCONLY	C12N2999/007		95
